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Synthesis of Structurally Diverse N-Substituted Quaternary 
Carbon Containing Small Molecules and Their Application 
as Novel Starting Points for Drug Discovery 
Sarah L. Kidd 
New bioactive small molecules are urgently required to seed both medicinal chemistry and 
chemical biology research. Within the two last decades, however, organic synthesis has been 
identified as a limiting factor in this regard owing to the historically uneven exploration of 
chemical space. Whilst fragment-based screening has proven a fruitful strategy for identifying 
novel bioactive small molecules, in a similar vein to high-throughput screening approaches, 
obstacles within this paradigm have been recognised. This relates to a lack of fragment 
novelty, the overrepresentation of sp2-rich compounds and the lack of readily accessible exit 
vectors currently demonstrated by commercial screening collections. Thus, the development 
of novel screening libraries that address these deficiencies is therefore of significant 
importance. Moreover, innovative strategies are required to aid the somewhat challenging hit 
validation phase. In this context, the development of high-throughput platforms to accelerate 
the synthesis of derivatives could provide the opportunity to lower the economic impact of this 
process. 
This thesis seeks to explore how diversity-oriented synthesis can be leveraged to tackle these 
issues. To populate new areas of fragment space, in the first chapter we utilise an α,α-
disubstituted amino alcohol building block to generate 12 novel three-dimensional fragments 
containing an underrepresented N-substituted quaternary carbon moiety. These molecules 
ultimately contributed to a screening library of 40 compounds featuring this key motif. 
Importantly, throughout the library medicinally relevant functionalities and modifiable 
substituents were installed to enable biological recognition and three-dimensional fragment 
growth. Finally, cheminformatic analysis demonstrated the broad molecular shape diversity of 
the library and adherence of the library to commonly adopted guidelines within the field. In 
addition, the library was also shown to compare favourably with existing commercial 
collections, exhibiting a higher number of chiral centres, a lower fraction aromatic and an 
improved molecular shape distribution. 
In the second chapter, we demonstrate the ability of this library to deliver novel hits against 
challenging biological targets and facilitate multidirectional fragment growth. To achieve this, 
state-of-the-art high-throughput X-ray crystallographic fragment screening was conducted, 
leading to the identification of six hits against three novel biological targets (CFI25, Activin A 
and Penicillin-binding protein 3). Utilising the modular nature of the synthetic route developed, 
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derivatives of each hit were readily generated interrogating several synthetic exit vectors, 
including the N-substituted quaternary centre. In turn, these analogues were successfully 
employed as a hit validation strategy, thus providing novel starting points for drug discovery or 
chemical probe development. 
Finally, the third chapter describes investigations toward the coupling of rapid analogue 
construction with the XChem screening platform to provide a direct structural-binding readout 
via screening of crude reaction mixtures. In this section, we demonstrate the applicability of 
this library toward high-throughput derivative synthesis using solid-phase catalysis to generate 
78 analogues in less than one week. In addition, these studies formed the basis of preliminary 
investigations toward the development of methodology to enable click chemistry to be 
implemented within the crude screening protocol. 
Together, these findings demonstrate the effective nature of structurally diverse N-substituted 
quaternary small molecules within a fragment-based screening context. Herein, we 
demonstrate libraries of this nature can provide novel three-dimensional scaffolds to seed 
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Finally, the third chapter describes investigations toward the coupling of rapid analogue 
construction with the XChem screening platform to provide a direct structural-binding readout 
via screening of crude reaction mixtures. In this section, we demonstrate the applicability of 
this library toward high-throughput derivative synthesis using solid-phase catalysis to generate 
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1.1 The role of small molecules within drug discovery 
The discovery of small molecules (SMs) with the ability to influence the function of biological 
macromolecules (e.g. proteins, DNA and polysaccharides) remains one of the greatest 
challenges within chemical biology.1 Firstly, these entities are crucial to enable chemical 
genetics, in which SMs are used to probe and elucidate biological mechanisms, to develop our 
understanding of these complex systems.2–4 Secondly, in a medicinal chemistry context where 
disease states are chemically modified,5 SMs have continued to play a vital role over the 
decades. Indeed, their invaluable application as chemical probes has aided both target 
selection and validation for drug discovery purposes,6 in addition to providing starting points 
for novel therapies (Figure 1.1). Crucially, whilst the development of new biologic entities 
(NBEs) such as antibody-based medicines have gained significant interest in recent years,7 
SMs continue to dominate pharmaceutical pipelines and the drug market.8  
 
Figure 1.1. An overview of the drug discovery pipeline highlighting the essential role of SMs. Figure 
adapted from reference.9 ID = identification, NME = new molecular entity.  
However, despite the many technological and scientific advances within Research and 
Development (R&D) in the 1960s, a steady decline in the efficiency of drug discovery has been 
identified within recent years.8 Indeed, since 1950 there has been a significant decrease in the 
number of New Molecular Entities (NMEs) approved per billion dollars spending (USD).10 
Strikingly in 2016 the FDA approved only 12 SM NMEs,11 the lowest in almost five decades, 
despite an increase in the average cost to bring a drug to market reaching $1.5bn in that 
timeframe.12 Encouragingly in 2017 this increased to 34 SM-based NMEs,13 however, 
staggeringly the costs are now estimated to be in the region of $2-3bn.14  
Whilst in part this decline can be attributed to more stringent safety regulations,14 other factors 
such as drug attrition remain a major challenge. Over the last few years, the percentage of 
clinical candidates progressing from Phase I to clinical approval has steadily increased, 
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however, this figure is still alarmingly low in the region of 10-14%.15,16 Previously the primary 
causes of attrition were attributed to poor bioavailability and pharmacokinetics, whereas 
failures are now understood to result from a lack of efficacy and safety issues, meaning more 
costlier late-stage failures.17–19 Among the factors accredited to contribute to this is a lack of 
sufficient target validation, often linked to the disparity in the effects observed when targeting 
a given protein with a SM compared to those observed using genetic association studies and 
knockout models, for example via DNA mutations.20–23 Thus, in order to draw robust disease 
hypotheses from these studies, there is an urgent need for new SM chemical probes with the 
ability to both inhibit and activate cellular pathways to complement these strategies.3,24 
In addition to tackling drug candidate attrition, there remains a need for the discovery of new 
SMs capable of interacting with challenging and underexplored targets.25 As the recent 
identification of SM inhibitors for the bromodomain and extra terminal (BET) family of 
bromodomains serves to demonstrate, these quests can indeed prove fruitful in enabling 
breakthrough chemical genetic research and inspiring the development of clinical candidates 
for novel oncology-based therapies.26–28 Nevertheless, whilst the number of protein targets 
exploited for therapeutic purposes has more than doubled since 2006, G-protein coupled 
receptors (GPCRs), ion channels, kinases and nuclear receptors remain the most dominant 
target families, accounting for 70% of all SM drugs.29 Moreover, a significant overlap between 
pharmaceutical portfolios has been identified, with over 58% of all targets and 46% of novel 
targets being pursued by more than one organisation in 2013.30 Thus, a significant proportion 
of biological space remains underexploited for research and drug discovery purposes.  
Nevertheless, a major hurdle in these pursuits is the availability or development of appropriate 
SMs. In cases where the biological target or native ligand are well characterised, structure-
based or rational design strategies can be utilised.31 In the absence of this information, 
however, this process can be somewhat challenging. An alternative strategy is the high-
throughput screening (HTS) of SM libraries.32 Typically, sources of compounds to populate 
these libraries comprise those obtained through either isolation of Nature’s secondary 
metabolites (i.e. natural products) or chemical synthesis.33 However, in this case the selection 
criteria of molecules to populate these collections becomes vastly complicated.34 
1.2 Sources of small molecules 
A) Nature as a source of molecular diversity 
Owing to the exquisite structural complexity and diversity exhibited by natural products (NPs), 
these SMs continue to provide inspiration for novel tools to perturb biological systems.35 It is 
well established that these molecules interact with a wide range of targets and have delivered 
a rich source of drug discovery leads,36–38 with around half of all clinical drugs deriving from 
NPs.39 However, the isolation of these small molecules is non-trivial, and commonly purification 
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issues are faced.40 As a result, these compounds are often screened as mixtures, which can 
complicate the identification of the active species.41 As such, there has been a sustained 
interest within the synthetic and medicinal chemistry community in the artificial laboratory 
synthesis of such compounds and related analogues, which has aided our understanding and 
application of these SMs.42–44 However, due to their structural complexity, often with multiple 
stereocenters and sp3 rich motifs, the synthesis of these structures remains incredibly 
challenging and time-consuming.  
B) Commercially available and pharmaceutical collections: Our exploration of 
chemical space 
Commercially available and pharmaceutical compound collections constitute an alternative 
source of bioactive molecules. The era of combinatorial ‘split-pool’ libraries within medicinal 
chemistry resulted in the vast population of small molecule libraries for HTS campaigns with 
millions of compounds.45,46 As an inherent feature of their syntheses, however, these libraries 
commonly only feature appendage diversity around a limited number of molecular 
scaffolds.33,47,48 Nature sees small molecules in a 3-dimensional (3-D) fashion as a binding 
surface, and as such complex biological targets will only interact with molecules featuring a 
complementary 3-D surface. Thus, it has been argued that the intrinsic shape diversity of a 
library can be attributed to its functional diversity; those with a limited number of core scaffolds 
are limited in the number of biological targets the library may interact with.5 
Chemical space is astronomically vast with estimates in the region of 1063 of all possible SMs.49 
Whilst generation of every permutation is physically impossible, the coverage of chemical 
space by synthetic small molecule collections thus far can be considered sub-optimal. Indeed, 
an enlightening analysis of the CAS registry by Lipkus et al. highlighted fifty-percent of known 
molecules explored only 0.25% of all known molecular scaffolds, whilst the most popular 5% 
of scaffolds were present in over 75% of compounds.50,51 In addition to their methods of 
synthesis, this bias can be attributed to a historical preference of SMs fulfilling Lipinski’s Rule 
of Five (RO5) as a strategy to improve oral bioavailability and gauge ‘drug-likeness’.52–54 
Furthermore, recent analysis of large pharma company screening libraries suggested a 
substantial overlap and similarity of compounds within these collections.55 This overall lack of 
diversity is alarming and a factor which has often been attributed to the limited success of 
these libraries when seeking to identify novel bioactive agents.56 Moreover, this can lead to the 
assumption of a target as ‘undruggable’ due to the intractability when screening traditional 
compound libraries.57 
In addition to this structural bias, these libraries often contain a large percentage of scaffolds 
that are sp2 rich.48 It has been noted that molecules featuring multiple aromatic groups have 
reduced solubility and bioavailability due to increased intermolecular interactions resulting from 
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π-stacking.58 Thus, the inherent physicochemical properties that stem from the molecular 
framework of these libraries can also be considered sub-optimal. Arguably, the ‘flat’ nature of 
these libraries also restricts the expanse of bioactive chemical space that we can explore. 
Studies undertaken by Schreiber et al. highlighted the importance of chirality, increased sp3 
content within small molecules, and their ability to selectively bind to a panel of 100 different 
protein targets.59 Molecules displaying such structural features (mostly those derived from 
Diversity-Oriented Synthesis and natural sources) positively correlated to an increased binding 
selectivity and frequency relative to commercially available sources. More importantly, an 
increase in the fraction of sp3 atoms has been shown to have a positive correlation with 
increased solubility, pharmacokinetic-profile and successful transition of molecules from 
discovery stage, through to clinical trials and FDA approval.60   
In order to address the deficiencies of such screening collections, two strategies termed 
Diversity-oriented synthesis (DOS) and Fragment-based screening (FBS) emerged in the early 
years of this century offering alternative methodologies to develop novel chemical tools.53,61 
Often, molecules derived from DOS strategies resemble drug-like compounds with respect to 
their molecular mass and seek to populate novel and underexplored areas of chemical 
space;5,62 in contrast, the FBS technique approaches this challenge by screening much smaller 
(<300 Da) molecules to increase the chemical space sampling. It is worth mentioning that in 
addition to these strategies the development of lead-oriented synthesis,63–66 biology-oriented 
synthesis67–69 and collaborations between industry, small/medium enterprises (SMEs) and 
academics such as the European Lead Factory (ELF)70 in recent years has also provided tools 
for the generation of high-quality small molecule compound libraries. 
1.3 Diversity-Oriented Synthesis 
DOS emerged in the early 2000s71,72 as a strategy to construct compounds that interrogate 
large regions of chemical space via the efficient and deliberate synthesis of different molecular 
scaffolds in a divergent process.73 This involves the application of ‘forward’ synthetic analysis, 
in which common simple building blocks are transformed into a variety of structurally diverse 
products (Figure 1.2).5 In this case, the most challenging but important concept is the 
generation of high levels of skeletal diversity within the library to facilitate increased chemical 
space sampling.74 This opposes traditional target-oriented and combinatorial approaches, 
which follow linear and/or convergent sequences to generate a specific molecule or closely 
relating library occupying a defined area of chemical space.45,74  
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Figure 1.2. A comparison of target-oriented, combinatorial and diversity-oriented synthesis strategies 
for library generation and their respective molecular shape space distribution, depicted by principle 
moment of inertia plots. Adapted from references.9,40,75 
The definition of a ‘scaffold’ and its diversity is a subjective concept, which can vary depending 
on the context of their use. Typically, however, the literature describes four types of molecular 
diversity that are commonly identified and include: 
1) Skeletal diversity – different molecular architectures which result from a variation in 
ring structure/other rigidifying features, which determine the overall molecular 
shape. 
2) Appendage diversity – variation in the building block and therefore substituents 
around a common scaffold. 
3) Stereochemical diversity – variation in the spatial projection of different elements 
from the scaffold. 
4) Functional group diversity – variation of the different functional groups present 
within a molecule that have the potential to interact with features present within the 
biological macromolecule in question. 
Accordingly, a successful DOS library should incorporate all four elements to maximise the 
chemical space coverage. 
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1.3.1. Diversity-Oriented Synthesis approaches: reagent, substrate and multi-
component-based methods 
Commonly two methods to generate skeletal diversity are adopted within DOS.5,76 The first 
involves a reagent-based approach whereby a common pluripotent building block is utilised in 
a branching pathway via the employment of varied reaction conditions and co-substrates that 
dictate the stereochemical and skeletal diversity that is produced. (Scheme 1.1, A).77 To enable 
this, the building block usually features dense functionalisation of pluripotent handles to 
facilitate complexity generation.  
The second strategy involves the employment of folding pathway, in which diverse starting 
materials featuring pre-encoded functionality are subjected to common reaction conditions to 
effect the scaffold formation (Scheme 1.1, B).78,79 In this case, at least two appendages are 
encoded within the starting material, which in turn dictate the skeletal information when 
subjected to the common reaction conditions. Often, however, these approaches are not 
mutually exclusive and often modern DOS campaigns involve a combination of both 
strategies.5  
 
Scheme 1.1. DOS can be achieved using several strategies to generate structural complexity and 
diversity. Adapted from reference.9  
1.3.2. The Build/Couple/Pair algorithm 
Independent of the DOS approach employed, a general method to describe the use of a 
systematic modular scheme was proposed by Nielsen and Schreiber, termed as the 
Build/Couple/Pair (B/C/P) algorithm (Scheme 1.2).80 It was noted that DOS strategies to 
generate skeletally and stereochemically diverse products commonly adopt a three-stage 
process involving: 
1) Build Phase – assembly of building blocks containing orthogonal functionalities, often 
including chiral motifs to introduce stereochemical diversity. 
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2) Couple Phase – intermolecular coupling reactions between the building blocks and 
other commercially available and/or readily synthesised molecules to obtain an array 
of molecules featuring additional functionality. 
3) Pair phase – intramolecular coupling of different moieties within the precursors leading 
to the rigidified complex scaffolds. This stage is usually where the skeletal diversity is 
installed. 
Recent advancements in the application of this strategy include the development of multi-
dimensional approaches, whereby different linking motifs are utilised during the couple phase 
to increase the structural diversity of the respective library. This has been exemplified as an 
effective approach for the generation of novel macrocyclic SMs.81 
 
Scheme 1.2. The build/couple/pair strategy. Grey circles represent coupling functional group, green 
circles represent pairing functional group (non-polar) and purple circles represent pairing functional 
groups (polar). Adapted from reference.5 
Typically, a DOS strategy is limited to five synthetic steps starting from the chosen building 
block in order to maximise efficiency, a concept which is key due to the large cost overheads 
associated with synthesis.82 Thus, within a DOS approach it is desirable to utilise reactions 
that generate high levels of complexity and diversity. As such, strategies which feature 
multicomponent,83 domino/tandem reactions,84,79 and cycloadditions85,86 have commonly been 
employed. 
1.3.3. The success of DOS  
Since its conception, DOS has had significant impact upon the biomedical community. Indeed,  
its vision of addressing screening collection deficiencies has instigated efforts towards library 
enrichment within pharmaceutical collections.61,87 Due to the molecular size, compounds 
resulting from DOS are commonly utilised in high-throughput and phenotypic screening 
contexts,9 vitally providing tools for the discovery of SMs in the absence of structural 
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information or knowledge into the target responsible for eliciting a given phenotype.61 Indeed, 
due to the diverse and 3-D nature of compounds created through DOS, these libraries have 
proven particularly successful in this regard. This includes the identification of compounds with 
a broad range of bioactivities, including new anticancer agents,88,89 novel antimalarials,90,91 and 
chemical probes such as modulators of autophagy92,93 and β-cell apoptosis (Figure 1.3).94 
Importantly, molecules discovered through DOS have also been shown to interact with 
biological targets that have previously been difficult to modulate and are of increased biological 
relevance including protein-protein interactions (PPIs),95,96 those with transcription factor 
activity,97 drug resistant MRSA pathogens,98,99 and those which activate membrane receptors 
(Figure 1.3).100 
 
Figure 1.3. A selection of novel SM leads derived from DOS campaigns. 
1.4 FBS 
An alternative strategy for lead generation is the application of FBS. First described in 1996 by 
co-workers at Abbott,101 this strategy relies on the screening of libraries of low molecular weight 
(<300 Da) compounds to identify weak (μM to mM affinity) ligands for a given target. In turn, 
these ‘fragment’ binders are grown,102 linked103 or merged104 through an iterative process of 




Figure 1.4. The three strategies commonly used in FBS to elaborate a hit. A) Fragment growth can be 
achieved utilising structural binding information to achieve potency through picking up additional 
interactions. B) If two fragments are bound within the pocket or adjacent pockets these two motifs can 
be chemically linked. C) If two fragments overlap within a binding pocket these entities can be merged 
to generate a more potent lead.  
Whilst the basis of FBS appears counterintuitive for lead generation due to the weakly binding 
nature of the resulting hits, it is widely accepted that the screening of smaller molecules allows 
for a more efficient sampling of chemical space. Indeed, the number of possible ‘fragment’ 
chemical entities bearing 17 heavy atoms or fewer (1011)105 is considerably lower than the 
value possible HTS molecules with 30 heavy atoms or fewer (1063).49 A direct consequence is 
that much smaller fragment libraries, commonly in the region of 103 members, are required to 
effectively sample ‘fragment space’. In comparison, whilst HTS libraries are often in the order 
of 106 in magnitude, these can only fractionally cover the astronomical drug-sized space.106 
Crucially, due to this superior sampling significantly higher hit rates are generally observed 
with FBS campaigns compared to those conducted via HTS.107 
This higher hit-rate can also be explained by considering the notion of molecular complexity 
and the probability of matching the binding site for a given target, a theory proposed in 2001 
by Hann and co-workers.108 According to this model, the larger and more complex a compound 
becomes, the greater the number of interactions between the molecule and a binding site. 
Thus, the window of opportunity of finding a hit becomes significantly narrower with more 
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complex molecules due to the reduced chance of complementarity. As a result, in addition to 
the enhanced chemical space sampling, it would be expected that smaller fragments with 
reduced complexity should also lead to a higher number of hits against a larger number of 
targets.109,110  
Another contributing factor toward the success of FBS, is the identification of efficient binders 
that form higher-quality interactions with their targets, despite their lower potency.111 Often this 
factor is judged by the binding energy per atom, or ligand efficiency (LE).112 Thus, fragment-
sized molecules of higher or equal potency but with less atoms than their more drug-like 
counterparts can be considered more efficient binders.113 Nevertheless, as a result of the 
reduced size and affinity, the challenge of hit identification is more problematic in FBS and 
biophysical methods of hit detection are often required.114,115 Typically, this involves the use of 
X-ray crystallography, surface plasmon resonance (SPR) and NMR-based techniques due to 
their increased sensitivity.116,117 Often, however, these results can provide ambiguity and 
commonly more than one technique is required to decipher true hits from artefacts, false 
positives and false negatives.118–120  
One crucial consideration with FBS is the availability of structural information to leverage the 
power of structure-based design for hit elaboration.110,121,122 Indeed, the utilisation of structural 
information has been shown to dramatically increase the success of obtaining potent inhibitors 
from 33% to 93%.123 Nevertheless, the availability of crystal structures is not a trivial pursuit 
and the viability of this process often remains highly dependent on the nature of the target and 
the conformation of the protein in its crystal form. Thus, alternative approaches to guide hit 
optimisation have been explored, including NMR and computational modelling methods124 and 
examples of successful campaigns devoid of structural information have emerged.125 
In order to retain the advantages of FBS, the assembly of suitable screening libraries remains 
key. In 2003, a series of guidelines were proposed by co-workers at Astex termed the ‘Rule of 
Three’ (RO3, molecular weight <300 Da, clogP <3 and number of H-bond donors/acceptors 
<3), derived from analysis of the physicochemical properties of successful fragments.126 
Among these, the most important descriptor is considered to be molecular size, often also 
calculated by the number of non-hydrogen atoms (HAC), with fragments typically considered 
to contain 20 or less in order to maintain the efficiency of chemical space sampling.110 Whilst 
recently smaller fragments have tended to be favoured (HAC < 16),115 the utility of fragments 
at the upper limit of fragment space (~300 Da) has been demonstrated, for example in the 
development of inhibitors of challenging targets such as PPIs.127 Finally, due to the low affinity 




1.4.1 The success of FBS 
Since its emergence over two-decades ago FBS has been widely adopted throughout industry 
and academia.128,129 In this timeframe, this technique has proven particularly effective 
delivering two marketed drugs (Vemurafenib and Venetoclax)130,131 and more than 30 clinical 
candidates.110,132 Importantly, amongst these lie inhibitors of challenging targets, such as 
members of the Bcl-2 family and BACE-1,133 which previously proved intractable with HTS 
approaches.111,134 One such example is the development of a novel mode of action candidate, 
Navitoclax, a dual Bcl-2 and Bcl-XL inhibitor Navitoclax, which disrupts intracellular PPIs 
between other Bcl-2-family members (Figure 1.5).135 At the other end of the size spectrum, 
owing to the smaller initial hits, FBS has also provided clinical candidates with reduced 
molecular weight and lipophilicity, characteristics which positively correlate with reduced 
attrition.136,137 The ability of FBS to provide both large molecule (PPI inhibitors) and small 
molecules is one of the reasons why this approach has seen a dramatic development in the 
last decade. 
 
Figure 1.5. The initial fragment hits and final candidate against Bcl-XL developed by co-workers at 
Abbott adapted from reference.111 
In the context of chemical probe discovery FBS approaches have also been highly successful, 
enabling the development of selective modulators for a wide range of targets.138–141 Among the 
many examples, notably this includes the development of the Bcl-XL-selective chemical probe 
A-1155463142 and the CHK1-selective compound CCT244747 (Figure 1.6).143 In both cases, 
these targets had previously only explored in a dual-inhibitory manner, importantly providing 




Figure 1.6. Two examples of chemical probes developed by FBS methods. The two core components 
of A-1155643 were developed by combining HTS (portion in blue) and FBS (portion in red) strategies. 
The original fragment hit constituent of CCT244747 is highlighted in red. 
1.4.2 Outstanding challenges  
Despite these successes, in a similar vein to HTS screening collections, organic synthesis has 
been identified as a significant hurdle within FBS. More specifically, this relates to the lack of 
fragment space coverage by commercial collections, in addition to an overreliance on sp2-rich 
fragments of limited shape diversity.61,144,145 Despite the potential for 3-D fragments to display 
lower hit rates when considering Hann’s view of molecular complexity (vide supra), 
complementary tools to existing collections are required to interrogate challenging target 
classes with low tractability.144 Recent work by Foley et al. indeed validated this theory through 
the screening of 52 3-D fragments against three epigenetic targets from two mechanistic target 
classes (BRD1, JMJD2 and ATAD2), resulting in the identification of 17 novel binders.146 
Importantly, this included seven hits against ATAD2, a novel oncology target previously 
deemed to have low druggability (Figure 1.7).147 Nevertheless, whilst the growing demand for 





Figure 1.7. Screening of diverse 3-D fragments enabled the identification of novel binders against a 
challenging epigenetic target. 
In addition to their utility against challenging targets, sp3-rich fragments also offer the prospect 
of increased numbers of fragment growth vectors. This has been noted as another significant 
deficiency of commercial libraries,115,121 yet the incorporation of synthetic handles remains a 
crucial factor in enabling rapid fragment elaborations without the requirement of new synthetic 
route development. Thus, calls from within the scientific community for novel fragments 
featuring multi-directional exit vectors with synthetic tractability have been made. One example 
of research meeting this criteria was conducted within the Spring group by Twigg et al.151 
describing the development of a modular route to partially saturated bicyclic aromatic (PSBH) 
fragments (Figure 1.8). This work resulted in the formation of 15 fragments based on five 
scaffolds, varying in saturated ring size and heteroatom content in addition to the adjacent 
heterocycle. Furthermore, an alkene and either an amino, nitro or chloro handle were 





Figure 1.8. The partially saturated bicyclic heteroaromatic library presented by Twigg et al. featuring 
enhanced sp3 character and synthetic handles for fragment elaboration. LDA = Lithium diispropylamide, 
TFA = Trifluoroacetic acid, RCM = Ring closing metathesis.  
However, only a handful of additional examples seeking to tackle this issue have been 
published in recent years.152,153 Thus, the development of methodologies seeking to generate 
many different scaffolds via a single strategy to rapidly populate fragment space whilst 
maintaining synthetic tractability would be highly beneficial. Moreover, whilst notable examples 
of strategies to access novel sp3-rich fragments have been reported, the biological relevance 
of such libraries remains underexplored. Consequently, new research into the utility of such 
collections is required. 
Another reason to generate fragments bearing readily functionalisable handles is that, due to 
the low affinity and sometimes ambiguous nature of initial hits resulting from X-ray screening 
campaigns, access to analogues is often required to probe the binding interactions.121 Often 
this can be achieved using commercially available derivatives, however, this aspect can be 
more difficult with novel libraries. Moreover, within drug discovery the balance of compound 
value with resource investment is an important consideration.154 Thus, the early stages of hit 
validation and elaboration not only presents a synthetic, but also an economic challenge.  
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1.5 Thesis overview and aims 
Traditionally, DOS and FBS have been regarded as competing technologies, but in recent 
years examples of the intersection of these two fields have blossomed within the 
literature.146,155–158 Moreover, direct calls from leaders in the field have encouraged the 
development of fragment-focused DOS to address the aforementioned deficiencies with 
commercial screening libraries.121 With these points in mind, this dissertation describes how  
DOS approaches can be leveraged to tackle these important outstanding challenges within the 
field. 
The design and synthesis of novel, sp3-rich and diverse fragment libraries to 
complement existing screening collections. As discussed in this chapter, there remains a 
need for the development of novel chemotypes to expand the FBS toolbox. Thus, Chapter Two 
describes the application of DOS methodology for the construction of a novel N-substituted 
quaternary carbon-containing screening library utilising α,α-disubstituted amino ester building 
blocks (Scheme 1.3). This resulted in the generation of a fragment collection based on 40 
distinct scaffolds incorporating this important and currently underrepresented 3-D motif. In 
addition, modifiable groups were installed at a range of positions to enable multidirectional 
fragment growth. Computational analysis was conducted to demonstrate the high levels of 
diversity achieved, the importance of the quaternary centre and the applicability of this library 
toward FBS. Moreover, the collection featured a higher number of chiral centres and lower 
fraction aromatic compared to commercial collections. 
 




Demonstration of the utility of DOS fragment libraries for enabling the discovery of 
chemical leads against challenging targets and structure-activity relationship 
exploration from multiple vectors around a ligand. Since DOS libraries offer increased 
structural diversity, and therefore chemical space sampling, these collections should be well-
suited to identify hits against challenging targets. Accordingly, Chapter Three describes the 
implementation of the quaternary DOS collection within multiple X-ray based fragment 
screening campaigns, illustrating the biological relevance through the identification of hits 
against several novel targets. Importantly, we also demonstrate the advantages of the 
inherently modular and flexible nature of DOS for enabling the construction of rationally 
designed analogues. This included the exploration of several 3-D fragment growth vectors, 
including the quaternary centre, to enable hit validation and probe the binding (Figure 1.9).  
 
Figure 1.9. An example of the exit vectors and modifiable groups that were used as synthetic handles 
to derivatise the molecules in a 3-D manner. 
The development of novel methodologies for rapid analogue generation coupled to a 
structural-binding readout to accelerate the evolution of weak hits to potent lead 
compounds. Due to the weakly binding nature of fragment hits, the evolution process of initial 
hits to achieve compounds with activity in solution assays remains a significant hurdle. Thus, 
the development of novel methodologies to accelerate this process would have significant 
utility for FBS. Accordingly, Chapter Four describes the development of a novel high-
throughput strategy to enable rapid analogue construction via the formation of 1,2,3-triazoles 
utilising liquid handling robotics (Scheme 1.4). Firstly, we demonstrate the compatibility of the 
DOS chemistry both with this technology and solid-phase catalysis, enabling the formation of 
78 analogues. Importantly, it was envisaged this would facilitate widespread adoption of the 
DOS library within a FBS setting. Secondly, these studies formed the basis of preliminary 
investigations toward the implementation of crude reaction mixtures within an X-ray screening 





Scheme 1.4. Using liquid handling robotics analogues were constructed in a high-throughput manner 








2 Results and discussion: DOS for the synthesis of N-
substituted quaternary small molecules 
2.1 Background 
Strategies for the synthesis of non-flat fragment DOS libraries 
Among the different methodologies described in the literature to generate complex small 
molecules, the introduction of restricted elements such as cyclic structures or quaternary sp3 
carbons has received significant interest due to their increased 3-dimensionality and 
conformational restriction.159 Certainly, the construction of quaternary carbon motifs has 
represented an important but nevertheless challenging quest for synthetic chemists in recent 
decades, forming the focus of many natural product and drug molecule endeavours.160,161 The 
all-carbon variant of this motif represents an important structural feature within many marketed 
drugs,162 such as Oxycodone and Mometasone (Figure 2.1). Nevertheless, as a result of the 
difficult nature of constructing this congested centre, naturally-derived precursors are 
commonly employed in their syntheses.159,163 Thus, over recent years efforts toward the 
development of novel methodologies to engender all-carbon quaternary centres has 
surged.164–167 
 
Figure 2.1. Quaternary carbon-containing small molecule drugs. 
In addition to all-carbon quaternary centres, N-substituted quaternary carbons (NSQCs) 
represent an equally challenging but crucial variant of this motif.168–170 Indeed, the 
conformational restriction imparted upon α,α-disubstituted amino acids has been 
demonstrated as an effective biomimetic strategy for modification of the properties of bioactive 
peptides. Thus, novel strategies concerning the synthesis of non-proteinogenic amino acids 
have received significant attention in recent years.171–173 Moreover, the presence of NSQCs 
within natural products such as Manzacidin A, Altemicidin174,175 and the essential medicines 
Methyldopa and Ketamine176 (Figure 2.2) serves to highlight the relevance of this motif within 




Figure 2.2. Examples of NSQCs in A) Natural products and essential medicines and B) FBS-derived 
clinical candidates. 
More specifically to the FBS paradigm NSQCs have been demonstrated as crucial elements 
within several FBS-derived clinical candidates (Figure 2.2), with seven out of the thirty-two in 
trials during 2016 containing this motif.110 Five of these candidates, such as LY288682, relate 
to BACE-1 inhibition for Alzheimer’s disease therapy. In this context, it has been shown that 
the incorporation of a NSQC within such molecules can be vital to facilitate the projection of 
substituents into different pockets within the protein to enable key binding interactions, in 
addition to improving compound stability.177–179 Furthermore, examples such as the Akt 
inhibitors AZD5363 and AT13148 have additionally highlighted the potential of NSQC 
functionalities to mediate vital H-bond interactions, contributing to the Akt inhibitor 
pharmacophore.180–184 Moreover, the inclusion of molecules such as Ketamine within the Astex 
2012 Fragment Library145 highlights the relevance of NSQC-containing sp3-rich compounds 
within fragment screening collections.  
Despite their importance, however, due to the challenging nature of constructing this motif, 
NSQC-containing SMs remain underrepresented in screening collections. Furthermore, to date 
many examples of the incorporation of NSQCs within SMs have focused on Target-Oriented 
Synthesis (TOS) strategies, resulting in libraries of limited structural diversity.175,185 With these 
points in mind, the generation of flexible synthetic routes toward diverse, fragment- and lead-
like scaffolds that incorporate NSQCs are highly desirable. Thus, in recent years a number of 
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examples have emerged within the literature regarding the use of DOS methodology to 
construct screening libraries incorporating this structural feature.  
A) DOS starting from allyl proline derivatives 
Allyl-containing cyclic amino esters building blocks represent one strategy utilised within DOS 
campaigns to generate NSQC-containing fragments. A seminal paper published by Young et 
al. in 2011 described the first application of DOS toward the synthesis of sp3-rich fragments 
utilising this approach. In this research, a 35-member library was constructed utilising proline-
derived cyclic building blocks in a B/C/P algorithm (Scheme 2.1).186 A division of this work 
involved the employment of a quaternary allyl-proline substrate, which ultimately delivered a 
subset of the library comprising 14 NSQC-containing fragments. This approach involved the 
installation of a second allyl olefin via N- and ester- functionalisation to generate six 
intermediates, which were intramolecularly cyclised by RCM, hydantoin formation or oxo-
Michael reactions to yield a series of fused and spiro bicyclic compounds. Furthermore, 
following a previously reported procedure,187 two quaternary bicyclic azetidines were 
additionally synthesised from the same building block to enhance the scaffold diversity. Finally, 
members of the fragment library were additionally modified in a post-pair phase manner via 
functional group interconversion to modify the electronic properties and increase sp3 content. 
Importantly, the authors demonstrated the adherence of the full library to the  RO3 principles 






Scheme 2.1. The 14 compounds containing a NSQC were included in the fragment library, 12 of 
which were synthesised from a single quaternary proline building block. 
B) DOS starting from α,α-disubstituted amino acid-related scaffolds 
The second example in this field was reported in 2015 by Foley et al. (Scheme 2.2) describing 
the use of four Boc-protected α,α -amino acid derived building blocks in a matrix-like B/C/P 
approach.188 In this case, the four quaternary building blocks were diversified via N-alkylation 
or urea formation to produce five classes of trifunctional intermediates. Subsequent pairing of 
these functionalised substrates could then be achieved using six reaction methodologies to 
generate twenty-two NSQC-containing scaffolds. Notably, the resulting compounds featured 
medicinally relevant functionalities such as ureas, hydantoins and lactams, in addition to 
functional synthetic handles. Furthermore, the resulting library proved to possess a high 
degree of novelty, whilst subsequent virtual enumeration afforded a library of 1,110 lead-like 




Scheme 2.2. Using four α-allyl substituted amino acid derivatives 22 NSQC scaffolds were efficiently 
constructed in a matrix B/C/P fashion. 
Nevertheless, in both instances the biological utility of these NSQC-containing fragments 
remains unexplored. Accordingly, we envisaged the generation of a novel NSQC library would 
provide the potential to the opportunity to demonstrate the biological relevance of 3-D 
fragments featuring this motif.  
2.2 Project proposal  
Inspired by the successful reports on the utility of cyclic allyl-based quaternary substrates for 
the synthesis of diverse sp3-rich libraries, we hypothesised that acyclic propargyl-based α,α-
disubstituted amino esters could serve as an orthogonal and novel approach for this purpose. 
Owing to the acyclic nature of these moieties, it was envisaged that the differential reactivity 
of the three synthetic handles (the alkyne, amino and ester functionalities) could be exploited 
to generate extensive scaffold diversity. Importantly, it was hoped that the development of 
modular DOS methodology in this context would be well-suited to address the aforementioned 
challenges within FBS. More specifically this related to the incorporation of multiple modifiable 
substituents for exit vector exploration, in addition to a versatile quaternary substituent for 3-D 
fragment growth. Preliminary studies in this regard were conducted in the Spring group by Dr. 




Scheme 2.3. DOS starting from α,α-disubstituted propargyl amino esters. 
Stemming from this work, we hypothesised that an interesting complementary extension could 
involve utilising simple ester reduction to furnish a densely functionalised quaternary propargyl 
amino alcohol building block. Consequently, it was envisioned incorporation of this hydroxyl 
moiety would enable expansion of the scope of chemistries that could be employed within the 
DOS strategy (Scheme 2.4). In this instance, it was anticipated that pairing of the electrophilic 
alkyne (Scheme 2.4, pathway A) or the nucleophilic hydroxyl with a functionalised amino 
functionality (Scheme 2.4, pathway B) would enable access to 3-D oxygen-linked constrained 
fragments.  
 
Scheme 2.4. The pluripotent nature of the quaternary propargylic amino alcohol in DOS. 
With this concept in mind, a general strategy for the construction of the new library was 
proposed following a B/C/P format. In this manner, it was envisioned the starting amino alcohol 
building block(s) I (build phase) could be transformed into a variety of highly functionalised 
linear precursors II through varying both the linking motifs and substrates used (couple phase) 
(Scheme 2.5). Subsequent pairing of the resultant structures through intramolecular 
rigidification of the linear intermediates would afford multiple complex and diverse scaffolds in 




Scheme 2.5. DOS of a 3-D fragment library following a B/C/P approach. 
Initially, a racemic strategy to generate I was proposed owing to the fact that fragment 
racemates are often preferred within FBS campaigns to enable the screening of both 
enantiomers.115 It was envisaged that the first stage of the project would focus on the 
construction of building block I in a four step procedure starting from the α-keto ester III (R = 
alkyl or aryl) as follows: (1) imine V formation; (2) regioselective nucleophilic addition of the 
propargylic chain; (3) protecting group cleavage and (4) reduction of the ester functionality 
(Scheme 2.6). Another important aspect of this project was the versatile nature of the proposed 
synthetic route, allowing for modification of the substituent at the quaternary stereocenter 
simply through selection of the desired ketoester III. Accordingly, this would enable the 
incorporation of a cohort of substituents at this position to generate additional diversity and 
facilitate further fragment growth.  
 
Scheme 2.6. The proposed route to building block I. Aux = auxiliary. 
Inspired by the dense functionalities embedded within I, a divergent branching scheme for the 
DOS strategy was proposed (Scheme 2.7). This involved the generation of multiple linear 
precursors using a variety of transformations including ether synthesis, hydroxyl substitution 
and amine acylation. In the subsequent pair phase, it was anticipated that the employment of 
a wide range of complexity-generating and multi-component-coupling reactions would 
generate high levels of scaffold diversity across the library. This included ruthenium-catalysed 
intramolecular enyne metathesis (RCEYM), cobalt-catalysed [2+2+2] cyclotrimerisations, 1,3-
dipolar cycloaddition reactions, and base-mediated cyclisations. Consequently, different 
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atomic skeletons such as morpholinones, benzoxepanes, aziridines and dihydropirans bearing 
a quaternary sp3 carbon would be constructed from a single common precursor.  
 
Scheme 2.7. The proposed DOS strategy starting from I. * = stereocenter, PG = protecting group, 
PKR = Pauson Khand reaction, RCEYM = ring closing enyne metathesis, CT = [2+2+2] 




2.3 Library synthesis 
2.3.1 Synthesis of the key amino alcohol building block I 
In line with the project proposal, initial investigations began with the racemic synthesis of the 
key amino alcohol intermediate I bearing a methyl substituent at the quaternary stereocenter. 
In this manner, construction commenced with the formation of imine 1 through condensation 
of the commercially available methyl pyruvate and p-anisidine (Scheme 2.8). However, despite 
previous reports on the formation of p-methoxy phenyl (PMP)-imino esters189–191 we observed 
that overheating the reaction and purification of the intermediate imine 1 led to a considerable 
reduction in the yield. Instead, it was found that a simple work-up (via trituration and filtration) 
was sufficient to isolate the crude imine, which was then immediately subjected to the next 
reaction conditions without further purification. 
 
Scheme 2.8. The synthetic route to amino ester 2. 
Treatment of 1 with propargyl bromide in the presence of Zn under Barbier-type conditions 
facilitated the regioselective formation of the key quaternary centre.192,193 As a result of 
isomerisation194–196 alkyne 2 was obtained together with allene 3 in a 4:1 ratio, respectively 
(determined by 1H NMR), however both isomers were separable by column chromatography. 
The scalability of this synthetic procedure was demonstrated by the preparation of a 12 g 
mixture of 2 and 3 in a simple two-step operation. Thus, this route proved a viable procedure 
for the large-scale synthesis of I sufficient to enable the DOS investigations. 
With 2 in hand, mild cerium(IV) ammonium nitrate (CAN) radical-mediated removal of the PMP 
group afforded the desired free amine 4 in good yield (Scheme 2.9). This amine could be 
isolated in good purity via an acidic/basic work-up, avoiding the need for potentially problematic 
column chromatography of the polar amino compound. Disappointingly, however, when a 
direct reduction was carried out upon ester 4 no desired amino alcohol 5 could be isolated 





Scheme 2.9. CAN-mediated PMP deprotection and first attempt to obtain the key amino alcohol. 
In order to access the desired alcohol functionality, it was therefore decided to first protect the 
amine with an alternative group and subsequently reduce the ester to furnish the desired 
hydroxyl building block (Scheme 2.10). Thus, amino ester 4 was heated with an excess of di-
tert-butyl dicarbonate (Boc2O) in THF affording the N-Boc protected derivative 6 in high yield. 
This was subsequently subjected to a lithium-mediated ester reduction generating the desired 
starting quaternary amino alcohol 7 in excellent yield. It is worth mentioning that the use of an 
acid-labile protecting group was chosen to enable regioselective modifications to both N- and 
O- functionalities as required. 
 
Scheme 2.10. The final synthetic steps to yield 6 and 7. 
Exemplification of the building block versatility 
As a means to exemplify the versatile nature of the synthetic route to the starting building 
blocks, it was decided to generate an alternative substituent at the quaternary centre. In line 
with the project proposal, it was hoped that simply through variation of the ketoester used in 
the first step a substituent of choice could easily be installed at this position. To demonstrate 
this, applying the previously developed route, the phenyl variant of 7 was synthesised (Scheme 
2.11). Pleasingly, upon reflux of commercially available methyl benzoylformate with p-anisidine 
and catalytic amounts of p-toluenesulfonic acid, imine 8 was isolated in an 88% yield. 
Subsequent subjection of 8 to the same Barbier reaction conditions used previously, achieved 
the nucleophilic propargyl addition. In this case, alkyne 9 and allene 10 were observed in a 6:1 
ratio (determined by 1H NMR), again separable by column chromatography. 
 
Scheme 2.11. Synthesis of a phenyl building block derivative. 
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Accordingly, applying the previously developed synthetic sequence the amine was 
subsequently deprotected to give 11, followed by N-Boc protection to afford 12 and ester 
reduction to afford the corresponding phenyl-substituted amino alcohol 13 in a moderate 
overall yield (Scheme 2.12). 
 
Scheme 2.12. Synthesis of the key amino alcohol with an alternative quaternary substituent. 
2.3.2 Preparation of highly functionalised intermediates and further cyclisation: 
Couple and Pair phase 
With building blocks 7 and 13 in hand an exploration into the potential to form 3D diverse 
scaffolds from these substrates was undertaken. This was achieved in two parts: (i) cyclisation 
of the hydroxyl and alkyne moieties (Figure 2.3, type A) or (ii) cyclisations between the nitrogen 
and hydroxyl moieties (Figure 2.3, type B). It was envisaged that during this, manipulation of 
the N- or O- moieties through the introduction of additional reactive functionalities would 
expand the scope, allowing the generation of multiple heterocyclic scaffolds. 
 




2.3.2.1 Investigations into hydroxyl and alkyne pairing via pathway A 
Direct intramolecular cyclisations 
Substituted dihydropyrans (DHPs) and their fully saturated counterparts are found in many 
interesting natural products such as Irciniastatin A, with anti-tumour properties,197 Omarigliptin, 
under development for the treatment of type 2 diabetes,198,199 and the antiviral Laninamirvir, 
under development for the treatment of Influenza A and B200 (Figure 2.4). Given the presence 
of this characteristic motif in such structures, we envisioned that the generation of fragment-
like, NSQC-bearing scaffolds via a versatile synthetic route would be of great interest. 
 
Figure 2.4. DHP motifs within bioactive molecules. 
Inspired by recent examples of the reactivity of ruthenium vinylidene complexes with N/O/S 
nucleophiles,201 we envisioned a disubstituted DHP could be afforded via O-mediated 
nucleophilic attack at the alkyne upon exposure of 7 to transition metal catalysts201(Scheme 
2.13). To this aim, following the procedure developed by Zacuto et al., CpRu(PPh3)2Cl was 
used to initiate the cyclisation, affording DHP 14 in moderate yield (Scheme 2.13). 
Furthermore, to demonstrate the versatile introduction of different substituents at the 
quaternary carbon within the final small molecules, the corresponding phenyl derivative 15 was 
additionally synthesised, furnishing the scaffold in a similarly moderate yield. 
 





Hydroxyl alkylation strategies 
Whilst oxepane-containing scaffolds are less well explored in drug discovery than their aza-
counterparts,202 this ring structure can be found embedded within several bioactive natural 
products,203 whilst oxepanes flanked by two aromatic rings are commonly found within central 
nervous system (CNS)-active drugs, such as doxepin or asenapine.204 As such, there remains 
a sustained interest in the development of novel methodologies to construct these motifs. 
Indeed, the privileged nature of this moiety has led to the development of novel methods to 
generate oxepane-based sp3-rich libraries for the ELF205 and as a chemical navigator within 
biology-oriented synthesis campaigns.206 
Inspired by these reports, we next considered the scope of introducing additional pendant 
functionalities to 7 via alkylation of the hydroxyl motif for generating oxepane-containing 
scaffolds. Accordingly, it was hoped the reactivity of these newly introduced functionalities 
could be harnessed to generate different polycyclic scaffolds in a chemoselective fashion. 
More specifically it was envisaged that the introduction of an additional unsaturation within the 
molecule would provide the opportunity to utilise different transition-metal based cyclisations 
to afford novel oxepane-fused scaffolds (Scheme 2.14). 
 
Scheme 2.14. Cyclising the pendant groups and the alkyne following pathway A. 
Metathesis-Diels Alder cascade 
With this proposal in mind, our investigations initially focused on the installation of an allyl 
group in the hope to afford enyne variant 16 (Scheme 2.15). Thus, with the N-Boc protected 
amino alcohol in hand, alkylation was investigated using allyl bromide and NaH as a base in 
DMF. Starting from 7, only a moderate 57% yield of 16 was achieved, with crude 1H NMR 
analysis suggesting secondary N-alkylation to be the origin of the low observed yield.  
 
Scheme 2.15. Alkylation of N-protected amino alcohol 7. 
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In order to mitigate this, an alternative N-protection strategy was explored. Thus, starting from 
the unprotected amino ester 4, benzyl bromide and DIPEA were added in excess to yield the 
corresponding diprotected amino ester 17 in high yield (Scheme 2.16). Then, treatment of 17 
with LiAlH4 to mediate ester reduction afforded 18 in an excellent 93% yield. Pleasingly, 
applying the same ether formation of the same conditions to 18, 19 was isolated in an improved 
79% yield. 
 
Scheme 2.16. Synthesis of benzyl protected amino ether 19. 
With enynes 16 and 19 in hand, it was envisaged that RCEYM under Mori conditions207,208 
would afford tetrahydrooxepines 20 or 21 (Scheme 2.17). Indeed, upon exposure of these 
intermediates to Grubbs second generation catalyst using a reduced reaction molarity (0.0255 
mol dm-3) the intramolecular reaction was promoted, furnishing 20 and 21 in moderate yields. 
In this case, the yield of this procedure was attributed to the observed instability of the resulting 
diene products under TLC analysis, suggesting decomposition at room temperature after only 
24 hours. 
 
Scheme 2.17. RCEYM of 16 and 19 afforded dienes 20 and 21. 
In a divergent manner, it was thought that dienes of this nature would serve as ideal substrates 
to participate within further transformations via a DAR using different dienophile components 
to create multiple diverse scaffolds.206,207 To this aim, the [4+2] cycloadditions could be 
promoted through thermal activation of 2 in the presence of N-methylmaleimide yielding 
bicycles 22 and 23, as a mixture of diastereoisomers (dr ca. 3:1, determined by 1H NMR) which 
could be easily separated by flash column chromatography (Scheme 2.18). In the case of 20, 




Scheme 2.18. DAR of 1,3-diene 21 with N-methylmaleimide to afford 22 and 23. 
The relative configuration between the quaternary carbon and the three new stereocenters 
formed after the DAR was deduced by nOe correlation analysis in both tricycles 22 and 23 
(Figure 2.6). It was found that within the nOe spectrum of 22, an interaction was present 
between the two protons of the newly formed stereocenters (Ha) and (Hb) indicating a cis 
relationship and the presence of the endo product. The relative orientation of these 
stereocenters to the remainder of the molecule could also be determed through the observed 
strong nOe interactions between the Ha proton and Hc proton within the cyclohexene ring and 
the axial phenyl protons of the benzyl group.  
 




Similarly, within the nOe spectra of 23 the endo product was again confirmed through the 
interaction between Ha with both Hb and Hc, whilst the presence of the alternative 
diastereomer was suggested through an additional interaction between Ha and the axial 
methyl protons Hd (Figure 2.6). This provided sufficient information to allow the determination 
of the relative stereochemistry of both polycyclic compounds 22 and 23. 
 
Figure 2.6. The NOESY 2-D spectra for diastereomer 23. 
With the success of this sequence in mind, it was thought to investigate alternative dienophiles 
which could be employed to generate additional novel scaffolds. Thus, in light of the previous 
evidence of the influence of the N-protection strategy on the ease of separation of 
diastereomers, both the diene products 20 and 21 were subjected to the DAR conditions with 
nitrosobenzene (Scheme 2.19). However, in the case of 21 only an inseparable mixture of the 
four possible regio- and stereoisomers was generated (ca. 4:2.2:2:1.8 ratio by crude 1H NMR 
analysis). The analogous reaction of the N-Boc diene 20 afforded a 4.6:3.6:1.0:0 distribution 
of regio and stereoisomers (determined by crude 1H NMR analysis). Pleasingly, in this case 
the major isomer from this mixture could be isolated in a 31% overall yield. Attempts to 
deprotect the amine under acidic conditions using trifluoracetic acid to improve the separation 
of the remaining isomers proved in vain, with only a complex mixture obtained in this case and 




Scheme 2.19. Using nitrosobenzene as a dienophile, novel sp3 rich architectures could be constructed. 
Efforts to determine the relative position of the substituents present within 24 were 
subsequently investigated. Unfortunately, nOe experiments proved inconclusive to definitively 
determine the diastereomer generated due to lack of both diastereomers for analysis and 
overlap of vital 1H NMR signals. Furthermore, no X-ray data could be obtained for the product 
due to the oily composition of the resulting compound. 
Cycloaddition pair phase of enyne 23 
With 22, 23 and 24 in hand, alternative methodologies to pair the alkene and alkyne moieties 
within the branching intermediates 16 and 19 were then pursued. The Pauson Khand reaction 
(PKR) is a widely used method of forming fused cyclopentenone derivatives, mediated via 
Cobalt catalysis.209 It was proposed that the alkene and alkyne moieties could be additionally 
paired through such a [2+2+1] cycloaddition to yield cyclopentenone-fused [5,7]- ring system 
25 (Scheme 2.20). 
To this aim, our first efforts in the preparation of bicyclic system 25 were based on conditions 
reported using similar substrates.210 This involved using stoichiometric amounts of the 
Co2(CO)8 catalyst along with 10 equivalents of the oxidant (NMO) to effect the transformation. 
When bis-benzyl protected intermediate 16 was subjected to these conditions, we were 
disappointed to observe only complete decomposition of the starting material and no desired 
product formation. Moreover, a similar result was obtained when subjecting N-Boc protected 
amine 19 to the same conditions. In order to maintain focus on investigating the scaffold 
diversity as opposed to detailed optimisations the formation of this scaffold was abandoned. 
 




Alkylation of the hydroxyl with a second propargyl group 
Inspired by the success of the metathesis cascade pair phase of enynes 16 and 19, it was 
envisaged that alkylation of the hydroxyl with an alternative unsaturated moiety would provide 
the opportunity to form different complex molecules. Thus, alcohols 7 and 18 were subjected 
to the same ether-formation conditions instead using propargyl bromide to form 26 and 27 
(Scheme 2.21). Analogous to the previous alkylations of these substrates, this reaction was 
found to be significantly more successful with the N-benzyl building block 18 delivering 27 in 
88% yield, compared to only 53% of 26 from 7. 
 
Scheme 2.21. The formation of diynes 26 and 27. 
[2+2+2] cyclotrimerisation pair phase 
According to previous results on the formation of N-containing heterocycles via [2+2+2] 
cyclotrimerisations211 it was envisaged that different [6,7]-bicyclic compounds could ultimately 
be synthesised starting from 26 and 27 (Scheme 2.22). Indeed, transition-metal catalysed 
[2+2+2] cyclotrimerisations have been extensively used to generate benzene derivatives due 
to the exceptional synthetic versatility of this methodology to construct complex molecules in 
an efficient manner.212,213 Modern synthetic advancements in this reaction describe 
modifications to the procedure including the use of alternative variants of the third ‘ene’ such 
as nitriles and isocyanates to generate both pyridine and pyridinone moieties,214–216 both of 
which are medicinally relevant motifs.202 
 
Scheme 2.22. Scaffold diversification through [2+2+2] cyclotrimerisation starting from dialkyne 26 or 
27. 
To this aim, intermediate 27 was subjected to a range of cyclisation conditions, employing 
benzonitrile as a third ‘pair’ component, with the objective of forming scaffolds 28 and 29 
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(Scheme 2.23). Two different catalyst systems were trialled - CpCo(CO)2 and Wilkinson’s 
catalyst – however, in both cases only a complex reaction mixture was observed upon crude 
1H NMR analysis of the resultant reaction mixture. Conditions reported by Nicolaus et al.217 
suggested the use of PPh3 may be beneficial in order to stabilise the metal in the catalytic 
cycle, thus increasing the reactivity of such processes when also used in conjunction with 
microwave heating. However, these conditions also proved unsuccessful with only starting 
material observed in both cases. 
 
Scheme 2.23. [2+2+2] cyclotrimerisations were attempted using 23 to form oxepinopyridine scaffolds. 
It was hypothesised that the lack of reactivity could be attributed to the nature of the third ‘pair’ 
component. Thus, using the same reaction conditions, phenyl isocyanate was employed, 
replacing benzonitrile, to generate bicyclic pyridinones 30 and 31 (Scheme 2.24). However, 
following this procedure once more only a complex mixture was observed when using both 26 
and 27. 
 
Scheme 2.24. Attempts toward the synthesis of pyridinones 30 and 31. 
Literature observations suggested that terminal alkynes can display reduced activity compared 
to substituted alkynes when they are exposed to [2+2+2] cyclotrimerisation reactions. Reports 
by Nicolaus et al.218 demonstrated that when similar oxygen-linked substrates were subjected 
to cyclotrimerisation conditions, methyl-substituted alkynes could be utilised to form the 
aromatic products, where the terminal alkynes failed (Scheme 2.25). In addition to changing 
the R substituents, this methodology was shown to tolerate a wide range of different substituted 





Scheme 2.25. [2+2+2] cyclotrimerisations using methyl-substituted alkynes.218 mW = microwave. 
Inspired by these reports, an alternative approach was proposed utilising substituted alkyne 
derivative within the [2+2+2] cyclotrimerization reaction. Thus, dibenzyl amino alcohol 18 was 
treated with 1-bromo-2-butyne to furnish internal alkyne 32 in good yield (Scheme 2.26). 
Pleasingly, upon subsequent subjection of 32 to Co catalysis and benzonitrile at 110 °C for 48 
hours, a single regioisomer 33, was isolated. 
 
Scheme 2.26. An alternative approach for the [2+2+2] cyclotrimerisations yielding scaffold 33. 
The formation of a single regioisomer during [2+2+2]-cyclotrimerisations had previously been 
rationalised by Boñaga et al.219 by considering the metallacyclopentadiene intermediate 
generated under the reaction conditions. In this manner, it was hypothesised that the increased 
steric clash between the phenyl and methyl substituents within intermediate of type 34 would 
be disfavoured. The poor yield of this reaction was attributed to decomposition of the starting 
material as a result of the forcing conditions required to promote the reaction. Nevertheless, 
considering the challenging nature of generating 7-membered rings compared to their 6- or 5- 
membered counterparts, in addition to the comparably low yields reported in the literature,218,219 
this result was still pleasing. Moreover, sufficient quantities of the compound were obtained to 
enable biological testing and it was envisioned that optimisation of this procedure could be 
achieved in the future, if required. 
The regiochemistry of 33 was established through means of HMBC 2-D NMR spectral analysis 
whereby coupling was observed between the single proton within the pyridine moiety (H7) to 
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those within the pendant phenyl ring (H8 and H9), in addition to the methylene adjacent to the 
quaternary centre (H5) (Figure 2.7). Furthermore, only coupling between the methyl protons 
(H14) to the quaternary carbons (H13 and H15) was observed. This evidence was further 
corroborated by the upfield shift of both the 1H peak of H7 and 13C peaks for C7, compared to 
the down field shift of C13 due to the differences in proximity from the deshielding nitrogen 
nucleus. 
 
Figure 2.7. 2-D HMBC analysis enabled determination of the regiochemistry of 33. 
Amine deprotection 
With 22, 23 and 33 oxepane scaffolds in hand, it was thought necessary to investigate the 
potential of scaffold deprotection to reveal the free primary amine to exemplify its use as a 
fragment exit vector. Previous efforts to remove the benzyl group from 35 to generate 36 
conducted by Dr. Natalia Mateu concluded that hydrogenolysis via the use of H-Cube 
apparatus at room temperature could be the optimum conditions capable to affect this 




Scheme 2.27. Previous success in N-benzyl removal was observed by Dr Mateu. However, this route 
proved unsuccessful for 22 and 33. 
Thus, both 22 and 33 were subjected to identical conditions (Scheme 2.27, B), however, no 
evidence of benzyl removal was observed with only starting material or a complex mixture 
observed in both cases. Moreover, it was hypothesised that alternative forcing conditions could 
result in undesirable loss of the alkene moiety within 22. Considering these findings and the 
difficulties experienced in removal of the N-Boc group from 24, an alternative strategy to enable 
modification at this position was devised. 
Alternative N-Acyl substituents 
To this aim, it was instead thought an alternative non-removable N-substituent, such as an 
acetamide, could be incorporated at this position. It was envisaged that in turn this functionality 
could be exploited as a fragment growth vector, if required upon the identification of a hit by 
means of biological testing. Accordingly, the N-acetamide variant of ester 37 was synthesised, 
followed by reduction to yield the key alcohol building block 38 (Scheme 2.28). 
 




Metathesis cascade strategy 
With 38 in hand, the identical alkylation-metathesis-Diels-Alder synthetic sequence developed 
previously was then explored (Scheme 2.29). Pleasingly, alkylation with allyl bromide 
proceeded smoothly, affording enyne intermediate 39 in good yield. Subsequent treatment of 
39 to Grubbs-II provided 40 in moderate yield, followed by reaction with N-methyl maleimide 
to generate scaffold 41 in an 85:15 ratio of endo product diastereomers (determined by crude 
1H NMR analysis). In this case, whilst both isomers were observed, due to the scale of the 
reaction and difficulties in separation of the diastereomers during purification, insufficient 
quantities of the minor diastereomer were isolated for full characterisation. Importantly, the 
major diastereomer was isolated in sufficient quantities for biological testing. 
 
Scheme 2.29. The metathesis-Diels Alder sequence using 38 to afford 41. 
In an analogous fashion to 22 and 23, nOe studies indeed proved fruitful in the determination 
of the relative positions of the substituents (Figure 2.8). It was found that within the nOe 
spectrum of 41, interactions were observed between the two protons of the newly formed 
stereocenters (Ha) and (Hb) indicating a cis relationship and between Ha and Hc, indicating 
the presence of the endo product. The relative orientation of these stereocenters to the 
remainder of the molecule could also be determed through the observed nOe interactions 




Figure 2.8. The NOESY 2-D spectra for diastereomer 41. 
[2+2+2] cyclotrimersiation strategy 
Satisfied by the success of the N-Acetamide strategy within the above route, the corresponding 
[2+2+2] methodology was hence investigated. To this end, 38 was alkylated with 1-bromobut-
2-yne, furnishing the internal alkyne 42 in good yield (Scheme 2.30). Subsequent subjection 
of this intermediate to the same Co-mediated [2+2+2] conditions, utilising benzonitrile as the 
third alkyne component, yielded fused pyridine scaffold 43. In a similar fashion, only one of the 






Scheme 2.30. The same [2+2+2] methodology was applied to 42 forming the fused oxepine 43. 
Analogous to the dibenzyl analogue 33, the regiochemistry of 43 was established through 
means of HMBC 2-D NMR spectral analysis, where the same evidence was utilised to 
determine the regiochemistry. 
Methodology expansion 
Due to the novelty of the fused-oxepane scaffolds generated using this route, it was envisioned 
that versatility of this methodology could be exploited to construct alternative challenging 
architectures in an efficient manner. Indeed, partially saturated heteroaromatic motifs have 
been of recent interest151 and remain important architectures to develop modular synthetic 
routes toward. These initial findings therefore formed the basis of a M.Sci project undertaken 
by Ben Mackworth (Spring Group) investigating the expansion of this methodology (Scheme 
2.31). 
To simplify the synthesis, it was proposed that the quaternary centre could be removed from 
the starting substrate, allowing the key intermediate to be constructed from commercially 
available materials in only one step. It was anticipated that modification of the linker length 
would enable the formation of five, six and seven membered fused cycles, whilst the use of 
both unsubstituted and substituted alkynes within the starting material would result in the 
incorporation of both mono- and di-substituted pyridine rings. Furthermore, installation of a 
nitrile within the building block would allow the construction of pyrimidine scaffolds. Research 
in this project is on-going within the Spring group, continued by Edward Ou (Spring Group) as 




Scheme 2.31. The proposed extension of the [2+2+2] methodology for the formation of multiple novel 
partially saturated architectures. 
2.3.2.2 Investigations into N- and O- pairing via pathway B 
Satisfied by the scope of pathway A, we next sought to explore pairings between the hydroxyl 
and alkyne motifs within I, following pathway B (Figure 2.9). It was envisioned this could be 
achieved in a similar manner to the exploration of pathway A - either through direct cyclisation 
or attachment of a pendant pairing functionality to generate additional scaffold diversity. 
 
Figure 2.9. Subsequent investigations into pathway B were explored. 
Direct intramolecular cyclisations 
With the presence of both nucleophilic (hydroxyl and nitrogen) and electrophilic (C-X and 
carbonyl) moieties within the N-Boc amino alcohol 7, it was envisaged that these functionalities 
could be exploited to form quaternary oxazolidinone 45, or aziridine 46 motifs through two 
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different intramolecular reactions (Scheme 2.32, A). Both oxazolidinone and aziridine motifs 
represent important medicinal chemistry functionalities, derivatives of which can be found 
within both bioactive molecules reported in the literature, (Scheme 2.32, B). 220–223 
 
Scheme 2.32. A) quaternary oxazolidinone and aziridine formation through intramolecular reactions. B) 
examples of bioactive molecules containing these motifs. 
It was proposed that by considering the Boc-protecting group as a coupling partner, 
oxazolidinone 45 could be furnished starting from 7 through the nucleophilic attack of the 
hydroxyl to the carbamate moiety (Scheme 2.33). Thus, upon treatment with t-BuOK, the 
cyclisation between the nucleophilic hydroxyl group and the carbonyl was promoted, affording 
constrained carbamate 45 in a moderate 67% yield. 
 
Scheme 2.33. Formation of the quaternary oxazolidinone 45. 
Alternatively, it was hoped that conversion of the hydroxyl within 7 to a suitable leaving group 
would promote N-substitution at the α-carbonyl centre, forming 46. Thus, initial work sought to 
investigate suitable methods to construct the aziridine moiety (Table 2.1). Firstly, a two-step 
procedure was trialled in which 7 was first transformed to a mesylate intermediate and 
subsequently subjected to t-BuOK to mediate the cyclisation (Table 2.1, Entry 1). 
Intramolecular-Mitsunobu reaction224,225(Table 2.1, Entry 2) via a phosphonium intermediate 
was also trialled, however in both cases only a poor yield of 46 was achieved. A literature 
search highlighted a simple alternative approach using tosyl chloride and potassium hydroxide 
in a one-pot process for the synthesis of aziridines.226 Gratifyingly, applying this methodology 
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to quaternary substrate 7, aziridine 46 was obtained in a pleasing 78% yield (Table 2.1, Entry 
3). 
 
Entry Conditions R Yield 
1 
i. MsCl, Triethylamine, CH2Cl2, 0 °C then 40 °C, 
4 h 
ii.  t-BuOK THF, r.t., 20 h 
Ms 13% 
2 PPh3, DEAD, THF, r.t. then 50 °C, 5 h PPh3 39% 
3 TsCl, KOH, Et2O, 40 °C, 20 h Ts 78% 
Table 2.1. Three different conditions were trialled in attempts to form aziridine 46. DEAD = 
diethyl azodicarboxylate. 
Further scaffold expansion via alkyne derivatisation 
The pluripotent nature of the terminal alkyne functional handle present within both 45 and 46 
prompted the hypothesis that this motif could be utilised in post-pair derivatisations to generate 
additional biologically relevant nitrogen heterocycles (Scheme 2.34). Examples of such 
transformations include the 1,3-dipolar cycloaddition between 45 and a suitable azide to form 
either a 1,4- or 1,5- triazole in a regioselective manner or alkyne-amide pairing. Such 5,5-linked 
scaffolds are analogous to those found in antibacterial analogues of Linezolid221,227 and in fact 
those found in BACE-1 inhibitors,228 demonstrating the biological relevance of such 
architectures. 
 
Scheme 2.34. Other potential post pair reactions using the alkyne motif to generate novel restricted 
small molecules. Het = heterocycle. 
To this aim, upon exposure of 45 to azidobenzene in the presence of CuSO4·H2O and sodium 
ascorbate, 1,4- triazole 47 was furnished in a 75% yield (Scheme 2.35). Alternatively, utilising 
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methodology developed by Nicolai et al.229 the fused 5,5-oxazolidinone 48 could also be 
generated. This was achieved through a two-step procedure in which the terminal alkyne was 
first converted to a vinyl iodide via radical-mediated in situ formation of HInCl2. Subsequent 
subjection of this intermediate to conditions developed by Buchwald230 to initiate amide 
vinylation afforded 48 albeit in low yield. Importantly, within both the scaffolds derived from 45, 
fragment growth vectors could be envisaged through modification of the azido substituent used 
in the triazole formation, or alternatively through modification of the alkene moiety within 48. 
 
Scheme 2.35. Modification of 45 via diversification of the alkyne moiety  to give 47 and 48. DIBALH = 
Diisobutylaluminium hydride. 
With exemplifications of 45 in hand, we next sought to investigate 1,5-triazole formation, 
instead using the alkyne within 46 (Scheme 2.36). Indeed, heating 46 with Cp*Ru(COD)Cl231 
and ethyl 2-azidoacetate afforded the substituted aziridine 49, albeit in a modest 42% yield. 
To exemplify the versatile nature of introducing alternative functionalities at this position benzyl 
2-azidoacetate was employed under the same reaction conditions affording 50 in an excellent 
95% yield. 
 
Scheme 2.36. Transformation of aziridine 46 into 1,5-triazoles 49 and 50 via ruthenium-catalysed 




Acylation strategies for the formation of morpholinone motifs using pathway A 
In addition to direct cyclisations that could be inflicted upon 7 we were also interested in 
exploring the incorporation of additional reactive functionality to the substrate following a 
traditional build/couple/pair DOS approach. The presence of both amine and hydroxyl 
nucleophiles within 7 prompted the idea that acylation of either the nitrogen or hydroxyl with 
chloroacetyl chloride would allow the formation of two distinct morpholinone motifs in a 
regioselective manner. This could be achieved via either (i) O- acylation followed by N-
mediated cyclisation to give 53 or vice versa (ii) N-deprotection and acylation followed by O-
mediated cyclisation to give 54 (Scheme 2.37). 
 
Scheme 2.37. The proposed N- or O- acylation, followed by ring closure to form morpholinones 53 and 
54. 
Accordingly, subjection of 7 to 1.2 equivalents of chloroacetyl chloride, in the presence of 
triethylamine afforded 51 in a good yield (Scheme 2.38). Then, TFA–mediated deprotection of 
the Boc-protecting group, followed by the exposure of the resulting TFA salt to an excess of 
triethylamine promoted the ring closure to afford the morpholin-2-one 53 in 76% yield over two 
steps. 
 
Scheme 2.38. Synthesis of morpholin-2-one 53. 
Similarly, the alternative regioisomer of 54 could also be furnished in a two-step fashion 
(Scheme 2.39). This was achieved through firstly Boc group deprotection under acidic 
conditions, revealing the free amine in situ, followed by N-acylation via the addition of 
chloroacetyl chloride and excess base. Following the isolation of 52, the resultant intermediate 
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could then be cyclised through the addition of t-BuOK as a base, promoting intramolecular 
substitution to afford the desired morpholin-3-one 54 in a good overall yield. 
 
Scheme 2.39. The synthesis of morpholin-3-one 54. 
Furthermore, analogous to our previous examples (see Scheme 2.35), it was envisaged that 
the terminal alkyne handle within these scaffolds would provide the opportunity for further 
rigidification and/or scaffold expansion to furnish additional medicinally relevant heterocycles 
(Scheme 2.40). Thus, it was proposed that intramolecular cyclisation of the alkyne with the 
preinstalled amide functionality within 54 could be used to generate fused scaffold 55. Indeed, 
using the same reaction conditions as for the formation of 48, the 6,5-bicyclic scaffold 55 was 
isolated albeit in a low yield. Unfortunately, however, attempts to modify the alkyne within 53 
and 54 using Click chemistry proved unsuccessful using both Ru- and Cu- catalysed methods. 
 




2.4 The complete DOS library  
In addition to the synthetic efforts described herein, research carried out by Dr. Natalia Mateu 
(Spring Group) resulted in the synthesis of a further 28 compounds via investigations into utility 
of the amino ester 4 directly within a DOS strategy (data not shown).232 In total, 31 structurally 
diverse compounds were constructed (Figure 2.10). The resultant combined library featured a 
broad range of heterocyclic scaffolds, polar and medicinally relevant motifs and the key N-
substituted quaternary centre throughout. Importantly, the efficiency of the DOS approach was 
maintained since no more than five (and an average of only three) synthetic steps were 
required to access each scaffold starting from the amino ester 4. 
 
Figure 2.10. The full library of compounds synthesised from amino ester 4. Compounds in black 
synthesised by Dr. Mateu. The synthesis of compounds in blue is described in this thesis. 
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Furthermore, through these joint efforts, the utility of the alkyne within several scaffolds was 
exemplified via diversification of five scaffolds to give nine additional compounds. This included 
either a Cu-mediated 1,4- substituted triazole formation, Sonogashira reaction to produce 
substituted alkynes, Pd-mediated reduction to an alkyl chain, or Ru-promoted regioselective 
1,5- substituted triazole formation (Figure 2.11, see appendix for structures). 
 
Figure 2.11. Exemplification of additional viable alkyne modifications. 
Importantly, whilst the library was synthesised in a racemic manner for screening purposes, a 
flexible asymmetric route to access both (R)- and (S)- enantiomer of the amino ester was also 
developed by Dr. Mateu (Scheme 2.41). In this manner, upon the identification of a screening 
hit the desired enantiomer of a given library member could be synthesised, demonstrated 
through the synthesis of (R)-71 from (R)-4.232 
 
Scheme 2.41. The asymmetric route to (R)-4 developed by Dr Mateu and demonstration of the synthesis 




2.5 Cheminformatic assessment of the DOS library 
2.5.1 PMI analysis 
With the DOS library in hand, focus was subsequently placed on investigating computational 
methods of assessing the diversity of the library. PMI analysis is commonly adopted to 
investigate the 3-dimensional molecular shape diversity of a given compound collection.233 
This technique requires the computation of the normalised ratios of principal moment of inertia 
(npr1/npr2) for each molecule, which are plotted on a two-dimensional triangular graph. The 
three vertices of the graph represent the three extreme shapes of rod, disk and sphere and 
therefore allow assessment of the 3-dimensionality of a given collection. 
PMI analysis of the DOS library was conducted using the Molecular Operating Environment 
software package 2012.10 from the Chemical Computing Group (see Appendix for details). 
This data highlighted the compounds access a broad region of the molecular shape space with 
rod to spherical-like features and few disk-like compounds (Figure 2.12). Furthermore, when 
considering the boundaries of sp2-rich ‘flatland’ as compounds with npr1 + npr2 < 1.1, as 
proposed by Morley et al.,144 pleasingly only 7% of the DOS library appeared within this region 
further highlighting the 3-D nature of the molecules. 
 
Figure 2.12. PMI plot analysis of the DOS library (blue circles). Dashed line represents npr1 + np2 = 
1.1 and the boundary of flatland.144 
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In addition to computing values for the synthesised DOS library, it was thought that virtual 
enumeration could be utilised to ‘construct’ an analogous collection whereby the phenyl 
quaternary centre had been installed throughout. Subsequent PMI analysis and comparison 
with the methyl collection would allow conclusions to be drawn on the effect of changing the 
quaternary centre on the molecular shape diversity. Accordingly, the fragments were 
enumerated, and as expected upon modification of the quaternary centre, PMI analysis indeed 
demonstrated that the molecular shape distribution was in fact altered (Figure 2.13). In this 
case, the Ph DOS library tended toward the right hand more spherical region of the plot, whilst 
importantly now 0% of the fragments appeared within flatland. Since molecular shape can be 
considered an essential factor in determining protein binding, it could therefore be 
hypothesised that the installation of the modifiable quaternary centre throughout the DOS 
library could serve as an important tool to modifying molecular shape and therefore the binding 
of a compound upon hit identification. 
 
Figure 2.13. PMI plot comparing the DOS library and virtual Ph DOS library. 
Finally, comparisons were then made between the commercially available Maybridge ‘Rule of 
Three Diversity Core Collection’ fragment set comprising 1000 compounds and the two DOS 
libraries (Figure 2.14). Staggeringly, using the same analysis it was found that 72% of the 
commercial library lay within the flatland region of the plot, demonstrating the 
overrepresentation of flat structures within commercial fragment collections. Moreover, upon 
visual inspection of the Maybridge library, only two compounds were found to contain a N-
substituted quaternary centre, exemplifying the underrepresentation of this motif within 
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screening collections. These results further highlight the success of the DOS library in terms 
of both molecular shape diversity and the incorporation of this key quaternary motif within novel 
screening libraries. 
 
Figure 2.14. PMI plot analysis of the DOS library (blue circles), Ph DOS library (red squares) and the 
Maybridge commercial fragment set (green triangles). 
2.5.2 Physicochemical property analysis 
With the chemical space constraints of FBS in mind, computation of the physicochemical 
properties relating to commonly adopted guidelines within the field115,121,234,235 were considered. 
Accordingly, the compounds were analysed for the following properties: SlogP (lipophilicity), 
molecular weight (MW), polar surface area (PSA), number of hydrogen-bond acceptors (HBA), 
number of hydrogen-bond donors (HBD), HAC, number of rotatable bonds (RBC), number of 
chiral centres and fraction aromatic (the number of aromatic atoms expressed as a fraction of 
the total number of heavy atoms). The distribution of the data is displayed in a series of 
histograms in Figure 2.15, A-I. 
When considering the core RO3 guidelines (MW < 300, clogP < 3, HBD/HBA < 3), pleasingly, 
only 10% of the library had a marginally higher SlogP than three (Figure 2.15, A) only eight 
compounds had a MW greater than 300 (Figure 2.15, B), and all members were in-line with 
HBD rule (Figure 2.15, E). When considering the number of HBA, however, a significant 
number (28%) had more than the upper limit of three HBA (Figure 2.15, D). Despite these 
55 
 
findings, overall using these principles as a guideline the library showed acceptable properties 
for use within FBS. 
 
Figure 2.15. Histograms showing the distribution of predicted physicochemical properties for 
compounds in the DOS library. 
However, when considering the supplementary rules of PSA < 60 and RBC < 3 (Figure 2.15, 
C and G), some notable discrepancies were found. Namely, these included a PSA of > 60 for 
56 
 
all but one of the library members, and 30% of the library with a RBC > 3. Whilst not fatal to 
the application of the library within a FBS setting, when considering upon hit identification, 
these properties should be considered to improve the oral bioavailability236 and/or the blood-
brain barrier penetration237 of the resulting compounds during the fragment elaboration 
process. 
To enable comparison of the DOS library with those calculated for the Maybridge and 
Chembridge151 commercial collections, the mean values of the physicochemical properties 
were subsequently calculated (Table 2.2). In general, the DOS library compared near equally 
with both commercial collections. In addition to the PSA and RBC, the mean HAC lay 
marginally outside the Astex guidelines. Nevertheless, importantly an increased number of 
chiral centres and decreased fraction aromatic were observed. Overall, these results were 
pleasing since the primary aim of the project was to incorporate an increased fraction of sp3 
atoms and a NSQC motif within a fragment library to address deficiencies within commercially 
available libraries, a hypothesis which was also validated through these comparisons.  
Property [a] 
Guidelines  Maybridge 'RO3' 
Chembridge 
RO3 Astex  DOS  collection 
SlogP <3 0-2 1.37 1.92 1.31 
MW <300 140-230 237 182 222 
PSA <60 - 120.7 104.7 53.9 
HBA <3 <3 2.63 1.83 1.81 
HBD <3 <3 0.78 1.01 1.04 
HAC - 10-16 16.8 12.5 15.5 
RBC <3 <3 3.18 1.99 3.20 
Chiral centres - 0-1.5 1.10 0.14 0.27 
Fraction Ar - - 0.29 0.52 0.42 
Table 2.2. Mean values of the DOS fragment library compared to the Maybridge RO3 core collection 
and Chembridge commercially available fragment libraries. Green = within guidelines, yellow = values 
at the extremes of the guidelines, red = values outside the guidelines. 
Importantly, in a similar vein to the application of Lipinski’s RO5, several discussions within the 
literature have emphasised the application of RO3 as indeed only a guideline rather than a 
definitive boundary.235 Certainly, as screens conducted by Köster et al.238 have demonstrated, 
non-compliant libraries can still prove fruitful in FBS campaigns, providing high hit-rates and 
enabling the identification of additional chemo-type diverse hits that would otherwise have 
been missed through stringent application of the RO3.  
Furthermore, as discussed in the Practical Fragments Blog239 and reinforced in a paper 
published by Hann,240 it is often considered that molecular obesity should be the major 
consideration for both fragment-based drug discovery (FBDD) and traditional drug discovery 
programs. In this case, the importance of MW and lipophilicity across a fragment library could 
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be considered the pivotal constraints for shaping the starting points of these campaigns. 
Finally, as discussed previously, larger fragments can be useful when targeting challenging 
biological targets such as PPIs.127 Consequently, the application of the DOS library in question 
can therefore be further justified and it is envisioned this library will serve as an excellent 
complementary collection to those already available. Accordingly, in line with the second 
objective, we next sought to investigate the biological utility of these fragments and 







3 Results and discussion: Investigations into the 
application of N-substituted quaternary carbon fragment 
libraries 
3.1 Background 
3.1.1 X-ray crystallography-based methods for fragment screening 
Among the many different methods utilised to conduct fragment screening, X-ray 
crystallography remains a well-established technique within the field of FBS in both academic 
and industrial settings. This can be attributed to the powerful nature of this technique to 
simultaneously acquire both hit identification and structural information for a given molecule 
bound to a target of interest.110 In the early phases of FBS, X-ray crystallographic methods of 
screening proved fruitful134,241 and the technique was used extensively, resulting in many 
successful medicinal chemistry programs.133,136 Over time, however, presumably due to the 
low-throughput nature of this technique, faster and higher-throughput technologies such as 
SPR or NMR were often employed to conduct primary fragment screens or utilised as pre-
filters to identify smaller numbers of compounds to be screened via X-ray methods.115,120,242,243 
Nevertheless, although effective it has been found that these biophysical methods can result 
in a large proportion of false negative results, vitally highlighting that fragment hits can evade 
detection by these methods when compared to X-ray based fragment screens.244 Thus, the 
powerful ability of X-ray crystallography to identify fragments across a range of binding 
affinities, including very weak binders should not be overlooked. 
3.1.2 The XChem screening platform 
Recent developments in the foundational technologies within this screening paradigm such as 
third generation synchrotrons and the advancement of high-throughput technologies has 
however reinstated this methodology as a feasible and well-used tool for primary FBS.115,245–
247 Over the last few years the von Delft group have pioneered the development of a cutting-
edge high-throughput fragment-screening platform, XChem, which enables rapid screening of 
thousands of compounds within only a 1-2-week period via X-ray crystallographic methods 
(Figure 3.1).248 Based at the i04-1 beamline at the Diamond Light Source synchrotron (DLS) 
in Oxford, importantly this platform provides the opportunity to conduct screens in a singleton 
format, as opposed to cocktails (solutions containing 2-10 fragments).241,249 The XChem 
strategy of expediating the fragment screening protocol relies on the implementation of several 




Figure 3.1. A comparison between conventional and XChem methods for fragment screening.  
Adding compounds to crystals 
Using Formulatrix® plate imagers, images of the crystal plates can be viewed over 1-, 4-, 7-
day and weekly time intervals to monitor the crystal growth in each well. Through subsequent 
application of TexRank algorithm developed by Tsing Ng et al.250 the resulting images are 
ranked according to their likelihood of containing crystals for manual inspection. During this 
process, the desired crystal(s) and precise location within the well for the soaking event to 
occur are then chosen, denoted by x-y coordinates given from the centre of the well (Figure 
3.2). 
 
Figure 3.2. Clicking a specific location on the crystal image in TexRank records the x-y coordinates for 
the crystal soaking event. 
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An Echo® 550 (Labcyte, Inc., Sunnyvale, California, USA) acoustic liquid handler is used for 
dispensing compounds in singleton format onto the required crystal wells, allowing for 
compound diffusion into the protein binding sites through the solvent channels within the 
crystal lattice.251 Aside from significant speed advantages (the soaking of 1000 crystals within 
only 10 minutes), the accuracy of this machinery results in the precise shooting of 2.5 nL 
aliquots of compound solution to specific locations within a crystal well. As a result, compound 
solutions can be accurately delivered to a specific site (pre-defined using TexRank) as to avoid 
crystal breakage. 
Crystal harvesting 
Whilst the crystal harvesting process is conducted manually, the employment of the Shifter 
(robotic x-y staging linked to a microscope)252 significantly increases the output of this process. 
Utilising robot controlled mechanical navigation of the crystal plate under the microscope, the 
user is automatically sequentially directed to the pre-selected crystal wells required for 
harvesting where each crystal can be extracted using Mitegen loops. The implementation of 
this technology has been particularly effective, enabling the harvesting of typically >100 
crystals per hour, even by an untrained user. Upon cryogenic cooling, these samples can then 
be stored in pucks within dewars until data collection is required.  
Data collection 
Near continuous data collection has been achieved within the XChem platform through the 
implementation of a BART robot, facilitating the automated collection of 700 crystals within a 
24-hour period, allowing for fully unattended beamtime.253 
Hit finding 
The analysis of X-Ray diffraction data to generate crystal structures is non-trivial, requiring the 
co-operation of several software packages to complete each stage of the process. In response 
to this challenge, Krojer et al.254 developed the XChemExplorer (XCE) tool to provide a 
graphical workflow to enable the seamless transition between the tools required to process, 
solve and refine protein-ligand structures. This interface retrieves information stored within the 
corresponding SQLite database, SoakDB, which collates the data collected during the previous 
four stages for a given crystal. Following the workflow, diffraction data can be retrieved from 
auto-processing pipelines using the Datasets tab, initial maps and ligand constraints are 
generated using DIMPLE, AceDRG and RDkit in the Maps & Restraints tab, whilst the Hit 
Identification and Refinement tabs are utilised to identify binding fragments and generate the 
corresponding crystal structures through the employment of the Pan-dataset density analysis 




Figure 3.3. The XCE workflow interface comprising of four tabs: Datasets, Maps & Restraints, Hit 
Identification and Refinement.  
PanDDA 
The detection of electron density resulting from weakly binding fragments is vastly complicated 
since it is often challenging to identify such changed states due to the presence of fractionally 
present molecular states within the ground state of a protein crystal form. To overcome this 
challenge the PanDDA algorithm was developed by Pearce et al. in 2017.255 This tool utilises 
the statistical analysis of density distributions within ~30 hit-free crystals to build an accurate 
ground state model, which can then be subtracted from the bound state data to elegantly reveal 
changes in electron density (Figure 3.4). As a result, the detection of these changed states, 
i.e. ligand binding, is vastly simplified. This provides an additional advantage when 
implemented within the XChem platform, since only the changed state events identified by the 
algorithm are required for manual inspection and ligand modelling/refinement. Thus, the 
application of this tool within the XCE interface greatly streamlines the process of hit 





Figure 3.4. PanDDA map highlighting changed states of electron density (green and red) compared to 
the ground state (blue), simplifying the identification of a bound fragment hit.  
XChem success 
Since its development in 2015, the XChem Platform has facilitated the screening of over 60 
protein targets and enabled the identification of >1000 fragment hits, with users spanning both 
academia and industry. Moreover, this system has proven successful against a variety of 
protein targets, including those related to epigenetic gene regulation,248,256 oncology257 and 
neurodegenerative disease.258 Thus, through the ability to identify particularly weak fragment 
binders and leverage structure-based design, this technology provides a powerful strategy to 
tackle the FBS of challenging targets.  
In the early stages, commonly commercially available fragment collections such as Maybridge 
(see Chapter 2) were employed within this platform. Whilst these proved fruitful, due to the 
deficiencies of such libraries in terms of 3-dimensionality, novelty and fragment growth vectors, 
the XChem team had sought to supplement these collections.  
3.2 XChem screening of fragment-like DOS libraries 
In 2017, a collaboration was established between the Spring group and XChem to enable the 
routine screening of 3-D fragments derived from DOS. Thus, considering the excellent 
properties of the NSQC compounds described in Chapter 2, these fragments were the first to 
be incorporated into the pipeline. This library was created using 250-500 mM stock solutions 
of the compounds in d6-DMSO in line with the XChem standard protocols. To initially validate 
the utility of this library within this platform, a proof-of-concept fragment screen was conducted. 
3.2.1 CFI25 
Cleavage factor 25kDa (CFI25, also known as CPSF5 or NUDT21), a promising oncology target 
currently under research by the Huber and von Delft groups in the Structural Genomics 
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Consortium, Oxford. CFI25 is a member of the Nudix superfamily of hydrolases, characterised 
by the presence of the characteristic Nudix box generated by a conserved 23-residue 
sequence, which is in turn incorporated into a distinctive α/β/α fold motif. These so called 
‘house-keeping’ proteins function to catalyse the hydrolysis of a diverse range of Nucleoside 
diphosphates linked to other moieties, X, Nudix substrates including nucleoside triphosphates, 
capped RNA and dinucleotide coenzymes. Importantly, however, CFI25 is devoid of hydrolase 
activity due to the absence of two key glutamate residues required for catalysis, instead 
replaced by Leu124 and Ile128.259,260 
The NUDT21 gene encodes the CFI25 protein, which is a sub-unit of the pre-mRNA cleavage 
factor Im (CFIm) component of polyadenylation machinery (Figure 3.5).261 In its entirety, CFIm 
consists of two CFI25 units in a heterotetramer with either CFI59 or CFI68. Importantly, it is 
thought that within this complex the CFI25 component is responsible for UGUA RNA motif 
recognition and binding, whilst the remaining CFI59 and CFI68 domains facilitate RNA looping 
and enhance the RNA binding due to the presence of an RNA recognition motif.262 Around 19 
other complexes and proteins are involved in the remainder of the polyadenylation 
machinery.263  
 
Figure 3.5. A subsection of the metazoan polyadenylation machinery composed of ~20 proteins and 
complexes. The CFI machinery (in pink) is formed by two units of CFI25 (responsible for UGUA 
recognition) and either CFI59 or CFI68. Adapted from reference.263 
The crystal structures of the free and diadenosine tetraphosphate (Ap4A, a native Nudix 
hydrolase substrate264) complex of CFI25 were published in 2008 by Coseno et al.260 More 
recently, Yang et al.265 similarly disclosed the crystal structure of CFI25 in complex with 
UUGUAU RNA sequence. In both instances, interaction of these substrates with Arg63 was 
identified as crucial for binding between with the phosphate component of Ap4A or the U3 
element of the RNA sequence. Moreover, the significance of this residue was further 
demonstrated through mutation of this residue to Serine, which was shown to almost entirely 
eradicate RNA binding.265 
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Importantly, studies have demonstrated the role of the CFIm machinery in the alternative 
polyadenylation (APA) of mRNA, an important mechanism involved in gene regulation.263 
Indeed, the CFIm complex has been shown to play a key role in determining the size of the 3’ 
untranslated region of mRNA leading to different mRNA isoforms by mediating APA.266 More 
specifically to the significance of CFI25, RNA interference knockdown of CFI25 has revealed a 
significant number of genes with shortened 3’ untranslated regions, which Masamha et al.267 
were able to demonstrate results in the increased expression of several oncogenes, ultimately 
affecting both tumour growth and tumour size in glioblastoma cells.  
In addition to its potential role in cancer, studies by Gennarino et al.268 recently demonstrated 
the relationship between CFI25 and the post-translational gene regulation of the mRNA 
encoding methyl CpG-binding protein 2 (MeCP2), an important protein involved in brain 
function and the development of neuropsychiatric disease. Through the study of 
lymphoblastoid cells of patients exhibiting copy number variants of the NUDT21 gene and 
neuropsychiatric syndromes, significantly, differential levels of the MeCP2 protein were 
identified. Moreover, siRNA-mediated knockdown of NUDT21 resulted in adjustment of these 
levels to those of the wild-type or healthy individuals. Ultimately, the authors were able to 
attribute these findings to regulation in the expression of the short or long isoforms of the 
related mRNA by CFI25.268  
Despite these pivotal findings, however, to the best of our knowledge there are currently no 
literature small molecule chemical probes for CFI25. As a result, the identification of novel 
fragment hits for this purpose represented an exciting avenue of research to enable further 
investigations into the associated biology. 
X-Ray screening 
Due to the robust and replicable nature of CFI25 crystals, this protein was deemed amenable 
to fragment screening via the XChem platform in collaboration with the Structural Genomics 
Consortium. Thus, in July 2017 a fragment screening campaign was conducted against CFI25 
utilising the NSQC library. Upon analysis of the resulting PanDDA event maps, four X-Ray hits 
were identified (Figure 3.6). Importantly, as a result of the diverse nature of the DOS library 
these hits related to several different chemotypes, highlighting the potential of this collection 




Figure 3.6. The four hits identified during the XChem screen against CFI25. 
Superimposing the resulting crystal structures of these hits revealed three different fragment 
binding sites within the protein (Figure 3.7).  
 
Figure 3.7. An overlay of the crystal structures containing hits highlighted three different fragment 
binding sites. 
Binding site 1 hits 
Binding site 1 (BS1) was found to be the most significant with both NM450 and NM466, and 
within a single hydrophobic pocket formed by five residues; Leu53, Leu97, Ile128, Pro188 and 
Tyr191 (Figure 3.8, A). Of significant importance is the location of BS1 within Nudix box region 
of the protein (residues 109-131)260 highlighted by the role of Ile28 in the formation of the 
pocket. Contextualisation of this binding site through comparison to the binding site for the 
Ap4A260 and the UUGUAU RNA sequence265 between Thr101 and Ala61 revealed BS1 to be 
in close proximity, located at the back of the open cavity where these moieties bind (Figure 
3.8, B and C). Interestingly, comparison of the Ap4A, UUGUAU-bound structures with those 
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of the DOS fragments revealed a substantial shift in the location of Tyr191 in the latter case, 
resulting in an expanded lipophilic binding pocket.  
 
Figure 3.8. A) The hydrophobic pocket BS1 formed by Leu53, Leu 97, Ile128, Pro188 and Tyr191 
(orange sticks) in relation to the natural substrate binding location marked by Thr101 and Ala61 (white 
labels) and Arg63 (blue-grey sticks). B) Reported crystal structure of CFI25 in complex with Ap4A,260 
(green and red sticks) with the residues responsible for BS1 highlighted in orange. C) Reported crystal 
structure of CFI25 in complex with UUGUAU,265 with the residues responsible for BS1 highlighted in 
orange. 
Significantly, it was found that upon binding of NM450, this hydrophobic pocket was further 
extended in an open conformation, mediated through additional movement of Leu97 to 
accommodate the phenyl ring (Figure 3.9, dashed white line). It is worth mentioning that whilst 
the electron density for the phenyl and triazole components proved to be well defined, the 
pyrrolidinone portion was ambiguous. In this regard, determination of the enantiomer 
preference of the protein was not possible. Modelling of both enantiomers, however, revealed 
interactions could be made in both instances and thus it was hypothesised that the 





Figure 3.9. Crystal structures of A) NM450 (green sticks) and B) NM466 (purple sticks) within the main 
pocket of CFI25. In (A) the dashed white line demonstrates the closed conformation of the lipophilic 
pocket whilst in (B) the protein backbone for NM450 is shown in cyan and the white arrow highlights the 
significant loop shift between the two fragments binding. Dashed yellow lines represent polar 
interactions with the protein. 
The crystal structure of NM466 within CFI25, revealed the fragment to sit in an alternative 
binding mode to NM450. Here, the key hydrophobic pocket was found in the closed 
conformation, with the aromatic component instead binding in the position of the triazole ring 
of NM450 (Figure 3.9, B). This observation was corroborated through comparison of the 
corresponding binding pockets and backbone location, highlighting a significant loop shift 
between that observed in the binding of NM450 (highlighted in cyan) to NM466.  
Binding sites 2 and 3 
The second two binding sites, Binding site 2 (BS2) and Binding site 3 (BS3), represented two 
shallow grooves on the surface of the protein. During the screen, one fragment was identified 
as binding within each site (Figure 3.10). The binding of NM461 in BS2 was unexpected due 
to the similarity in structure to NM450, differing only through the quaternary heterocycle 
present. This result was not presumed to be an anomaly due to the replication of this binding 
event within the duplicate of run the screen. Instead, two potential hydrogen bonds between 
the Asp133 residue and oxazolidinone were believed to anchor NM461, whilst the aromatic 




Figure 3.10. Additional binders were identified to bind in two further sites within CFI25 A) NM461 within 
BS2 and B) SK351 within BS3. 
In the case of SK351, however, no polar contacts could be predicted between the fragment 
and the protein. In view of this and the location along the crystal contacts of the protein, this 
hit was deemed to be insignificant.269  
Importantly, these exciting results not only provided the opportunity to highlight the advantage 
of the DOS-derived libraries for analogue formation, but additionally served as initial starting 
points for lead-generation. Thus, two objectives were envisaged: (1) rapid multidirectional 
derivatisation of the hits to showcase the modular chemistry and explore the binding modes, 
followed by (2) screening of further analogues to provide hit validation.  
To address the first objective, it was anticipated that the amenability of the DOS chemistry 
toward multi-directional vector growth could be demonstrated via derivatisation to almost every 
functionality within NM450 (Figure 3.11). Specifically, in line with the structural data, it was 
thought these investigations could include modification of the benzene ring through 
substitution, variation in the bridging heterocycle, modification of the quaternary substituent 
and derivatisation of the pyrolidinone heterocycle via amide growth, α-alkylation and ketone 
modification. Moreover, it was also important to demonstrate the potential to access varied 




Figure 3.11. Potential structural modifications to NM450. 
The second objective of hit validation, however, was more challenging. Whilst X-Ray 
crystallography can be used to identify very weakly binding compounds, as discussed often 
issues can arise in the detection or validation of these compounds using orthogonal biophysical 
methods.244 Moreover, due to the novel and challenging nature of the protein in question, the 
development of these techniques was non-trivial. Initial attempts within the Huber group to 
characterise the eight hits using biophysical methods (SPR and an AlphaScreen) proved 
unsuccessful. Whilst, several of the fragments could in fact be detected (data not shown), 
inconsistencies in the results achieved with both techniques suggested further optimisation 
would be required to produce reliable and consistent results. Investigations into this and the 
application of additional techniques for this purpose is on-going within the Huber group.  
As an alternative initial hit validation strategy, the XChem platform had previously found 
success in validating initial X-Ray hits through the screening of related analogues. Following 
this procedure, a second round of synthesis was generally first conducted to generate small 
libraries of derivatives. Through screening of these libraries false positives could then be 
identified and true positives validated upon binding of related analogues, simultaneously 
providing structural binding information for subsequent medicinal chemistry explorations. Thus, 
the derivatives formed for the first objective would additionally serve as useful tools in this 
context.  
To exemplify this, analogues of NM450 were initially pursued due to the interesting binding 
mode observed. It is worth mentioning, that due to the lack of conclusive data regarding the 
stereochemistry of the bound fragment hit, a racemic synthesis of the corresponding 
analogues was initially pursued. 
3.2.2 Follow-up compounds to NM450 
Following the proposed synthetic plans (vide supra), firstly, it was envisioned that initial access 
to derivatives bearing aromatic substituent variation would serve as simple analogues that 
could be used to confirm the binding, whilst exploring the scope of several growth vectors. Due 
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to the presence of this moiety within an open pocket, it was anticipated that a variety of 
substituent vectors would be viable (Figure 3.12). Moreover, utilising the modularity of the DOS 
route, it was hoped that analogues of this nature could be easily generated through 
disconnection of the triazole ring to its constituent aromatic azide and heterocyclic alkyne 
components. 
 
Figure 3.12. The crystal structure of NM450 suggested substitution of the aromatic ring to be a viable 
at a range of positions. Disconnection at the triazole ring would enable rapid analogue synthesis. 
Computational modelling predicted both electron-withdrawing and electron-donating groups in 
ortho/meta/para-positions could be tolerated. Thus, ten commercially available aromatic 
azides were selected incorporating functionalities at different ortho/meta/para positions, in 
addition to variation in the size and polarity of the functionality (Figure 3.13).  
 
Figure 3.13. The substituted analogues chosen for synthesis. 
The original synthesis to NM450 involved acylation of amino ester 4 to give 77, followed by 
Dieckmann condensation and decarboxylation to yield alkyne 60.  In turn, subjection of the 
terminal alkyne within 60 to Cu-mediated regioselective 1,4-triazole formation using 
azidobenzene under standard click conditions afforded NM450 (Scheme 3.1).232 However, this 
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click reaction proved to not be reproducible upon variation of the aryl-azide and as a result an 
alternative synthetic route was designed. 
 
Scheme 3.1. Original synthesis to NM450 developed by Dr. N Mateu. 
It was hypothesised that alternatively, the aromatic substituents could be introduced at the 
previous step via click reaction of the linear acylated moiety 77. Subsequent cyclisation could 
then be achieved following the same procedure as previously established, to isolate the 
desired analogues of NM450 (Scheme 3.2). Furthermore, it was hoped that generation of the 
substituted intermediates of type 78, in addition to the fully cyclised compounds would be 
advantageous for biological evaluation to provide additional SBR datapoints. Thus, a gram-
scale synthesis of 77 was successfully conducted following the pre-established procedure. 
 
Scheme 3.2. The proposed route to afford multiple analogues for screening purposes. 
As an initial proof of concept, the click reaction of 1-azido-2-(trifluoromethyl)benzene with 77 
was trialled (Table 3.1, Entry 1). It is worth mentioning that a 1:0.9 ratio of alkyne to azide was 
selected to mitigate isolation of potentially explosive unreacted azide substrate. Accordingly, 
77 was subjected to standard Copper click reaction conditions, affording 79 in a good 69% 












R Yield Product 
1 1 0.9 o-CF3 70% 79 
2 1 0.9 o-Cl 69%* 80 
3 1 0.9 o-OMe 65% 81 
4 1 0.9 o-Me 12%* 82 
5 1 0.9 m-OMe 69% 83 
6 1 0.9 m-CF3 84% 84 
7 1 0.9 m-Cl 68% 85 
8 1 0.9 p-F 83% 86 
9 1 0.9 p-Cl 74% 87 
10 1 0.9 p-Me 66% 88 
Table 3.1. The Cu-mediated click reaction of 77 with ten substituted aromatic azides proceeded 
smoothly, except in the case of entry 4, generating 79 - 88. * = second batch of CuSO4·H2O added. 
Incorporation of ortho- chloride and methoxy substituents proceeded smoothly yielding 80 and 
81, however a significantly lower yield was obtained using 2-azidotoluene (Table 3.1, entries 
2-4). It could be hypothesised that this could have been a result of the diminished electron 
withdrawing effect induced by the methyl substituent relative to the -Cl and -OMe groups, 
reducing the nucleophilicity of the corresponding ortho azido functionality. Attempts to improve 
the yield via the addition of a further 20 mol% of Cu and increased reaction time proved in vein. 
Gratifyingly, however, the remaining six transformations all proceeded smoothly affording the 
meta and para substituted products 83 – 88 in moderate yields (Table 3.1, entries 5-10). 
Concurrently, investigations into the compatibility of this reaction using a flow reactor were 
initiated due to the potential to provide both a safer and faster route to access substituted 
triazoles of type 78.270 Preliminary efforts in this regard, however, had limited success. 
Next, compounds 79 – 88 were taken forward for cyclisation with the aim of affording the 
desired pyrrolidinone analogues 89 – 97 (Table 3.2, entries 1-10). Applying the standard 
Dieckmann condensation conditions followed by thermal decarboxylation indeed returned 
analogues 89 – 97 in good yields. Due to the lack of material isolated during the formation of 
82, no cyclisation was attempted and instead only 82 was retained for biological evaluation 







R Cyclisation Product 
1 79 o-CF3 64% 89 
2 80 o-Cl 51% 90 
3 81 o-OMe 62% 91 
4 82 o-Me NA NA 
5 83 m-OMe 78% 92 
6 84 m-CF3 74% 93 
7 85 m-Cl 66% 94 
8 86 p-F 73% 95 
9 87 p-Cl 62% 96 
10 88 p-Me 70% 97 
Table 3.2. Cyclisation of substrates 79 – 88 under standard Dieckmann conditions followed by 
decarboxylation to yield 89 - 97. 
Heterocycle analogues 
In addition to producing analogues of NM450 bearing variation in the aromatic substituents, it 
was envisioned that alternative bridging heterocycles could additionally be introduced, 
showcasing the versatility of the DOS route to introduce alternative moieties at this position. 
Indeed, variation in the position of heteroatoms within an aromatic cycle in such a manner is a 
commonly adopted technique within medicinal chemistry pursuits. Accordingly, it was expected 
this could be achieved utilising the pluripotent nature of the terminal alkyne present within the 
key building block to generate alternative heterocycles in a modular approach (Scheme 3.3). 
 
Scheme 3.3. The alkyne motif could be used as a pluripotent handle to generate alternative bridging 
heterocycles. 
In addition to the reactivity of alkynes with azides to form triazoles, chlorooximes have been 
used in a similar fashion, whereby under basic conditions a reactive nitrile oxide 1,3 dipole can 
be generated (Scheme 3.4).271 In turn, reaction of this species with a suitable alkyne under 
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either Ruthenium or Copper catalysis can produce 1,5- or 1,4- substituted isoxazoles, 
respectively, in a regioselective manner.272,273 In relation to the binding of NM450 within CFI25 
pocket, investigation into the binding mode of the fragment via the synthesis of both isoxazole 
isomers proved an interesting avenue of research. 
 
Scheme 3.4. The formation of a reactive nitrile oxide to generate 1,4- or 1,5- isoxazoles regioselectively. 
To this aim, alkyne 77 was subjected to Copper-mediated cycloaddition conditions274 to furnish 
the 1,4- substituted isoxazole 98 (Scheme 3.5). Following the pre-established procedure, this 
could then be cyclised to generate the analogue 99.  
 
Scheme 3.5. 1,4- regio selective isoxazole formation, yielding 99. 
As previously mentioned, it was hypothesised that the alternative 1,5-regioisomer of 101 could 
also serve as an interesting SBR data point. Consequently, following conditions developed by 
Grecian et al.,273 reaction of 77 under Cp*Ru(COD)Cl catalysis with α-chlorobenzaldoxime and 
base, 1,5-triazole 100 was isolated in good yield (Scheme 3.6). Finally, following the pre-
established cyclisation conditions 101 was afforded in good yield. 
 
Scheme 3.6. Ru-mediated formation of the 1,5-isoxazole regioisomer 100. 
Quaternary centre modifications 
With the crystal structure of NM450 in mind, it was hypothesised that the utility of the 
quaternary centre growth vector within NM450 could likewise be demonstrated. This 
functionality appeared to sit within a larger, more open pocket within the binding site (Figure 
3.9), and it was therefore envisioned that much larger substituents could be tolerated at this 
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position. With the phenyl amino ester already in hand (see Chapter 2), it was proposed that 
this could be utilised to generate the corresponding phenyl variant of NM450. Thus, amino 
ester  was acylated using the pre-established conditions, affording 102 in an excellent 94% 
yield (Scheme 3.7). Subsequent reaction under the Cu-catalysed click conditions then afforded 
103, whilst finally condensation followed by decarboxylation, delivered analogue 104.  
 
Scheme 3.7. Synthesis of 104, an analogue of NM450 bearing an alternative quaternary substituent. 
Since the prior aim of this research was to investigate the rapid synthesis of NM450 analogues 
for hit validation, further derivatives of this nature were postponed until validation of NM450 
binding had been acquired. It was anticipated, however, that following the demonstration of 
the viability of this procedure through the formation of 104, alternative functionalities could be 
indeed introduced following this route if required. 
Investigations into late-stage diversifications of NM450 
Finally, hypothesis-driven proposals of additional more 3-D modifications to the molecule 
based around the pyrrolidinone core were considered. Whilst the aromatic portion of the 
molecule was buried within the hydrophobic pocket, the pyrrolidinone core was found to be 
situated within a much larger channel providing scope for expansion across multiple growth 
vectors (Figure 3.14). Accordingly, it was envisaged that a range of transformations could be 
explored including amide derivatisation, ketone modification and growth from the enolisable α-
keto position to enable fragment growth. Importantly, to maintain synthetic efficiency we 






Figure 3.14. A) X-ray crystal structure of NM450 bound within CFI25, showing the pyrrolidinone within 
an open pocket. B) Potential fragment growth vectors of interest. 
Ketone modifications 
With the pluripotent nature of the ketone functionality within NM450 in mind, we hypothesised 
that several additional derivatives could be easily accessed via modification of this moiety. It 
was envisaged that this could be achieved following three different strategies: (1) α-alkylation, 
(2) ketone reduction or (3) ketone elimination (Scheme 3.8). 
  
Scheme 3.8. Investigating methods to modify the ketone functionality within NM450. 
Encouragingly upon treatment of NM450 with MeI under basic conditions the dimethylated 
species 105 was isolated, albeit in low yield (Scheme 3.8). Furthermore, subjection of NM450 
to sodium borohydride mediating reduction of the ketone functionality afforded a mixture of 
diastereomers of the resulting alcohol product 106 in almost quantitative yield. However, 
attempts to remove the ketone via mesylation followed by DBU-prompted elimination yielded 
only starting material with no evidence of the desired product 107 observed. It is envisaged 
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that on-going investigations into the applicability of differences bases could prove fruitful in this 
regard. 
We next considered extension of the molecule from the amide vector through the application 
of various amide arylation conditions to furnish 108 (Scheme 3.9). The JackiePhos ligand was 
developed in response to challenges associated with the N-arylation of secondary amides, 
substrates which often prove challenging with more conventional Buchwald-type ligands. 
During ligand development it was established that the specific substitution of the JackiePhos 
ligand increased the electrophilicity, whilst reduced the steric demands of the Palladium 
intermediate, encouraging the otherwise rate-limiting transmetallation step.275 Thus, this 
seemed an ideal starting point to facilitate the arylation of the secondary amide within NM450. 
Accordingly, investigations began using the commercially available JackiePhos Pd G3 pre-
catalyst system.  
 
Scheme 3.9. Attempts to modify the amide nitrogen proved unsuccessful. 
Discouragingly, however, it was found that alteration to the equivalents and nature of the aryl 
bromide in addition to the temperature and duration of microwave heating proved 
unsuccessful, with only trace amounts of product observed in all cases. In light of the failures 
experienced using the JackiePhos Pd Buchwald conditions, alternative Cu-catalysed Ulmann-
type coupling conditions were considered. Consequently, NM450 was subjected to CuI and 
iodobenzene in the presence of DMEDA as a ligand under thermal heating conditions. 
Disappointingly, in this case only a complex mixture was obtained with no evidence of 108 
formation observed by 1H NMR. 
In a final attempt to install functionality at this position, it was anticipated that NM450 may be 
amenable to alkylation methods to introduce further functionality. Thus, NM450 was treated 
with benzyl bromide under basic conditions. Encouragingly, complete consumption of the 
starting material was observed in this case. However, 1H NMR analysis of the resulting 
compound suggested alkylation to had instead taken place at the α-keto position, with some 
evidence of di-alkylation present. With these findings in mind, it was hypothesised a more 
viable route to modify the amide nitrogen position would instead involve installation of 
functionality at an earlier and less sterically hindered stage of the synthesis, for example prior 
to cyclisation of 78 or triazole formation from 77.  
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Considering the first objective, the highly modular DOS strategy successfully enabled the rapid 
synthesis of 26 NM450 derivatives. Building on previous research in the field of DOS fragments 
for hit evolution,153 in this example we have demonstrated how this can be achieved in a 
multidirectional fashion through leveraging the inherent modularity, the NSQC motif and sp3 
carbons (Figure 3.15). Thus, in addition to the physicochemical properties (see Chapter 2), we 
have highlighted the potential of the NSQC library to address key outstanding requirements 
within the field of FBDD.  
 
Figure 3.15. These investigations resulted in 26 derivatives exploring a number of fragment growth 
vectors. 
3.2.3 Hit validation 
With the library of 26 analogues in hand, a second round of X-Ray screening was subsequently 
conducted to address the second objective. In a similar fashion, this was completed at the 
XChem screening facility at DLS, and all compounds were screened in duplicate. Gratifyingly, 
upon analysis of the resulting data using PanDDA four hits were successfully identified (Figure 
3.16).  
 
Figure 3.16. The four hits identified from the follow-up X-Ray screen. 
Evaluation of the structural X-Ray data generated revealed that in relation to the ten substituted 
aromatic analogues screened, only the para-fluoro analogue 95 was in fact tolerated (Figure 
3.17, A). This data revealed the aromatic portion of the molecule to bind in a similar fashion to 
NM450 within BS1, with the amide carbonyl interacting with Lys56 within the protein back bone. 
Intriguingly, however, a second portion of electron density was identified for the molecule within 
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BS2 with the same binding mode as NM461 (Figure 3.17, B). It was hypothesised, however, 
that this could be a crystallographic artefact, potentially binding between the crystal contacts. 
This theory was corroborated by the fact no polar interactions could be identified between the 
molecule and protein. 
 
Figure 3.17. The crystal structure of 95 within A) BS1 and B) BS2. 
The binding of 99 revealed that the alternative isoxazole bridging heterocycle could also be 
tolerated. Importantly, selectivity for the 1,4-regioisomer could be inferred from these results 
since no binding of the 1,5 isomer 101 was identified. Inspection of the structural data revealed 
99 bound in the same manner as NM450 within BS1 (Figure 3.18, A). In this instance polar 
interactions could be predicted between the amide carbonyl and the isoxazole heteroatoms 
within the CFI25 backbone. Similarly, 101 also exhibited this binding mode (Figure 3.18, B). 
Interestingly, in this case the gem-dimethyl substituents and NSQC were oriented toward 
different channels within the protein, suggesting these could be utilised as two alternative 3-D 




Figure 3.18. The crystal structures of A) 99 and B) 105 within BS1 of CFI25. 
Finally, the most significant and unexpected result was the data for the hydroxyl variant 106. 
Upon analysis of the crystal structure it was found that this compound bound within the 
substrate channel for both ApA4 and the UUGUAU motif (vide supra, Figure 3.8). Moreover, 
importantly this predicted a polar interaction between the amide carbonyl and the key Arg63 
residue responsible for ApA4 and UUGUAU binding and Arg150. Moreover, further interactions 
could be identified between the amide nitrogen toward Arg63 and the triazole with Gln157 
(Figure 3.19, A and B). It its worth mentioning, however, as with NM450 and all bound 
derivatives once more the aromatic region proved to be much more defined, whilst the electron 
density for the quaternary heterocycle was ambiguous. Thus, whilst these interactions could 
be hypothesised, screening of the single diastereomer and enantiomer variants of 106 would 






Figure 3.19. The crystal structure of 106 bound within the substrate channel of CFI25 with the predicted 
hydrogen bonds and important residues highlighted in A) and the substrate binding channel surface 
highlighted in B). 
In view of these results, the initial NM450 hit was successfully validated through the 
identification of the binding of additional analogues, meeting the second objective proposed. 
Consequently, NM450 therefore serves as a novel lead for the development of the first small 
molecule modulators of CFI25. Thus, as this example demonstrates, DOS fragment libraries 
can be effective in delivering new hits against challenging targets. It is envisioned that future 
efforts will involve hit evolution in line with the results described utilising the chemistry 
developed and crystal structures presented herein. In particular, one important objective would 
involve the synthesis of the single enantiomer variants of these compounds to determine the 
enantiomer preference of the protein to aid the application of structure-based design for 
fragment growth. Moreover, as discussed previously, methods to measure the binding affinity 
of these fragments using biophysical techniques are currently under development within the 
Huber group. In due course, once established, it is expected these this data will enable 
prioritisation of subsequent fragment evolution and guide the development of novel leads for 
this important biological target.  
Importantly, as a result of its success, the library was subsequently made openly available to 




3.2.4 Activin A 
The first collaborator to utilise the NSQC library was Joseph McLoughlin from the Hyvӧnen 
group during a screen seeking to identify novel fragment binders of activin A. Activins are 
members of the transforming growth factor β (TGF-β) superfamily of growth factors, which play 
an essential roles in homeostasis and development and have been studied for many years.276 
Research has shown activins mediate an intramolecular signalling cascade via binding to the 
extracellular domains of transmembrane serine/threonine kinases known as Type I or Type II 
receptors.277,278 In turn, this conduces the phosphorylation of type I receptors by the kinase 
domain of the type II receptors. This then enables the subsequent phosphorylation of receptor-
Smad proteins, which results in their translocation to the nucleus where they are involved in 
the regulation of target gene expression.279 Importantly, in this context, binding of the type II 
receptors has been shown to be crucial for type I receptor binding and therefore vital to 
generate the first step of this signalling pathway.  
Several studies have associated the role of activin A signalling with the regulation of 
embryogenesis, stem cell differentiation and wound healing, among other processes.280–282 
Moreover, dysregulation of activin A signalling or expression has been linked to human disease 
such inflammatory conditions and cancer.280,283,284 Indeed, recently STM434, a fusion protein 
of the type II receptor extracellular domain with a human Fc domain, entered clinical trials for 
the treatment of ovarian cancer and other solid tumours, suggesting inhibition of this protein 
can be exploited for therapeutic benefit.285 However, negative off-target effects were observed, 
hypothesised to result from bone morphogenic protein 9 inhibition.286  
Nevertheless, despite the potential of this target, to the best of our knowledge no small 
molecule modulators of this protein exist to enable further investigations into the associated 
biology. Following their recent success in determining the crystal structure of the pro-domain 
of activin A,276 the Hyvӧnen group became interested in pursuing the development of novel 
activin SM modulators. This included investigating the potential to develop novel small 
molecule inhibitors of this protein via high-throughput fragment screening methods. This 
provided the possibility to explore an orthogonal approach to the development of stapled 
peptide-based libraries against Activin A, also under investigation within the both the Hyvӧnen 
and Spring research groups. 
From these efforts, a single hit from the NSQC library was identified, NM466. Inspection of the 
crystal structure of this hit revealed the fragment bound within a lipophilic pocket lined by 
Trp25, Trp28, Ile29, Tyr93, Met91, Ile105 and Met108 of chain A with Phe58 of chain B (Figure 
3.20, A). Importantly, it was believed the fragment was anchored within this site via hydrogen 
bond interaction between the carbonyl of the tertiary amide within NM466 toward Trp28 from 
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chain A of the protein backbone, whilst the propyl chain bound tightly over a shelf generated 
by Phe58 of chain B.  
 
Figure 3.20. A) The fragment binding site of NM466 within activin A B) An overview of the NM466 
binding site in relation to chain A (depicted in grey) and chain B (depicted in blue) of activin A C) The 
crystal structure of activin A (Chain A depicted in grey and Chain B depicted in blue) bound to the 
extracellular domains of the type II receptor (ActRIIb-ECD) (depicted in red and orange).287 
Moreover, comparison of the fragment binding site (Figure 3.20, B) to the reported crystal 
structure of activin A bound to the extracellular domains of the type II receptor (ActRIIb-ECD)287 
(Figure 3.20, C) highlighted the NM466 to be bound in close proximity to one such domain. It 
could therefore be hypothesised that conformational changes induced through binding of 
NM466 could enable modulation of the activin A signalling cascade.  
Analogous to the CFI25 project, these results once more provided the opportunity to showcase 
the DOS chemistry, in addition to potentially providing novel starting points for lead generation. 
Importantly, during modelling and refinement of the crystal structures it was found that only 
(R)- variant of NM466 was capable of fitting the electron density, suggesting the preferential 
or sole binding of this enantiomer. As a result, the first priority was the synthesis of both the 
(R)- and (S)- enantiomers to confirm this hypothesis utilising the modular chemistry. Secondly, 
once more devoid of biophysical hit validation methods due to the challenging nature of 
developing such techniques for novel targets, it was anticipated the synthesis of NM466 
analogues would address this objective. 
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With the crystal structure and modular DOS route in mind, several analogues were envisioned 
for this purpose (Figure 3.21). More specifically, it was proposed that benzodiazepine core of 
the molecule provided the opportunity for several points of derivatisation, including simple N-
alkylation, aromatic substitution and alkyne chain modifications. Thus, a synthetic strategy to 
enable the generation of such analogues was devised. 
 
Figure 3.21. The crystal structure of NM466 bound to Activin A and the proposed positions of 
derivatisation. 
3.2.5 Follow-up compounds to NM466 
The original synthetic route to NM466 developed by Dr. Natalia Mateu is outlined in Scheme 
3.10.232 This straightforward four-step procedure involved acylation of 4 with 2-azidobenzoyl 
chloride to give 109, followed by methylation to give 110. Subsequent Zn-mediated azide 
reduction followed by subjection of the crude intermediate to basic conditions promoted the 
intramolecular cyclisation to deliver the benzodiazepine 59 in good yield. Finally, Pd-mediated 
reduction was then employed to generate the desired propyl chain from the alkyne moiety to 





Scheme 3.10. The original route to NM466 developed by Dr. Natalia Mateu starting from amino ester 
4. 
Initially, during library construction this route had been designed with the vision of accessing 
additional scaffolds through derivatisation of the intact alkyne within 59. However, with respect 
to the activin A project, this motif was not required. Alternatively, it was envisioned that direct 
analogues of NM466 could instead be accessed via a nitro variant of 110. Accordingly, a 
condensed three-step synthetic route from the key amino ester 4 was proposed (Scheme 
3.11). It was anticipated that this alternative route could employ commercially available 2-
nitrobenzoyl chloride derivatives in place of 2-azidobenzoyl functionalities. In turn, it was hoped 
that in this instance Pd-mediated reduction could be instead utilised to simultaneously affect 
the reduction of both alkyne and nitro moieties in a single step, prior to cyclisation. 
 
Scheme 3.11. The proposed shorter three-step route to access NM466 analogues. 
Following this procedure, firstly utilising the (R)- or (S)- variant of 4, the corresponding single 
enantiomers of NM466 could be constructed. In turn, to access derivatives it was envisioned 
that acylation could be used to introduce aromatic core variation using commercially available 
materials, alkylation could be used to explore amide substitution, whilst modifications to the 
benzodiazepine core could be introduced using late-stage functionalisation once the scaffold 
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was constructed. Finally, modification of the amine 4 used in the first step could allow for 
alternative quaternary substituents to be introduced.  
Accordingly, initial efforts sought to generate the (S)-amino ester 4 following the synthetic 
procedure established by Dr. Natalia Mateu (Scheme 3.12).232 Synthesis began with the 
formation of the cyclic imine 114 via microwave-assisted condensation of (S)-phenyl glycinol 
and methyl pyruvate. In turn, this intermediate was subjected to zinc-mediated Barbier 
conditions to install the quaternary substituent, with the stereochemistry controlled via rear-
face attack due to top-face steric hindrance induced by the phenyl substituent. In a similar 
fashion to the racemic synthesis of 4 (see Chapter 2), both the alkene and allene products 
were detected by crude 1H NMR analysis. It was found that the temperature of the reaction 
heavily influenced the observed ratio of these two species, with reactions carried out at -20 °C 
offering the best ratio of 6:1 alkyne to allene (determined by 1H NMR). Fortunately, the major 
isomer could be separated using column chromatography. 
 
Scheme 3.12. Phenyl glycinol was employed as a cheap chiral auxiliary in the asymmetric route to 
assess optically pure (S)-115. 
Following this, thionyl chloride-mediated ring opening of 115 was utilised to afford 116 
(Scheme 3.13). Finally, auxiliary cleavage using lead (IV) acetate delivered the enantiopure 
(S)-4 amino ester in a good 81% yield.  
 
Scheme 3.13. Ring cleavage and auxiliary removal afforded the enantiopure amino ester (S)-4. 
With (S)-4 in hand, the shortened synthetic route to NM466 was subsequently investigated. 
Accordingly, (S)-4 was treated with 2-nitrobenzoyl chloride and triethylamine, yielding the 
acylated intermediate (S)-111 (Scheme 3.14). Following this, methylation of this intermediate 
proceeded smoothly, affording (S)-111 in a 79% yield. Finally, subjection of (S)-112 to 10 mol% 
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of Pd/C under a hydrogen atmosphere promoted the simultaneous reduction of both nitro and 
alkyne functionalities. It was found that in an analogous fashion to the original Zn-mediated 
procedure, filtration of the reaction through Celite proved to be a sufficient work-up and upon 
treatment of the crude intermediate to sodium hydride in DMF, the desired product (S)-NM466 
was isolated in a good 78% yield (over two steps). 
 
Scheme 3.14. Using (S)-4 the corresponding (S)-NM466 was rapidly constructed. 
In light of these findings, the synthesis of the remaining (R)-enantiomer and further analogues 
of NM466 formed the basis of an M.Sci project undertaken by Till Reinhardt within the Spring 
group. This project proved to be particularly successful leading to the synthesis of an additional 
15 analogues for screening (Figure 3.22). This included sequential growing of the fragment 
from the alkylated amide position (117 - 120), variation in the alkyne and quaternary 
substituents (121 - 124), in addition to modification of the secondary amide (126 & 127) and 
complete removal of the quaternary centre (128). This was achieved using computational 




Figure 3.22. The 15 analogues successfully synthesised by Till Reinhardt to validate and probe the 
binding of NM466 to Activin A.  
Thus, once more, the utility of the NSQC library and DOS chemistry in a fragment screening 
setting has been demonstrated. Additionally, through these efforts we also exemplified the 
flexibility of the DOS strategy through the generation of a condensed three-step synthetic route 
to access NM466, enabling the rapid generation of derivatives. By exploiting the modularity of 
this methodology, both the (R)- and (S)- enantiomers could be easily accessed in efforts to 
validate our original findings relating to the preferential binding of (R)-NM466. Moreover, in line 
with the crystal data, several vectors of the molecule have been explored (Figure 3.23). 
Importantly, this included the generation of a third ethyl quaternary substituent, highlighting the 
potential of this motif to be utilised as a 3-D fragment growth vector.  
 
Figure 3.23. An overview of the vectors from NM466 explored during these efforts. 
3.2.6 Hit validation 
Preliminary X-Ray screening data conducted by Joseph McLoughlin of 117, 118 and 124 
successfully validated the initial binding of NM466 through the additional binding of 117 and 
115. The screening of the remaining 12 analogues is yet to be completed. Thus, these NM466 
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therefore represents a novel starting point for the development of new chemical leads. On-
going work in this regard is focused on the screening of the remaining analogues in order to 
confirm the viable vectors for fragment growth. Moreover, to guide the hit evolution, the 
development of NMR-based and biophysical methods to determine binding affinity is also 
underway within the Hyvönen group. It is envisioned that with these techniques in hand, further 
analogues could be rapidly accessed to develop the binding affinity and/or potency as required. 
3.2.7 On-going screening collaborations 
In addition to the examples described herein, the NSQC library has subsequently been utilised 
in other XChem screenings. Once more, this library has proven fruitful in this context and 
provided novel fragment leads. This includes the hit NM413 against penicillin binding protein 
3 (PBP-3), in collaboration with the Dowson group at The University of Warwick. On-going 
follow-up chemistry efforts in this regard are under investigation by Elaine Fowler and will be 
published in due course. It is worth mentioning, that in a similar fashion to the above examples 
in this context the DOS strategy has facilitated exploration of several fragment growth vectors 
(Figure 3.24), including modification to the quaternary substituent.  
 
Figure 3.24. On-going work conducted by Elaine Fowler exploring the 3-D growth of NM413. 
As these examples demonstrate, the NSQC library has proven effective in delivering novel 
leads against challenging biological targets, owing to the broad range of scaffold diversity. 
Additionally, as an inherent feature of its synthesis access to derivatives can be achieved in a 
straightforward fashion without the requirement of novel synthetic route development. 
Moreover, as the latter two cases exemplify, the NSQC-motif can provide an additional 3-D 
exit vector, with both alkyl and aryl substituents described. Thus, overall this work 
demonstrates that this library serves as an excellent complementary collection to commercial 
fragments, and considering the success described, it is envisioned that these molecules will 
prove fruitful in many future FBS campaigns. Future work will focus on building upon these 
preliminary results with the vision of obtaining potent compounds against all three targets.  
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4 Results and discussion: Investigations into high-
throughput methods of analogue production 
4.1 Background 
One significant challenge within the FBS screening paradigm lies with the subsequent hit 
validation and evolution process to attain compounds with measurable potency in solution 
assays. Indeed, due to the low affinity (μM to mM) and sometimes ambiguous nature of initial 
hits resulting from these efforts, this process is dramatically complicated.110,115 Often, the first 
stage of this process can be achieved in an ‘off-the-shelf’ approach using commercially 
available fragment analogues (termed SAR-by Catalogue).288,289 However, in some cases this 
method can be more challenging, for example when screening novel compound libraries. Thus, 
the availability of appropriate compounds for this purpose in a time- and cost- efficient manner 
is crucial. 
In view of these challenges, the Diamond and SGC Poised Fragment Library (DSPL) was 
developed by Cox et al.248 with the aim of enabling the rapid synthesis of compound analogues 
to facilitate hit validation and optimisation. This entailed the generation of a ‘poised’ strategy 
relying on the utility of 23 robust and reliable reactions commonly adopted within medicinal 
chemistry290 and used to form heterocycles291 to enable reliable disconnection of fragments 
into readily available synthons (Figure 4.1). Accordingly, upon the identification of fragment 
hits, the corresponding synthons could be readily enumerated using commercial collections 
and analogues readily synthesised in one synthetic step. Using these principles, a screening 




Figure 4.1. Generation of analogues using the DSPL library. Adapted from reference. 248 
In a proof-of-concept study, the authors demonstrated the utility of this poised strategy and the 
DPSL using a case study screening campaign against PHIP(2), an atypical bromodomain.248 
Following an initial X-ray screen four fragment hits (129 – 132) within the key acetyl-lysine 
binding region were identified, corresponding to three different ‘poised’ chemotypes of 
thioureas, amides and oxazoles (Figure 4.2). Through exploitation of the poised chemistry 
handles, the subsequent construction of 64 analogues could be achieved in a relatively short 
time period, which ultimately resulted in the identification of novel micromolar inhibitors. This 




Figure 4.2. The poised approach case study against PHIP(2). Three hit chemotypes were rapidly 
enumerated leading to micromolar affinity analogues detected by an AlphaScreen assay.  
Within the XChem setting (see Chapter 3) the DPSL has proven particularly successful, 
enabling the identification of several initial hits and subsequent analogue syntheses across 
several therapeutic targets.248,257 Building on these promising results, the second generation 
library, Diamond, SGC and iNext Poised (DSi-P) library was developed and is now routinely 
proposed to XChem users. To aid library uptake, the DSi-P library was recently made available 
from the chemical supplier Enamine.292 However, a challenge in the application of the library 
remained in instances where researchers sought to access compounds outside the initial 
library scope. As a result, the XChem team sought to enhance this collection with additional 3-
D libraries, including those containing restricted elements such as NSQCs, that allow rapid 
multi-directional structure-activity relationship exploration. In this regard, the NSQC library (see 
Chapter 2 and 3) seemed an ideal library to compliment the DPSL due to its excellent 
physicochemical properties and successful applications toward challenging targets. 
One challenge arising from the application of both libraries concerned the availability of 
bespoke analogues. It is generally recognised that within the medicinal chemistry paradigm 
organic synthesis remains a significant rate-limiting step due to the large significant cost and 
time overheads associated with this phase of a project.154 In this regard, machine-assisted 
synthesis has demonstrated significant merit within recent years, and calls toward the 
demonstration of reaction compatibility with automisation technologies have been made.154 
Thus, within recent years the application of automatable technologies towards reaction 
discovery,293–295 reaction optimisation296,297 and the miniaturised synthesis of high-value 
medicinal compounds298–300 has transformed the landscape of synthetic chemistry. Certainly, 
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the ability of such platforms to accelerate the timescale and increase the efficiency of such 
procedures cannot be rivalled, importantly providing one solution to overcoming the 
aforementioned barriers within drug discovery. More recently, literature examples have also 
emerged demonstrating the powerful integration of high-throughput methods of synthesis with 
bioactive screens for SAR exploration301,302 enabling a direct bioactivity readout for the 
resulting compounds. 
Inspired by these reports, unpublished work undertaken by researchers at the XChem facility 
sought to investigate the possibility of merging the novel XChem screening platform with high-
throughput strategies of analogue synthesis (Figure 4.3). More specifically, it was hoped that 
in this instance the bottleneck of reaction purification303 could be mitigated by instead utilising 
the exquisite nature of protein binding specificity, observed for example in crystal soaking 
methods during fragment screening, to exclusively bind to the reaction component of choice. 
In this case, it was envisioned that crude reaction mixtures could be directly employed in crystal 
soaking events to identify follow-up analogue hits, letting the protein crystal filter out reagents 
and side-products. Moreover, this would serve as an orthogonal method to existing 
technologies such as activity-directed synthesis,304,305 nanoscale synthesis and affinity 
ranking302 and crude SPR,306,307 enabling the simultaneous rapid acquirement of structural 
binding information of the resultant compounds. 
Figure 4.3. An overview of the high-throughput crude workflow. 
To initially investigate this proposal, it was envisioned that by taking advantage of the inherent 
poised nature of the DSPL, liquid handling robotics could be utilised to rapidly generate 
analogues in a high-throughput manner. To achieve this, the Opentrons robot was selected 
due to the ability to generate customised protocols using Python and economic benefits 
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including low maintenance, outlay and consumable costs.308 As a proof-of-concept study, 
investigations carried out by Dr. Anthony Aimon sought to re-synthesise a series of previously 
confirmed analogues of 136 via amide coupling reactions utilising the Opentrons in a 96-well 
format (Figure 4.4).309  
 
Figure 4.4. Disconnection of 136 via the poised synthetic handle to give the corresponding synthons for 
variation. 
Utilising stock solutions of amines (Reagents A) and either carboxylic acids or acids chlorides 
(Reagents B), in addition to troughs of base, coupling agent and solvent, the replication of 176 
compounds was successfully achieved (Figure 4.5). It was found that, if required, the resulting 
reaction mixture could be subjected to a surrogate aqueous work up via sequential pipette 
injections and aspirations, allowing for the removal of aqueous soluble reaction by-products. 
Additionally, liquid transfers of the crude mixtures to screening and quality-control plates in 
bespoke format (96/384/1536 wells) or solvent (Acetonitrile, DCM, DMSO) were facilitated, 
although this required utilisation of an evaporation system, e.g Genevac.  
 
Figure 4.5. The proof-of-concept amide formation reaction to generate a small library of analogues and 
robotic set-up. Work carried out by Dr. Anthony Aimon, XChem. 
In turn, reaction progression was assessed by means of LCMS analysis and upon completion 
the crude reactions were subsequently directly employed in crystal soaking experiments 
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against the target of interest following the XChem workflow (see Chapter 3). Gratifyingly, upon 
screening of the crude reaction mixtures identical hit compounds were identified from both the 
purified and crude compounds (for example 137) confirming the validity of this process (Figure 
4.6). To provide open-access, the initial Python code for this procedure was subsequently 
generalised and a repository created by Dr. Anthony Bradley on the open-source platform 
GitHub.310 
 
Figure 4.6. Compound 137 and the electron density map of the crude compound within the pocket of 
the desired protein. Work carried out by Dr. Anthony Aimon, XChem. 
4.2 DOS library application and toolbox expansion 
Whilst the application of the DPSL within the high-throughput crude platform had proven 
successful, two tasks remained outstanding: (1) demonstration of the compatibility of the 
technology with more 3-D fragment libraries and (2) expansion of the crude toolbox to show 
compatibility with alternative reaction conditions. In line with these aims, we hypothesised that 
the inherently modular nature of the quaternary DOS strategy could be exploited to this 
address these objectives. To achieve this, it was envisioned that a library of second-generation 
of NM450 follow-up compounds (see Chapter Three) could be rapidly synthesised utilising this 
technology. It was hoped this would showcase the potential of the DOS library, whilst enabling 
exploration into the application of a second reaction methodology.  
In view of the presence of the key bridging triazole within six DOS library members, including 
the fragment hit NM450, we hypothesised that the generality and robust nature of triazole-
forming click chemistry could be harnessed for this purpose. The classical Cu(I)-catalysed or 
strain-promoted Huigsen 1,3-dipolar cycloaddition between an alkyne and azide to generate 
1,2,3-triazoles constitutes an important click chemistry variant owing to its characteristic 
features of high selectivity, reliability and bio-compatability.311,312 Indeed, the utility of this 
reaction within the drug discovery paradigm has been previously demonstrated by applications 
in bioconjugation including peptide stapling,313–315 DNA modification316,317 and cell surface 
labelling.318 In view of the merits of this reaction, utilising the NM450 hit in a proof-of-concept 
97 
 
study, it was proposed that following a combinatorial approach, libraries of analogues 
exhibiting variation in both the aromatic substitution and quaternary heterocycle could be 
generated in an automated fashion (Figure 4.7). 
 
Figure 4.7. The combinatorial-type approach proposed for use in the crude high-throughput synthesis. 
4.2.1 High-throughput synthesis 
To investigate this proposal, initially six quaternary alkyne substrates were chosen to be 
combinatorially reacted with nine commercially available aromatic azide substrates to generate 
54 corresponding analogues of NM450. However, a major concern was the imperative use of 
copper agents in the reactions, which we hypothesised may result in a reduction in the 
diffraction quality and resolution of the crystals.319 To minimize this, it was decided to 
investigate the use of solid-supported copper sources, in addition using the conventional 
reaction conditions.  
The first approach, developed by Girard et al.,320 entailed the non-covalent attachment of CuI 
to an Amberlyst-21 polymer resin via chelation to the amine-functionality within the polymer 
(Figure 4.8). Importantly, due to the use of CuI within this procedure, the active Cu(I) species 
is generated within the reaction mixture, therefore removing the requirement of reducing 
agents to promote the reaction. Furthermore, the reported reaction scope of this procedure 
appeared sufficiently broad and thus seemed a promising option. 
 
Figure 4.8. A) Attachment of CuI to polymer resin via chelation.320 B) The formation of nanoparticle 
Cu/C reported by Lipshutz et al.321 
The second strategy, developed by Lipshutz et al.,321 involved impregnation of activated wood 
charcoal particles with copper nitrate to afford nanoparticles of Cu/C (Figure 4.9). In a similar 
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fashion, the requirement for a reducing agent was also eliminated due to the presence of both 
CuO and Cu2O within the matrix. Moreover, the reaction was shown to proceed with or without 
the addition of base, although the addition of one equivalent of NEt3 was shown to be 
beneficial. If successful, it was envisaged that the removal of such nanoparticles could be 
mediated via the incorporation of a reaction mixture filtration step. 
Consequently, both catalysts were synthesised following the reported procedures and an 
investigation into their ability to transform 77 to 78 using azido benzene was initiated. When 
77 was treated with Cu/C and azidobenzene, disappointingly no evidence of 78 was observed 
with only starting material present (Table 4.1, Entry 1). Initial subjection of 77 to the 
Amberlyst21-Cu system and azidobenzene at room temperature proved sluggish, however, 
upon heating of the reaction to 40 °C full conversion was observed and a good 75% yield of 
78 was obtained (Table 4.1, Entry 2). Finally, for a better compatibility with the XChem 
screening platform, the traditional solution phase CuSO4 procedure was modified by switching 
from t-butanol to DMA successfully (Table 4.1, Entry 3). 
 
Entry Copper source Conditions Result 
1 Cu/C 
DMA:H2O 
rt then 40°C 18 hr 
Only SM by TLC 
2 Amberlyst21-Cu 
DMA:H2O  
rt then 40 °C 18 hr 
Full conversion, 75%  
3 CuSO4 
Sodium ascorbate (0.3 equiv) 
DMA:H2O 
Full conversion, 58% 
Table 4.1. Investigations of reaction conditions for automated synthesis. 
Considering the identification of two alternative binding sites for NM450 and NM461 within 
CFI25 (see Chapter 3), it was envisaged that variation of the quaternary heterocycle would 
provide valuable information into the binding preference of such molecules. With this theory in 
mind, four biologically relevant motifs that could be obtained in one-step transformations from 
4 were selected for synthesis (Scheme 4.1). In addition, alkynes 77 and 60 were also included 
to serve as controls, delivering the corresponding triazole NM450 and 78 previously 
synthesised. Hence, 4 was treated with ethyl isocyanate yielding urea 138, whilst the 
corresponding pyrrole was achieved via application of Clauson-Kass conditions,322,323 
proceeding smoothly to yield 139. Next, acylation of 4 with acetyl chloride or trifluoracetic 
anhydride afforded the N-acetamide variants 140 and 141. Finally, acylation with ethyl malonyl 
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chloride afforded 77 and subsequently, half of this material could then be cyclised via a 
Dieckmann condensation and decarboxylation to deliver the pyrrolidinone 60.  
 
Scheme 4.1. Six alkynes were readily synthesised via N-modifications from amine 4. 
With the alkynes in hand, nine commercially available azides (142 – 150) were selected 
matching those used in the conventional synthesis (Figure 4.9, see Chapter 3) and varying in 
substitution and functionality around the aromatic core. It should be noted that the screening 
of the analogues described in Chapter 3 was conducted concurrently to these investigations 
and as such the SBR data obtained from the follow-up library screening could not be utilised 
to inform azide selection at this stage. 
 
Figure 4.9. Commercially available azides used in this initial study. 
With these substrates in hand, investigations into the utility of this methodology within the high-
throughput synthesis platform were initiated. The reactions were carried out on a 0.05 mmol 
scale using 0.8M stock solutions of each alkyne in DMA. Due to the instability of the azide 
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functionality within the aromatic substrates, these materials were commercially provided in 
0.5M solutions in tert-butyl methyl ether. As a result, the reactions were conducted in DMA, 
which was later removed via Genevac evaporation and subsequently dissolved in DMSO to 
enable X-ray screening. In an analogous fashion to the conventional triazole synthesis (vide 
supra) a 1:0.9 ratio of alkyne to azide was once more utilised to avoid the isolation of unreacted 
azide substrate. Agitation and gentle heating to 37 °C was achieved through employment of 
an orbital shaker incubator. After 24 hours the reaction plates were cooled to room 
temperature, the solvents were exchanged, and the reaction progression was analysed by 
LCMS. 
Firstly, considering the Amberlyst21-Cu system, 33 of the 45 reactions that were successfully 
analysed showed greater than 70% conversion (assessed through ELSD chromatograms) 
(Table 4.2). For nine reaction wells instrumental measurement errors resulted in poor 
determination of the reaction conversion, however pleasingly the desired product mass was 
still observed on three occasions. Interestingly, the same trend of reduced reactivity of the 1-
azido-2-methylbenzene alkyne (see Chapter 3) was observed with poor conversion to the 






Azide 77 60 138 139 38 140 
141   Mass found    
142    No signal   
143       
144       
145       
146       
147      Mass not 
found 
148   Mass found  Mass found  








Table 4.2. Reactions conducted under Amberlyst21-Cu catalyst conditions: Approx. 4 mg Amberlyst21-
Cu, DMA:H2O. Dark green = excellent conversion (100%), Pale green = good conversion (70 - 90%), 
Yellow = moderate conversion (50 - 60%), Orange = low conversion (20 - 40%), Red = poor conversion 




The corresponding reactions employing the copper in solution protocol were analysed (Table 
4.3). It should be noted that in this case, due to insufficient quantities of alkyne 140, only the 
reactions of alkynes 38, 60, 77, 138 and 139 were investigated. Gratifyingly, LCMS analysis 
revealed a similar trend with the majority of the reactions (30 out of 39 successfully analysed 
wells) displaying greater than 70% conversion. Once more instrumental error was observed in 
six cases whereby the conversion could not be assessed, however in all cases the desired 
product masses were still in fact detected. 
 
 Alkyne 
Azide 77 60 138 139 38 
141      
142      
143      
144      
145      
146      
147  Mass found  Mass found  
148  Mass found   Mass found 
149  Mass found   Mass found 
Table 4.3. Reactions conducted under standard conditions: 10 mol% CuSO4·5H2O, 30 mol% Sodium 
ascorbate, DMA:H2O. Dark green = excellent conversion (100%), Pale green = good conversion (70 - 
90%), Yellow = moderate conversion (50 - 60%), Orange = low conversion (20 - 40%), Red = poor 
conversion (< 20%). Grey = detection error no conversion could be determined. 
These results therefore validate the first objective of these investigations, demonstrating the 
applicability of the quaternary DOS library to a high-throughput synthesis setting. Firstly, this 
enabled the rapid formation of 78 analogues within one week, but secondly exemplified the 
compatibility of the library with solid-phase catalysis, potentially unlocking further applications 
of the screening library in a high-throughput context. Significantly, the modular nature of the 
synthetic strategy used to construct the library was leveraged to generate several alkyne 
synthons. Whilst only the nitrogen vector was explored in this instance, it is envisaged that 
other functionalities could be additionally enumerated (following the approaches described in 
Chapter 2) to generate more varied synthons. Thus, it could be hypothesised that multi-
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directional growth vectors of NM450 could be rapidly explored in high-throughput fashion using 
this approach. 
4.2.2 Crude screening results 
To investigate the second objective of crude toolbox expansion, the 96 crude mixtures were 
then screened against CFI25 using the XChem platform in duplicate. However, in all cases, 
upon analysis of the diffraction data using the PanDDA algorithm revealed no electron density 
relating to bound molecules was identified. Alarmingly, even the crude compound 
corresponding to the original hit NM450, which served as a control for this procedure was not 
detected by this analysis. 
Significantly, a large proportion of the crystals exhibited poor to no diffraction, conflicting the 
characteristic robust nature of this crystal system previously observed during the initial CFI25 
screening campaign. An average of 41% of the crystals subjected to solid-supported crudes, 
and 47% of the crystals subjected to the solution-phase crudes produced data which was 
inadequate for incorporation into the PanDDA algorithm. This suggested upstream processing 
issues as a result of the poor crystal diffraction and resolution as a result of copper exposure. 
With respect to the Amberlyst-21 system it was proposed that metal-leaching could have 
occurred,324 resulting in a higher concentration of copper within the crude reaction mixture, 
therefore explaining the similarity in results for both catalyst systems. With these points in mind, 
it is envisioned that future work on this project will involve the employment of metal scavenging 
reagents with the aim of reducing the in-solution copper levels. The application of these 
materials e.g. Quadrapure has previously been demonstrated, enabling the reduction to single 
digit parts per million.325–328 Overall, as these investigations have demonstrated, whilst the 
quaternary DOS library is amenable to a high-throughput synthesis platform, further reaction 








5 Conclusions  
An outstanding requirement within the field of organic synthesis is the development of novel 
strategies to access new SMs to seed both drug discovery and the development of new 
chemical probes. In a similar fashion to HTS approaches of identifying bioactive SMs, within 
the FBS paradigm organic synthesis has been identified as a limiting factor. Thus, in recent 
years calls for the development of new fragment libraries that feature increased diversity, 3-
dimensionality and multiple modifiable vectors have been made. Moreover, due to the 
challenges associated with detecting particularly weak fragment binders, the development of 
novel strategies to accelerate analogue formation could provide the opportunity to lower the 
economic impact of this process.  
DOS is a strategy that aims to generate varied molecular architectures in a modular and rapid 
fashion and is therefore well-suited to populate new areas of fragment space. Accordingly, in 
Chapter one, we described the design and synthesis of a 3-D fragment collection to address 
the aforementioned issues in fragment diversity by utilising this methodology. More specifically, 
this included the incorporation of a N-substituted quaternary stereocenter motif as a strategy 
for introducing 3-D character and conformational restriction throughout the library. This was 
achieved by harnessing the differential reactivity nature of α,α-disubstituted amino ester and 
alcohol substrates to generate quaternary-carbon containing SMs (Scheme 5.1). Initially, in 
the build phase, we developed robust and scalable synthetic routes to three building blocks 
with varied N-substitutions to enable the DOS investigations. Following this, systematic 
explorations into the couple and pair phases were conducted, resulting in the synthesis of 12 
sp3-rich heterocyclic scaffolds based on eight molecular frameworks. This included the 
formation of three-, five-, six- and seven-membered constrained cycles, in addition to a series 
of novel oxepane-fused motifs. Furthermore, modifiable substituents were installed at a range 
of positions to enable fragment elaboration in a straightforward manner. 
 
Scheme 5.1. The overall DOS strategy using an α,α-disubstituted amino alcohol building block. 
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Ultimately, these compounds were incorporated into a quaternary screening collection based 
on 40 distinct scaffolds incorporating medicinally-relevant motifs. The efficiency of these 
combined efforts was exemplified since no more than five synthetic steps were employed to 
generate each library member. Moreover, as an inherent feature of the building block motif, 
the quaternary centre was installed throughout the library, introducing a 3-D exit vector within 
the final molecules. The synthetic utility of this quaternary motif was demonstrated through the 
generation of the phenyl variant of the amino alcohol building block and subsequent 
incorporation of this motif into a final scaffold within the library.  
Subsequent computational analysis of this collection revealed the library accessed a broad 
range of molecular shape space, whilst the quaternary motif could be utilised to modify this 
distribution, illustrated via PMI plots. Thus, overall, we have shown that DOS can be used to 
synthesise a library of structurally diverse fragments featuring restricted elements to enhance 
their overall 3-D shape. Moreover, prediction of the physicochemical properties of the library 
demonstrated the amenability of this library to a FBS setting through RO3 guideline adherence. 
Finally, comparison of the DOS library to existing commercial collections revealed a lower 
fraction of aromatic atoms and an increased number of chiral centres was achieved in this 
work.  
In Chapter one, we sought to illustrate the broad skeletal and stereochemical diversity that 
could be achieved using the DOS approach however, the functional group and appendage 
diversity elements remain to be extensively explored. It is envisioned that computational virtual 
enumeration could be utilised to further expand the scope of the work presented. Firstly, this 
could be addressed through expansion of the quaternary motif through the incorporation 
different substituents at this position. As demonstrated through the synthesis of the phenyl 
derivative, this motif can simply be modified through variation of the commercially available 
keto ester utilised within building block construction. Thus, following this methodology 
appendage diversity could be introduced among the scaffolds presented (Scheme 5.2). 
Moreover, whilst the library was synthesised in a racemic fashion, owing to the demonstration 
of the asymmetric synthetic route, the corresponding enantiopure (R)- and (S)- variants of each 





Scheme 5.2. Virtual library enumeration through variation of the quaternary substituent. 
Alternatively, library enumeration could be investigated on an individual basis depending on 
the library member in question. In this instance, taking advantage of the modular synthetic 
strategy for constructing the quaternary precursors and the expanse of potential coupling 
partners employed at each stage, further appendage and functional group diversity could be 
achieved (Scheme 5.3). This would involve expansion of the functionalities previously 
demonstrated as viable positions for modification as disclosed in Chapter 2.  
 
Scheme 5.3. Virtual library expansion through R group variation. 
In the second chapter, the implementation of the DOS-derived library within a high-throughput 
X-ray crystallographic-based screening platform was described. Indeed, the biological 
relevance and structural diversity of the collection was highlighted through the identification of 
several novel binders against three challenging targets from distinct protein families (Figure 
5.1).  Remarkably, in the case of CFI25 these results represent the first examples of SM binders 
for this important target. These results therefore present an exciting opportunity to develop 




Figure 5.1. XChem screens revealed hits against targets from three different protein families. 
Subsequently, we initiated synthetic efforts toward hit analogues with the goal of hit validation. 
In this work, we successfully demonstrated the advantages of modular DOS-derived synthetic 
routes for enabling the rapid generation several derivatives of both hits (Figure 5.2). 
Importantly, this work highlighted the potential for fragment growth from a variety of different 
exit vectors as a result of utilising DOS chemistry, answering important calls from within the 
field. This included the exemplification of several viable synthetic strategies, enabling 
modification of almost every position around NM450 and NM466 to explore the binding mode. 
It is envisaged that upon biophysical determination of the binding affinity these explorations 
will prove beneficial to inform subsequent fragment growth. 
 
Figure 5.2. A summary of the synthetic efforts toward the generation of hit analogues demonstrating 
the feasibility of fragment growth from multiple vectors. 
In turn, these analogues were utilised to validate the initial crystallography results and therefore 
represent novel starting points for drug discovery or chemical probe development. Thus, 
following these initial results, subsequent investigations could be envisioned focusing on the 
development of these hits to generate potent and selective hit compounds. Indeed, on-going 
work in this area is focused on the exploration of appropriate biophysical methods to enable 
binding affinity measurement. Following this, pragmatic decisions on fragment growth could 
subsequently be made, building upon the preliminary follow-up investigations described 
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herein. In this context, the crystal structures generated in this work will provide valuable 
structural information to aid this process.  
Finally, in the third chapter we described initial developments toward novel methodology for 
high-throughput analogue production and crude reaction mixture screening in collaboration 
with XChem. Organic synthesis remains one of the most time-consuming and cost-intensive 
segments within drug discovery and the emergence of robot-automated methods of synthesis 
and removing the necessity for purification represents one strategy often utilised to tackle this 
hurdle. In this work, we successfully demonstrated the applicability of the quaternary DOS 
library with to both a high-throughput synthesis setting and solid-supported catalysis, through 
the formation of 78 1,2,3-triazoles. Thus, these proof-of-concept studies highlight the potential 
for DOS library enumeration and rapid derivative production to enable widespread adoption of 
the library. Whilst utility of this reaction in a crude screening context remain to be validated, we 
believe this initial work will provide a solid foundation for on-going optimisation studies toward 
reaching this goal. Future investigations should seek to explore the application of metal 
chelating resins in the hope to avoid crystal degradation.  
As this work serves to demonstrate, DOS methodology can be leveraged to tackle outstanding 
challenges within the field of FBS. Moreover, the establishment of translational collaborations 
can be particularly fruitful in enabling the identification of novel starting points for drug 
discovery stemming from such libraries. It is envisioned that the continued partnership of 








6.1 General Experimental Details 
Proton nuclear magnetic resonance (1H NMR) were recorded at ambient temperature on a Bruker 
DPX-400 (400 MHz), Bruker Advance 400 QNP (400 MHz,) and Bruker Avance 500 Cryo 
Ultrashield (500 MHz). Tetramethylsilane was used as an internal standard. 1H NMR chemical 
shifts (δH) are reported in parts per million (ppm), to the nearest 0.01 ppm and are referenced to 
the residual non-deuterated solvent peak (CDCl3: 7.26, CD3OD: 3.31, D2O: 4.79). Coupling 
constants (J) are reported in Hertz (Hz) to the nearest 0.1 Hz. Data are reported as follows: 
chemical shift, integration, multiplicity (s = singlet; d = doublet; t = triplet; q = quartet; qn = quintet; 
sep = septet; m = multiplet; or as a combination of these), coupling constant(s) and assignment. 
Carbon NMR (13C NMR) were recorded at ambient temperature on a Bruker DPX-400 (400 MHz), 
Bruker Advance 400 QNP (400 MHz,) and Bruker Avance 500 Cryo Ultrashield (500 MHz). 
Chemical shifts (δC) are quoted in ppm, to the nearest 0.1 ppm, and are referenced to the residual 
non-deuterated solvent peak (CDCl3: 77.16, CD3OD: 49.00).  
1H NMR and 13C NMR spectra assignments were supported by DEPT-135, COSY (2D, 1H-1H 
correlations), HSQC (2D, one bond 1H-13C correlations), HMBC (2D, multi-bonds 1H-13C 
correlations) where appropriate. The numbering of molecules used for 13C and 1H NMR 
assignments does not conform to IUPAC standards. High resolution mass spectrometry (HRMS) 
measurements were recorded with a Micromass Q-TOF mass spectrometer or a Waters LCT 
Premier Time of Flight mass spectrometer using Electrospray ionisation (ESI) techniques. Mass 
values are reported within the ±5 ppm error limit.  
Thin layer chromatography (TLC) was performed using pre-coated Merck glass backed silica gel 
60 F254 plates and visualised by quenching of UV fluorescence (λmax = 254 nm) or by staining with 
potassium permanganate. Retention factors (Rf) are quoted to 0.01. Flash column 
chromatography was carried out Merck 9385 Kieselgel 60 SiO2 (230-400 mesh) under a positive 
pressure of nitrogen unless otherwise stated. Visualisation was achieved via ultraviolet light (254 
nm) and chemical staining with KMnO4 as appropriate. 
Liquid chromatography mass spectroscopy (LCMS) was carried out using a Waters ACQUITY H-
Class UPLC with an ESCi Multi-Mode Ionisation Waters SQ Detector 2 spectrometer using 
MassLynx 4.1 software; EI refers to the electrospray ionisation technique; LC system: solvent A: 
2 mM NH4OAc in H2O/MeCN (95:5); solvent B: MeCN; solvent C: 2% formic acid; column: 
ACQUITY UPLC® CSH C18 (2.1 mm × 50 mm, 1.7 μm, 130 Å) at 40 °C; gradient: 5 – 95 % B with 
constant 5 % C over 1 minute at flow rate of 0.6 mL/minute; detector: PDA eλ Detector 220 – 800 
nm, interval 1.2 nm. Melting points (m.p.) were obtained using a Büchi Melting Point B-545 melting 
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point apparatus and are uncorrected. Infrared (IR) spectra were recorded neat on a Perkin-Elmer 
Spectrum One spectrometer using an ATR sampling accessory either as solids or films in CH2Cl2. 
Selected absorptions (νmax) are reported in wavenumbers (cm-1) with the following abbreviations: 
w, weak; m, medium; s, strong; br, broad. 
Ethyl acetate, methanol, dichloromethane, acetonitrile and toluene were distilled from calcium 
hydride. Diethyl ether was distilled from a mixture of lithium aluminium hydride and calcium 
hydride. Tetrahydrofuran was dried using Na wire and distilled from a mixture of lithium aluminium 
hydride and calcium hydride with triphenylmethane as an indicator. Petroleum ether was distilled 
before use and refers to the fraction between 40-60 °C. All other solvents and reagents were 
obtained from commercial suppliers and used without further purification. Reactions were carried 
out under a stream of dry nitrogen using oven-dried glassware unless otherwise stated. Room 
temperature (r.t.) refers to ambient temperature. All temperatures below 0 °C were maintained 




6.2 N-substituted quaternary fragments 
6.2.1 Synthesis of methyl 2-((4-methoxyphenyl)amino)-2-methylpent-4-ynoate 
(2) and methyl 2-((4-methoxyphenyl)amino)-2-methylpenta-3,4-dienoate (3) 
 
To a solution of p-anisidine (4.40 g, 35.7 mmol) in acetonitrile (ACN) (40.0 mL) was added 
methyl pyruvate (4.70 mL, 52.0 mmol) and the reaction heated to 50 °C for 80 minutes. Upon 
completion, the reaction was concentrated in vacuo and the crude imine was redissolved in a 
mixture of petroleum ether:CH2Cl2 (10:1). The resulting precipitate was removed by filtration to 
afford an orange/brown oil. The crude imine (7.10 g, 34.3 mmol) was dissolved in DMF (172 
mL) and cooled to 0 °C before propargyl bromide (4.87 mL, 45.2 mmol) was added, followed 
by activated Zn* powder (3.36 g, 51.7 mmol). The reaction was warmed to r.t. and then heated 
to 60 °C for 1 hour. Upon completion, the reaction was cooled to 0 °C and quenched with 
NH4Cl saturated aqueous solution. The product was extracted with EtOAc (3 x 60 mL) and 
washed with brine (4 x 50 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica gel; petroleum ether/EtOAc, 4:1) to give the products; 2 (4.16 g, 16.8 mmol, 47 %) and 
3 (1.04 g, 4.20 mmol, 12 %) as orange/brown oils. 
*Zn was stirred with 2N HCl (aq) for 10-15 minutes and then washed with H2O, EtOH, Et2O 
and rigorously dried before use.  
Data for 2: 
Rf = 0.43 (petroleum ether/EtOAc, 4:1); 1H NMR (400 MHz, CDCl3) δ 6.77 ─ 6.70 (4H, m, 
H3/4), 3.75 (3H, s, H12), 3.74 (3H, s, H1), 2.79 (1H, dd, J = 16.9, 2.7 Hz, H6a), 2.66 (1H, dd, 
J = 16.8, 2.7 Hz, H6b), 2.09 (1H, t, J = 2.7 Hz, H8), 1.55 (3H, s, H10); 13C (101 MHz, CDCl3) δ 
175.1 (C11), 154.7 (C2), 137.9 (C5), 121.4 (C4), 114.5 (C3), 79.7 (C7), 71.9 (C8), 61.3 (C9), 
55.6 (C1), 52.7 (C12), 28.0 (C6), 24.0 (C10); HRMS (ESI) calcd for [C14H18NO3]+: 248.1287, 
found 248.1275; IR max = 3283 (m, C≡C-H), 2952 (w, C-H), 2120 (w, C≡C), 1727 (s, C=O), 
1509 (s, C=C), 1108 (s, Ar-O-C). 
These characterisation data are in accordance with that previously reported in the literature.193 
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Data for 3: 
Rf = 0.50 (petroleum ether/EtOAc, 4:1); 1H NMR (400 MHz, CDCl3) δ 6.76 ─ 6.72 (2H, m, H4), 
6.68 ─ 6.64 (2H, m, H3), 5.55 (1H, t, J = 6.7 Hz, H6), 4.96 ─ 4.87 (2H, m, H8), 3.74 (3H, s, 
H1), 3.73 (3H, s, H12), 1.60 (3H, s, H10); 13C (101 MHz, CDCl3) δ 207.5 (C7), 175.0 (C11), 
153.6 (C2), 138.7 (C5), 118.9 (C4), 114.5 (C3), 95.3 (C6), 79.2 (C8), 60.6 (C9), 55.7 (C1), 52.9 
(C12), 24.5 (C10); HRMS (ESI) calcd for [C14H18NO3]+: 248.1287, found 248.1275; IR max = 
2952 (w, C-H), 1956 (w, C=C=C), 1728 (s, C=O), 1510 (s, C=C), 1236 (s, Ar-O-C). 
6.2.2 Synthesis of methyl 2-amino-2-methylpent-4-ynoate (4) 
 
To an ice-cooled solution of alkyne 2 (7.10 g, 28.8 mmol) in ACN (68.0 mL) was added a 
solution of cerium ammonium nitrate (CAN) (31.4 g, 57.4 mmol) in H2O (68.0 mL), dropwise 
over 30 minutes. The mixture was allowed to warm to r.t. and, upon completion, 2N HCl (120 
mL) was added and the reaction stirred for 20 minutes. The solution was washed with EtOAc 
(3 x 80 mL) and the aqueous layer then basified to pH 10 using Na2CO3. The resulting aqueous 
emulsion was then extracted with CH2Cl2 (2 x 150 mL) and the organic extracts combined, 
dried over Na2SO4, filtered and concentrated in vacuo to give 4 (2.80 g, 19.8 mmol, 67%) as a 
brown oil. 
Rf = 0.21 (petroleum ether/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3) δ 3.72 (3H, s, H7), 2.64 
(1H, dd, J = 16.5, 2.6 Hz, H4a), 2.44 (1H, dd, J = 16.5, 2.6 Hz, H4b), 2.04 (1H, t, J = 2.6 Hz, 
H2), 1.86 (2H, br s, NH2), 1.36 (3H, s, H5); 13C (101 MHz, CDCl3) δ 176.6 (C6), 79.8 (C3), 71.5 
(C2), 57.5 (C1), 52.6 (C7), 31.0 (C4), 26.0 (C5); HRMS (ESI) calcd for [C7H12NO2]+: 142.0863, 
found 142.0865; IR max = 3293 (w, C≡C-H), 2956 (C-H), 2114 (w, C≡C), 1730 (s, C=O), 1598 
(w, NH2), 1208 (s, C-O-C). 




6.2.3 Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-2-methylpent-4-ynoate 
(6)  
 
To a solution of 4 (1.00 g, 7.09 mmol) in THF (24 mL) was added Boc2O (2.32 g, 10.6 mmol) 
and the reaction heated to 70 °C for 18 hours in a sealed tube. The reaction was concentrated 
in vacuo and purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 3:1) 
to give 6 as a white solid (1.66 g, 6.88 mmol, 97%). 
Rf = 0.42 (petroleum ether/EtOAc, 3:1); m.p. 76.4 – 78.1 °C; 1H NMR (400 MHz, CDCl3) δ 5.24 
(1H, br s, NH), 3.76 (3H, s, H10), 2.95 – 2.86 (2H, m, H6), 2.02 (1H, t, J = 2.6 Hz, H4), 1.55 
(3H, s, H7), 1.44 (9H, s, H1); 13C (101 MHz, CDCl3) δ 173.7 (C9), 154.5 (C3), 80.2 (C2), 79.5 
(C5), 71.3 (C4), 58.4 (C8), 52.9 (C10), 28.4 (C1), 27.1 (C6), 23.4 (C7); HRMS (ESI) calcd for 
[C12H20NO4]+: 242.1392, found 242.1382; IR max = 3355 (w, C≡C-H) 2997 (w, C-H), 2123 (w, 
C≡C), 1733 (s, C=O), 1695 (s, C=O).  
These characterisation data are in accordance with that previously reported in the literature.330 
6.2.4 Synthesis of tert-butyl (1-hydroxy-2-methylpent-4-yn-2-yl)carbamate (7) 
 
To an ice-cooled solution of 6 (1.62 g, 6.70 mmol) in THF (30 mL) was added LiBH4 (438 mg, 
20.0 mmol) and the reaction stirred for 18 hours. Then, the reaction mixture was quenched 
with H2O and extracted with EtOAc (3 x 40 mL). The combined organic extracts were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel; petroleum ether/EtOAc 3:1) to give 7 as a white solid (1.36 
g, 6.38 mmol, 96%). 
Rf = 0.35 (petroleum ether/EtOAc, 4:1); m.p. 50.6 – 52.1 °C; 1H NMR (400 MHz, CDCl3) δ 4.88 
(1H, br s, OH), 3.68 (2H, s, H9), 2.73 (1H, dd, J = 16.8, 2.6 Hz, H6a), 2.45 (1H, dd, J = 16.9, 
2.7 Hz, H6b), 2.05 (1H, t, J = 2.7 Hz, H4), 1.43 (9H, s, H1), 1.29 (3H, s, H7); 13C (101 MHz, 
CDCl3) δ 156.2 (C3), 80.3 (C2/C5), 80.3 (C2/C5), 71.3 (C4), 69.2 (C9), 56.1 (C8), 28.5 (C1), 
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26.8 (C6), 22.7 (C7); HRMS (ESI) calcd for [C11H19NO3Na]+: 236.1257, found 236.1247; IR 
max = 3675 (b, OH), 3273 (W, C≡C-H), 2973 (s, C-H), 2110 (w, C≡C), 1667 (s, C=O). 
6.2.5 Synthesis of methyl (Z)-2-((4-methoxyphenyl)imino)-2-
phenylacetate (8) 
 
A solution of methyl benzyl formate (250 mg, 1.52 mmol), p-anisidine (197 mg, 1.60 mmol) and 
p-TsOH (14.4 mg, 0.0760 mmol) in toluene (3 mL) was heated to reflux with a dean-stark for 
190 minutes. The reaction was cooled to r.t. and concentrated in vacuo. The crude product 
was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 3:1) to give 
8 (361 mg, 1.34 mmol, 88%) as a yellow solid.  
Rf = 0.55 (petroleum ether/EtOAc, 3:1); m.p. 87.3 – 88.8 °C; 1H NMR (400 MHz, CDCl3) δ 7.87 
– 7.84 (2H, m, H7), 7.53 – 7.43 (3H, m, H8 & H9), 6.99 – 6.95 (2H, m, H4), 6.90 – 6.87 (2H, 
m, H3), 3.81 (3H, s, H1), 3.70 (3H, s, H12); 13C (101 MHz, CDCl3) δ 166.2 (C11), 159.3 (C10), 
157.5 (C2), 143.3 (C5), 134.3 (C6), 131.7 (C9), 128.8 (C8), 127.9 (C7), 121.3 (C4), 114.3 (C3), 
55.6 (C1), 52.1 (C12); HRMS (ESI) calcd for [C16H16NO3]+: 270.1133, found 270.1130; IR max 
= 2950 (w, C-H), 1733 (s, C=O), 1618 (m, C=N), 1576 (m, C=C), 1498 (s, C=C), 1226 (s, Ar-
O-C).  
6.2.6 Synthesis of methyl 2-((4-methoxyphenyl)amino)-2-phenylpent-4-ynoate (9) 
and methyl 2-((4-methoxyphenyl)amino)-2-phenylpenta-3,4-dienoate (10) 
 
To an ice-cooled solution of 8 (620 mg, 2.30 mmol) and propargyl bromide (0.484 mL, 3.57 
mmol) in DMF (13.6 mL) was added Zn* (301 mg, 4.60 mmol) and the reaction warmed to r.t. 
over 1 hour and then heated to 60 °C for 75 minutes. The reaction was quenched with NH4Cl 
saturated aqueous solution and extracted with EtOAc (3 x 30 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The 
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crude product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 
85:15) to give 9 (457 mg, 1.47 mmol, 64%) and 10 (76.2 mg, 0.246 mmol, 11%) both as orange 
oils. 
Data for 9: 
Rf = 0.48 (petroleum ether/EtOAc, 85:15); 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.55 (2H, m, 
H11), 7.40 – 7.31 (3H, m, H12 & H13), 6.65 – 6.61 (2H, m, H3), 6.42 – 6.38 (2H, m, H4), 4.97 
(1H, br s, NH), 3.72 (3H, s, H15), 3.69 (3H, s, H1), 3.39 (1H, dd, J = 16.4, 2.6 Hz, H7a), 3.21 
(1H, dd, J = 16.4, 2.6 Hz, H7b), 2.02 (1H, t, J = 2.6 Hz, H9); 13C (101 MHz, CDCl3) δ 173.1 
(C14), 153.3 (C2), 139.8 (C10), 137.9 (C5), 128.9 (C12), 128.2 (C13), 127.0 (C11), 118.8 (C4), 
114.5 (C3), 79.4 (C8), 71.9 (C9), 66.9 (C6), 55.6 (C1), 53.4 (C15), 25.04 (C7); HRMS (ESI) 
calcd for [C19H20NO3]+: 310.1443, found 310.1430; IR max =  3404 (w, C≡C-H), 2952 (w, C-H), 
2168 (w, C≡C), 1732 (s, C=O), 1511 (s, C=C), 1239 (s, Ar-O-R). 
Data for 10: 
Rf = 0.58 (petroleum ether/EtOAc, 85:15); 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.61 (2H, m, 
H11), 7.38 – 7.28 (3H, m, H12 & H13), 6.65 – 6.61 (2H, m, H3), 6.42 – 6.38 (2H, m, H4), 5.97 
(1H, t, J = 6.6 Hz, H7), 5.10 (1H, br s, NH), 4.88 – 4.78 (2H, m, H9), 3.69 (3H, s, H15) 3.69 
(3H, s, H1); 13C (101 MHz, CDCl3) δ 208.2 (C8), 173.0 (C14), 152.4 (C2), 140.1 (C10), 138.5 
(C5), 128.7 (C12), 128.0 (C13), 127.6 (C11), 117.0 (C4), 114.2 (C3), 92.5 (C7), 78.8 (C9), 66.9 
(C6), 55.6 (C1), 53.1 (C15); HRMS (ESI) calcd for [C19H20NO3]+: 310.1443, found 310.1434; 
IR λ max =  2951 (w, C-H), 1735 (s, C=O), 1509 (C=C), 1236 (Ar-O-C).  
6.2.7 Synthesis of methyl 2-amino-2-phenylpent-4-ynoate (11) 
 
To an ice-cooled solution of 9 (217 mg, 0.702 mmol) in ACN (6 mL) was added a solution of 
CAN (1.53, 2.80 mmol) in H2O (6.5 mL) dropwise. The mixture was allowed to warm to r.t. and 
then stirred for 23 hours. 2N HCl (aq) (6 mL) was added and the reaction stirred for 30 minutes. 
Upon completion, the reaction was extracted with EtOAc (3 x 20 m L) and the aqueous layer 
basified with Na2CO3 to pH 10. The resulting cream suspension was extracted with CH2Cl2 (3 
x 30 m L) and the combined organic extracts were dried over Na2SO4, filtered and concentrated 
in vacuo to give 11 (110 mg, 0.542 mmol, 77%) as a brown oil without further purification. 
Rf = 0.47 (petroleum ether/EtOAc, 3:2); 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.50 (2H, m, H6), 
7.38 – 7.33 (2H, m, H7) 7.32 – 7.28 (1H, m, H8), 3.75 (3H, s, H10), 3.14 (1H, dd, J = 16.5, 3.2 
Hz, H2a), 2.77 (1H, dd, J = 16.5, 2.5 Hz, H2b), 2.18 (2H, br s, NH2), 2.06 (1H, t, J = 2.6 Hz, 
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H4); 13C (101 MHz, CDCl3) δ 174.9 (C9), 141.5 (C5), 128.7 (C7), 128.1 (C6), 125.4 (C8), 80.0 
(C3), 71.6 (C4), 63.5 (C1), 53.0 (C10), 31.1 (C2); HRMS (ESI) calcd for [C12H14NO2]+: 
204.1021, found 204.1025; IR max = 3288 (m, C≡C-H), 2953 (w, C-H), 1730 (s, C=O), 1600 
(m, C=C). 
6.2.8 Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-2-phenylpent-4-ynoate 
(12) 
 
A solution of 11 (91.0 mg, 0.448 mmol) and Boc2O (146 mg, 0.672 mmol) in THF (4 mL) was 
heated to 75 °C for 18 hours in a sealed tube. Further Boc2O (48.0 mg, 0.219 mmol) was added 
and the reaction stirred at 80 °C for a further 6 hours then cooled to r.t. and stirred for 18 hours. 
The reaction was concentrated in vacuo and purified by flash column chromatography (silica 
gel; petroleum ether/EtOAc, 85:15) to give 12 (108 mg, 0.356 mmol, 80%) as a pale-yellow 
solid. 
Rf = 0.32 (petroleum ether/EtOAc, 9:1); m.p. 100.3 – 101.9 °C; 1H NMR (400 MHz, CDCl3) δ 
7.44 (2H, d, J = 7.5 Hz, H9), 7.38 – 7.34 (2H, m, H10), 7.32 – 7.38 (1H, m, H11), 6.03 (1H, br 
s, NH), 3.71 (3H, s, H13), 3.62 – 3.43 (2H, m, H5), 1.99 (1H, m, H7), 1.41 (9H, br s, H1); 13C 
(101 MHz, CDCl3) δ 171.9 (C12), 154.1 (C3), 138.5 (C8), 128.8 (C10), 128.3 (C11), 126.0 
(C9), 85.1 (C2), 79.6 (C6), 71.3 (C7), 64.5 (C4), 53.5 (C13), 28.4 (C1), 25.3 (C5); HRMS (ESI) 
calcd for [C17H21NO4Na]+: 326.1368 , found 326.1365; IR λ max = 3321 (w, C≡C-H), 2976 (w, 
C-H), 2012 (w, C≡C), 1736 (s, C=O), 1712 (s, C=O), 1487 (s, C=C), 1434 (C=C). 
6.2.9 Synthesis of tert-butyl (1-hydroxy-2-phenylpent-4-yn-2-yl)carbamate (13) 
 
To an ice-cooled solution of 12 (55.0 mg, 0.181 mmol) in THF (2 mL) was added LiBH4 (13.0 
mg, 0.594 mmol) and the reaction warmed to r.t before heating to 60 °C for 3 hours. The 
reaction was cooled to r.t. and quenched with H2O. The product was extracted with EtOAC (3 
x 20 mL), washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 
85:15) to give 13 (26.5 mg, 0.0962 mmol, 53%) as a white solid.  
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Rf = 0.10 (petroleum ether/EtOAc, 9:1); m.p. 119.1 – 120.5 °C; 1H NMR (400 MHz, CDCl3) δ 
7.42 – 7.35 (4H, m, H9 & H10), 7.31 – 7.27 (1H, m, H11), 5.45 (1H, br s, NH), 4.04 (1H, m, 
H12a), 3.92 – 3.81 (1H, m, H12b & OH), 3.06 (1H, dd, J = 16.9, 2.6 Hz, H5a), 2.95 (1H, dd, J 
= 16.9, 2.8 Hz, H5b), 2.04 (1H, br s, H7), 1.45 (9H, br s, H1); 13C (101 MHz, CDCl3) δ 156.1 
(C3), 141.2 (C8), 128.7 (C10), 127.7 (C11), 126.0 (C9), 80.5 (C2), 79.9 (C6), 72.2 (C7), 69.7 
(C12), 62.1 (C4), 28.4 (C1), 27.3 (C5); HRMS (ESI) calcd for [C16H22NO3]+: 276.1600, found 
276.1595; IR max = 3306 (O-H), 3076 (m, C≡C-H), 2046 (w, C≡C), 1682 (s, C=O), 1557 (s, 
C=C), 1582 (s, C=C). 
6.2.10 Synthesis of tert-butyl (3-methyl-3,4-dihydro-2H-pyran-3-yl)carbamate 
(14) 
 
A solution of 7 (19.0 mg, 0.0890 mmol), N-hydroxysuccinimide (5.00 mg, 0.0445 mmol), 
tetrabutylammonium hexafluorophosphonate (17.3 mg, 0.0445 mmol) and NaHCO3 (3.80 mg, 
0.00270 mmol) in DMF (1 mL) was degassed with an argon purge for 15 minutes. 
CpRu(PPh3)2Cl (6.00 mg, 8.26 μmol) and PPh3 (2.10 mg, 8.00 μmol) were added and the 
reaction heated to 80 °C for 56 hours in a sealed tube. The reaction was cooled to r.t. and 
filtered through celite, washing with EtOAc. The filtrate was washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel; petroleum ether/EtOAc 3:2) to give of 14 (9.10 mg, 0.427 mmol, 
47%) as a colourless oil.  
Rf = 0.39 (petroleum ether/EtOAc 19:1); 1H NMR (400 MHz, CDCl3) δ 6.36 (1H, dt, J = 6.1, 1.8 
Hz, H7), 4.67 – 4.63 (2H, m, H6 & NH), 4.04 (1H, d, J = 10.2 Hz, H8a), 3.56 (1H, d, J = 11.0 
Hz, H8b), 2.28 (1H, d, J = 16.9 Hz, H5a), 1.97 (1H, d, J = 17.2 Hz, H5b), 1.43 (9H, s, H1), 1.37 
(3H, s, H9); 13C NMR (101 MHz, CDCl3) δ 155.0 (C3), 143.3 (C7), 98.8 (C6), 79.3 (C2), 71.0 
(C8), 48.7 (C4), 32.6 (C5), 28.6 (C1), 22.9 (C9); HRMS (ESI) calcd for [C11H19NO3Na]+: 





6.2.11 Synthesis of tert-butyl (3-phenyl-3,4-dihydro-2H-pyran-3-yl)carbamate 
(15) 
 
To a solution of 13 (20.0 mg, 0.0726 mmol) in DMF (0.75 mL) was added N-hydroxy 
succinimide (4.20 mg, 0.0363 mmol), tetrabutylammonium hexafluorophosphonate (3.60 mg, 
9.29 μmol) and NaHCO3 (3.00 mg, 35.7 μmol). The solution was degassed with argon for 15 
minutes before CpRu(PPh3)2Cl (5.30 mg, 0.00730 mmol) and PPh3 (4.00 mg, 0.00145 mmol) 
were added. The reaction was heated to 80 °C for 18 hours in a sealed tube. Upon completion, 
the reaction was cooled to r.t. and diluted with water. The aqueous solution was extracted with 
CH2Cl2 (3 x 15 mL) and the combined organic extracts were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. The resulting oil was purified by flash column 
chromatography (silica gel; petroleum ether/EtOAc, 4:1) to give 15 (9.00 mg, 0.0329 mmol, 
45%) as a yellow/brown oil. 
Rf = 0.44 (petroleum ether/EtOAc, 19:1); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.33 (4H, m, H2 
& H3), 7.28 – 7.23 (1H, m, H1), 6.46 (1H, dt, J = 6.0, 1.7 Hz, H8), 5.09 (1H, s, NH), 4.84 – 4.80 
(1H, m, H7), 4.26 (1H, d, J = 10.1 Hz, H9a), 3.88 (1H, d, J = 10.9 Hz, H9b), 2.64 – 2.44 (2H, 
m, H6), 1.37 (9H, s, H12); 13C (101 MHz, CDCl3) δ 154.5 (C10), 143.5 (C8), 141.3 (C4), 128.6 
(C2), 127.3 (C1), 125.4 (C3), 99.3 (C7), 79.6 (C11), 70.6 (C9), 54.0 (C5), 32.3 (C6), 28.4 (C12); 
HRMS (ESI) cald for [C16H22NO3]+ 276.1607, found 276.1600; IR max = 2975 (w, C-H), 1698 
(s, C=O), 1655 (m, C=C), 1494 (m, C=C), 1164 (C-O-C). 
6.2.12 Synthesis of tert-butyl (1-(allyloxy)-2-methylpent-4-yn-2-yl)carbamate (16) 
 
To an ice-cooled solution of 7 (40.0 mg, 0.188 mmol) in DMF (2 mL) was added NaH (8.20 
mg, 0.206 mmol) and the reaction stirred for 15 minutes before allyl bromide (45.5 uL, 0.376 
mmol) was added and the reaction stirred for 90 minutes at r.t. Upon completion the reaction 
was diluted with H2O and extracted with EtOAc (2 x 30 mL). The combined organic extracts 
were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified 
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by flash column chromatography (silica gel; petroleum ether/EtOAc, 3:2) to give 16 (28.0 mg, 
0.111 mmol, 59%) as a colourless oil. 
Rf =  0.54 (petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ 5.94 – 5.84 (1H, m, 
H11), 5.27 (1H, m, H12a), 5.18 (1H, m, H12b), 4.84 (1H, br s, NH), 4.01 (2H, m, H10), 3.58 
(1H, d, J = 9.1 Hz, H9a), 3.42 (1H, d, J = 9.1 Hz, H9b) 2.78 (1H, dd, J = 16.3, 2.3 Hz, H6a), 
2.57 (1H, dd, J = 16.8, 2.7 Hz, H6b), 1.98 (1H, t, J = 2.7 Hz, H4), 1.43 (9H, s, H1), 1.39 (3H, 
s, H7); 13C (101 MHz, CDCl3) δ 154.9 (C3), 134.7 (C11), 117.2 (C12), 80.8 (C5), 79.3 (C2), 
74.1 (C9), 72.4 (C10), 70.5 (C4), 54.7 (C8), 28.5 (C1), 26.5 (C6), 21.6 (C7); HRMS (ESI) calcd 
for [C14H23NO3Na]+: 276.1576, found 276.1570; IR max = 3305 (w, C≡C-H), 2977 (w, C-H), 
1715 (s, C=O), 1496 (s, C=C), 1164 (C-O-C). 
6.2.13 Synthesis of methyl 2-(dibenzylamino)-2-methylpent-4-ynoate (17) 
 
A solution of 4 (400 mg, 2.83 mmol), DIPEA (2.47 mL, 14.1 mmol) and benzyl bromide (1.69 
mL, 14.1 mmol) in ACN (18 mL) was heated to 80 °C for 75 hours. The reaction was cooled to 
r.t., concentrated in vacuo and the resulting gum diluted with H2O and extracted with EtOAc (3 
x 50 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica gel; petroleum ether/EtOAc, 85:15) to give 17 (256 mg, 2.56 mmol, 90%) as an off-white 
solid.  
Rf = 0.54 (petroleum ether/EtOAc, 9:1); m.p. 65.2 – 66.7 °C; 1H NMR (400 MHz, CDCl3) δ 7.32 
(4H, d, J = 7.4 Hz, H3), 7.20 (4H, t, J = 7.4 Hz, H2), 7.12 (2H, t, J = 7.3 Hz, H1), 3.85 (4H, s, 
H5), 3.72 (3H, s, H12), 2.77 (1H, dd, J = 16.8, 2.6 Hz, H7a), 2.69 (1H, dd, J = 16.8, 2.6 Hz, 
H7b), 2.09 (1H, t, J = 2.8 Hz, H9), 1.50 (3H, s, H10); 13C (101 MHz, CDCl3) δ 174.4 (C11), 
141.1 (C4), 128.5 (C3), 128.1 (C2), 126.7 (C1), 81.0 (C8), 71.3 (C9), 66.7 (C6), 54.9 (C5), 51.8 
(C12), 28.2 (C7), 22.4 (C10); HRMS (ESI) Calcd for [C21H24NO2]+ 322.1807, found 322.1818; 





6.2.14 Synthesis of 2-(dibenzylamino)-2-methylpent-4-yn-1-ol (18) 
 
To an ice-cooled solution of 17 (581 mg, 1.81 mmol) in THF (14 mL) was added a suspension 
of LiAlH4 (137 mg, 3.62 mmol) in THF (4 mL) and the reaction stirred for 70 minutes whilst 
warming to r.t.. The reaction was quenched with 10% NaOH (aq) and extracted with EtOAc (3 
x 40 mL). The combined organic extracts were washed with brine, dried over Na2SO4, filtered 
and concentrated in vacuo to give 18 (496 mg, 1.69 mmol, 93%) as a pale pink solid.  
Rf = 0.35 (petroleum ether/EtOAc, 85:15); m.p. 66.2 – 67.9 °C; 1H NMR (400 MHz, CDCl3) δ 
7.25 – 7.14 (10H, m, H1, H2 & H3), 3.86 (2H, d, J = 14.5 Hz, H5a), 3.79 (2H, d, J = 14.5 Hz, 
H5b), 3.69 (1H, d, J = 11.2 Hz, H11a), 3.53 (1H, d, J = 11.2 Hz, H11b), 2.63 (1H, br s, OH), 
2.47 (1H, dd, J = 16.6, 2.6 Hz, H7a), 2.37 (1H, dd, J = 16.6, 2.7 Hz, H7b), 2.07 (1H, t, J = 2.7 
Hz, H9), 1.26 (3H, s, H10); 13C (101 MHz, CDCl3) δ 141.1 (C4), 128.5 (C2/3), 128.5 (C2/3), 
127.0 (C1), 81.5 (C8), 71.3 (C9), 66.1 (C11), 62.3 (C6), 53.5 (C5), 25.1 (C7), 19.6 (C10); 
HRMS (ESI) calcd for [C20H24NO]+ 294.1858, found 294.1849; IR max = 3426 (b, O-H), 3277 
(s, C≡C-H), 1598 (m, C=C), 1492 (C=C), 1450 (C=C). 
6.2.15 Synthesis of 1-(allyloxy)-N,N-dibenzyl-2-methylpent-4-yn-2-amine (19) 
 
To an ice-cooled solution of NaH (54.0 mg, 1.36 mmol) and allyl bromide (177 uL, 2.05 mmol) 
in DMF (3 mL) was added a solution of 18 (190 mg, 0.648 mmol) in DMF (3.8 mL) dropwise. 
The reaction was stirred for 2 hours at r.t., quenched with NH4Cl saturated aqueous solution 
and extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel; petroleum ether/EtOAc, 9:1) to give 19 (161 mg, 0.485 
mmol, 75%) as a colourless oil.  
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Rf = 0.38 (petroleum ether/EtOAc, 20:1); 1H NMR (400 MHz, CDCl3) δ 7.32 (4H, d, J = 7.3 Hz, 
H3), 7.18 (4H, t, J = 7.4 Hz, H2), 7.10 (2H, t, J = 7.2 Hz, H1), 5.95 – 5.85 (1H, m, H13), 5.28 
(1H, dd, J = 6.3 Hz, H14a), 5.17 (1H, dd, J = 4.0, H14b), 3.91 – 3.90 (6H, m H5 & H12), 3.52 
(1H, dd, J = 9.6 Hz, H11a), 3.46 (1H, dd, J = 9.6 Hz, H11b), 2.60 (1H, dd, J = 16.8, 2.6 Hz, 
H7a), 2.53 (1H, dd, J = 16.9, 2.6 Hz, H7b), 2.07 (1H, t, J = 2.6 Hz, H9), 1.26 (3H, s, H10); 13C 
(101 MHz, CDCl3) δ 142.2 (C4), 135.1 (C13), 128.5 (C3), 127.9 (C2), 126.4 (C1), 116.5, (C14), 
82.6 (C8), 75.0 (C11), 72.3 (C12), 70.5 (C9), 61.0 (C6), 54.3 (C5), 26.4 (C7), 21.2 (C10); 
HRMS (ESI) calcd for [C23H28NO]+: 334.2171, found 334.2175; IR max = 3301 (m, C≡C-H), 
2922 (m, C-H), 2120 (w, C≡C ), 1602 (m, C=C), 1493 (s, C=C), 1453 (s, C=C), 1090 (C-O-C). 
6.2.16 Synthesis of tert-butyl (3-methyl-5-vinyl-2,3,4,7-tetrahydrooxepin-3-
yl)carbamate (20) 
 
A solution of 16 (150 mg, 0.592 mmol) in CH2Cl2 (10 mL) was degassed with an argon purge. 
Grubbs-II (50.0 mg, 0.0592 mmol) was added the reaction was degassed with ethylene and 
stirred under this atmosphere for 18 hours. Then, the reaction was concentrated in vacuo and 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 19:1) to give 20 
(60.0 mg, 0.237 mmol, 40%) as a colourless oil.  
 
Rf = 0.30 (petroleum ether/EtOAc, 8:1); 1H (400 MHz, CDCl3) δ 6.32 (1H, dd, J = 17.4, 10.9 
Hz, H5), 5.87 (1H, t, J = 5.5 Hz, H7), 5.34 (1H, d, J = 17.4 Hz, H6t), 5.05 (1H, d, J = 10.9 Hz, 
H6c), 4.89 (1H, br s, NH), 4.29 (1H, dd, J = 15.0, 6.1 Hz, H8a), 4.12 (1H, dd, J = 15.2, 4.9 Hz, 
H8b), 3.91 (1H, d, J = 12.3 Hz, H9a), 3.50 (1H, d, J = 12.3 Hz, H9b), 3.19 (1H, d, J = 14.0 Hz, 
H3a), 2.39 (1H, d, J = 15.0 Hz, H3b), 1.39 (9H, s, H12), 1.37 (3H, s, H1); 13C NMR (101 MHz, 
CDCl3) δ 154.9 (C10), 140.0 (C5), 139.5 (C4), 129.9 (C7), 113.8 (C6), 81.6 (C9), 78.9 (C11), 
69.1 (C8), 52.8 (C2), 35.5 (C3), 28.4 (C12), 23.4 (C1), HRMS (ESI) calcd for [C14H23NO3Na]+: 
276.1576, found 276.1585. IR max = 3423 (w, N-H), 2975 (w, C-H), 1715 (s, C=O), 1494 (m, 




6.2.17 Synthesis of N,N-dibenzyl-3-methyl-5-vinyl-2,3,4,7-tetrahydrooxepin-3-
amine (21) 
 
To a solution of 19 (85.0 mg, 0.255 mmol) in CH2Cl2 (9 mL) previously degassed with an argon 
purge, was added Grubbs II catalyst (22.0 mg, 0.0259 mmol) and the reaction stirred under an 
atmosphere of ethylene for 18 hours. Upon completion, the reaction was concentrated in vacuo 
and the crude product purified by flash column chromatography (silica gel; petroleum 
ether/EtOAc, 19:1) to give 21 (52.0 mg, 0.156 mmol, 61%) as a colourless oil. 
Rf = 0.29 (petroleum ether/EtOAc, 19:1); 1H NMR (400 MHz, CDCl3) δ 7.26 (4H, d, J = 7.0 Hz, 
H3), 7.20 – 7.16 (4H, m, H2), 7.12 – 7.08 (2H, m, H1), 6.36 (1H, dd, J = 17.3, 10.8 Hz, H9), 
5.52 – 5.49 (1H, m, H11), 5.22 (1H, d, J = 17.4 Hz, H10t), 5.00 (1H, d, J = 10.7 Hz, H10c), 
4.49 (1H, d, J = 17.5 Hz, H12a), 4.22 (1H, d, J = 17.6, 3.5 Hz, H12b), 4.05 (1H, d, J = 12.9 Hz, 
H13a), 3.92 (2H, d, J = 15.0 Hz, H5a), 3.85 (2H, d, J = 15.0 Hz, H5b), 3.46 (1H, d, J = 12.8 
Hz, H13b), 2.97 (1H, d, J = 14.1 Hz, H7a), 2.44 (1H, d, J = 13.7 Hz, H7b) 1.04 (3H, s, H6); 13C 
(101 MHz, CDCl3) δ 142.1 (C4), 140.8 (C9), 137.2 (C8), 129.4 (C11), 128.5 (C3), 128.0 (C2), 
126.4 (C1), 111.5 (C10), 78.6 (C13), 71.6 (C12), 64.0 (C14), 54.5 (C5), 29.3 (C7), 23.9 (C6); 
HRMS (ESI) calcd for [C23H28NO]+: 334.2171, found 334.2175; IR max = 2969 (w, C-H), 1604 
(m, C=C), 1493 (m, C=C), 1453 (m, C=C), 1110 (C-O-C). 
6.2.18 Synthesis of (4R)-4-(dibenzylamino)-4,9-dimethyl-1,3,4,5,7,7a,10a,10b-




A solution of 21 (25.0 mg, 0.0755 mmol) and N-methyl maleimide (16.8 mg, 0.151 mmol) in 
toluene (0.75 mL) was heated to 110 °C for 1 hour 15 minutes. The reaction was concentrated 
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in vacuo and the crude product was purified by flash column chromatography (silica gel; 
petroleum ether/EtOAc, 3:2) to give 22 (15.6 mg, 0.0351 mmol, 46%) and 23 (4.90 mg, 0.0110 
mmol, 15%) both as colourless oils.  
Data for 22: 
Rf = 0.22 (1:4, EtOAc/PE 40-60); 1H NMR (400 MHz, CDCl3) δ 7.22 – 7.06 (10H, m, H1, H2 & 
H3), 5.52 – 5.51 (1H, m, H10), 4.37 – 4.33 (1H, m, H18a), 4.29 – 4.26 (1H, m, H19b), 4.23 
(1H, dd, J = 12.9, 3.8 Hz, H18a), 3.89 (2H, d, J = 14.7 Hz, H5a) 3.72 (2H, d, J = 14.7 Hz, H5b), 
3.27 (1H, d, J = 13.2 Hz, H19b), 3.20 – 3.16 (1H, m, H12), 3.11 (1H, dd, J = 8.7, 5.4 Hz, H16), 
2.93 – 2.91 (1H, m, H17), 2.90 (3H, s, H14), 2.69 (1H, dd, J = 15.1, 2.9 Hz, H8a), 2.50 – 2.55 
(1H, m, H11a), 2.50 (1H, d, J = 15.2 Hz, H8b), 2.21 – 2.16 (1H, m, H11b), 0.81 (3H, s, H6); 
13C (101 MHz, CDCl3) δ 180.1 (C13) 178.5 (C15), 141.3 (C9), 140.9 (C4), 129.1 (C3), 127.8 
(C2), 126.4 (C1), 123.3 (C10), 80.7 (C19), 72.6 (C18), 61.9 (C7), 52.4 (C5), 46.7 (C8), 43.0 
(C16), 41.8 (C17), 40.7 (C12), 25.1 (C11), 25.0 (C14), 18.9 (C6); HRMS (ESI) calcd for 
[C28H33N2O3]+: 445.2486, found 445.2474; IR max = 2938 (m, C-H), 1690 (s, C=O), 1493 (m, 
C=C), 1131 (s, C-O-C). 
Data for 23: 
Rf = 0.10 (petroleum ether/EtOAc, 4:1); 1H NMR (400 MHz, CDCl3) δ 7.22 – 7.15 (8H, m, H2 
& H3), 7.13 – 7.09 (2H, m, H1), 5.69 – 5.67 (1H, m, H10), 4.16 – 4.10 (2H, m, H18) 3.82 (2H, 
d, J = 14.9 Hz, H5a), 3.75 (2H, d, J = 14.9 Hz, H5b), 3.70 (1H, dd, J = 11.8, 2.1 Hz, H19a), 
3.64 (1H, d, J = 11.8 Hz, H19b), 3.14 (1H, m, H12), 3.01 (1H, dd, J = 8.7, 5.2 Hz, H16), 2.91 
(3H, s, H14), 2.74 – 2.71 (1H, m, H8a) 2.70 – 2.67 (1H, m, H11a), 2.58  - 2.56 (1H, m, H17), 
2.42 (1H, dd, J = 13.7, 2.0 Hz, H8b), 2.18 – 2.13 (1H, m, H11b), 1.02 (3H, s, H6); 13C (101 
MHz, CDCl3) δ 180.0 (C13) 178.3 (C15), 141.7 (C4), 141.3 (C9), 128.3 (C3), 128.1 (C2), 126.6 
(C1), 123.2 (C10), 81.0 (C19), 72.1 (C18), 61.6 (C7), 53.9 (C5), 42.7 (C16), 41.8 (C8), 41.7 
(C17), 41.1 (C12), 25.2 (C11), 25.0 (C14), 22.2 (C6); HRMS (ESI) calcd for [C28H33N2O3]+: 
445.2486, found 445.2474; IR max = 3025 (w, C≡C-H), 2920 (w, C-H), 1693 (s, C=O), 1601 
(w, C=C), 1124 (m, C-O-C). 
6.2.19 Synthesis of tert-butyl (6-methyl-2-phenyl-3,5,6,7,9,9a-hexahydro-2H-
oxepino[4,3-e][1,2]oxazin-6-yl)carbamate (24) 
 
To a solution of 20 (60.0 mg, 0.237 mmol) in toluene (2.5 mL) was added nitrosobenzene (51.0 
mg, 0.476 mmol) and the reaction heated to 110 °C for 4 hours. Then, the reaction was 
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concentrated under reduced pressure to give a mixture of diastereomers (dr ca. 46:36:10:0 
determined by 1H NMR). The major isomer was isolated by flash column chromatography 
(silica gel; petroleum ether/EtOAc 22:3) to give 24 (26.0 mg, 0.0721 mmol, 31%) as a yellow 
oil. 
 
Data for isolated diastereomer 24:  
Rf = 0.15 (petroleum ether/EtOAc 22:3); 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.25 (2H, m, H9), 
7.05 – 7.02 (2H, m, H8), 6.96 – 9.92 (1H, t, J = 7.3 Hz, H10), 5.71 (1H, d, J = 2.2 Hz, H5), 4.77 
(1H, br s, NH), 4.55 – 4.51 (1H, m, H6a), 4.31 – 4.26 (2H, m, H6b & H11), 4.02 – 3.97 (2H, m, 
H12a & H13a), 3.63 (1H, dd, J = 11.4, 9.5 Hz, H12b), 3.28 (1H, d, J = 12.7 Hz, H13b), 2.74 – 
2.65 (2H, m, H3), 1.44 (9H, s, H16), 1.30 (3H, s, H1); 13C (101 MHz, CDCl3) δ 154.7 (C14), 
147.6 (C7), 133.1 (C4), 129.0 (C9), 123.2 (C5), 121.8 (C10), 115.7 (C8), 80.9 (C15) , 78.2 
(C13), 72.0 (C12), 67.1 (C6), 61.8 (C11), 55.1 (C2), 45.7 (C3), 28.4 (C16), 22.3 (C1); HRMS 
(ESI) calcd for [C20H28N2O4Na]+: 383.1941, found 383.1931. IR max = 3360 (w, N-H), 2977 (w, 
C-H), 2934 (w, C-H), 1711 (s, C=O), 1596 (m, C=C),1491 (s, C=C). 
6.2.20 Synthesis of tert-butyl (2-methyl-1-(prop-2-yn-1-yloxy)pent-4-yn-2-
yl)carbamate (26) 
 
To an ice-cooled solution of alcohol 7 (40.0 mg, 0.188 mmol) in DMF (2 mL) was added NaH 
(8.20 mg, 0.206 mmol) and the reaction stirred for 15 minutes before propargyl bromide (44.7 
uL, 0.376 mmol) was added and the reaction stirred for 2 hours at r.t. Further NaH (1.00 mg, 
0.0250 mmol) was added and the reaction stirred for additional 2 hours. Upon completion the 
reaction was diluted with H2O and extracted with EtOAc (2 x 30 mL). The combined organic 
extracts was dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 3:2) to give the 
26 (25.0 mg, 0.0995 mmol, 52%) as a colourless oil. 
Rf =  0.48 (petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ 4.81 (1H, br s, NH), 4.21 
– 4.13 (2H, m, H10), 3.67 (1H, d, J = 9.0 Hz, H9a), 3.55 (1H, d, J = 9.0 Hz, H9b), 2.79 (1H, dd, 
J = 16.7, 2.0 Hz, H6a), 2.56 (1H, dd, J = 16.7, 2.6 Hz, H6b) 2.44 (1H, t, J = 2.4 Hz, H12), 1.09 
(1H, t, J = 2.7 Hz, H4), 1.43 (9H, s, H1) 1.39 (3H, s, H7); 13C (101 MHz, CDCl3) δ 154.8 (C3), 
80.6 (C5), 79.6 (C11), 79.4 (C2), 74.8 (C12), 73.9 (C9), 70.8 (C4), 58.7 (C10), 54.6 (C8), 28.5 
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(C1), 26.5 (C6), 21.6 (C7); HRMS (ESI) calcd for [C14H22NO3]+: 252.1600, found 252.1603; IR 
max = 3291 (w, C≡C-H), 2977 (w, C-H), 2122 (w, C≡C), 1697 (s, C=O).  
6.2.21 Synthesis of N,N-dibenzyl-2-methyl-1-(prop-2-yn-1-yloxy)pent-4-yn-2-
amine (27) 
 
To an ice-cooled solution of propargyl bromide (220 uL, 2.05 mmol) in DMF (7 mL) was added 
NaH (60.0 mg, 1.50 mmol), followed by a solution of 18 (200 mg, 0.682 mmol) in DMF (1 mL) 
and the reaction warmed to r.t. over 2 hours. The reaction was quenched with NH4Cl saturated 
aqueous solution and the product extracted with CH2Cl2 (3 x 30 mL).  The combined organic 
extracts were concentrated, washed with brine (2 x 20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (silica 
gel; petroleum ether/EtOAc, 4:1) to give 27 (200 mg, 0.604 mmol, 88%) as an orange oil. 
Rf =  0.64 (petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.31 (4H, m, H3), 
7.21 – 7.17 (4H, m, H2), 7.13 – 7.09 (2H, m, Hz, H1), 4.08 (2H, d, J = 2.3 Hz, H12), 3.91 (4H, 
s, H5), 3.63 (1H, d, J = 9.4 Hz, H11a), 3.58 (1H, d, J = 9.4 Hz, H11b), 2.59 (1H, dd, J = 16.9, 
2.7 Hz, H7a), 2.52 (1H, dd, J = 16.9, 2.7 Hz, H7b), 2.41 (1H, t, J = 2.5 Hz, H14), 2.08 (1H, t, J 
= 2.8 Hz, H9) , 1.26 (s, 3H, H10); 13C (101 MHz, CDCl3) δ 142.1 (C4), 128.5 (C3), 127.9 (C2), 
126.4 (C1), 82.3 (C8) , 80.0 (C13), 74.7 (C11), 74.4 (C14), 70.7 (C9), 60.8 (C6), 58.6 (C12), 
54.3 (C5), 26.4 (C7), 21.2 (C10); HRMS (ESI) calcd for [C23H26NO]+: 332.2009, found 
332.2002; IR max = 3294 (m, C≡C-H), 2949 (m, C-H), 2120 (w, C≡C), 1494 (m, C=C), 1453 
(s, C=C), 1114 (s, C-O-C). 





A solution of NaH (16.0 mg, 0.405 mmol) and 1-bromo-2-butyne (48.0 uL, 0.552 mmol) in DMF 
(0.8 mL) was cooled to 0 °C before a solution of 18 (54.0 mg, 0.184 mmol) in DMF (1 mL) was 
added dropwise. The reaction was warmed to r.t., stirring for 2.5 hours. The reaction was 
quenched with NH4Cl saturated aqueous solution and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 
85:15) to give 32 (43.5 mg, 0.126 mmol, 71%) as a colourless oil.  
Rf = 0.61 (petroleum ether/EtOAc, 19:1); 1H NMR (400 MHz, CDCl3) δ 7.31 (4H, d, J = 7.2 Hz, 
H3), 7.18 (4H, t, J = 4.4 Hz, H2), 7.11 – 7.08 (2H, m, H1), 4.04 (2H, m, H12), 3.91 (4H, s, H5), 
3.60 (1H, d, J = 9.5 Hz, H11a), 3.54 (1H, d, J = 9.5 Hz, H11b), 2.60 – 2.49 (2H, m, H8), 2.06 
(1H, t, J = 2.7 Hz, H10), 1.84 (3H, t, J = 2.3 Hz, H15), 1.25 (3H, s, H7); 13C (101 MHz, CDCl3) 
δ 142.2 (C4), 128.5 (C3), 127.9 (C2), 126.3 (C1), 82.5 (C9), 82.3 (C13), 75.5 (C14), 74.5 (C11), 
70.6 (C10), 60.9 (C6), 59.1 (C12), 54.3 (C5), 26.5 (C8), 21.3 (C7), 3.8 (C15); HRMS (ESI) 
calcd for [C24H28NO]+: 346.2171, found 346.2182; IR max = 3281 (s, C≡C-H), 2199 (w, C≡C), 
1600 (w, C=C), 1492 (s,C=C) 1089 (s, C-O-C). 
6.2.23 Synthesis of N,N-dibenzyl-4,9-dimethyl-7-phenyl-1,3,4,5-
tetrahydrooxepino[3,4-c]pyridin-4-amine (34) 
 
CpCo(CO)2 (96.0 uL, 0.540 mmol) and benzonitrile (104 uL, 1.54 mmol) and) were added to a 
solution of 32 (80.0 mg, 0.231 mmol) in toluene (3.8 mL) previously degassed with an argon 
purge, and then heated to 110 °C for 48 hours in a sealed tube. The reaction was cooled to r.t. 
and the solvents removed in vacuo. The crude product was purified by flash column 
chromatography (silica gel; petroleum ether/EtOAc, 9:1) 34 (22.0 mg, 0.0490 mmol, 21%) as 
a colourless oil.  
Rf = 0.28 (petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ 7.97 – 7.95 (2H, m, H15), 
7.47 – 7.43 (2H, m, H16), 7.39 (1H, m, H17), 7.35 (1H, s, H18), 7.23 (4H, m, H3), 7.20 – 7.16 
(4H, m, H2), 7.13 – 7.09 (2H, m, H1), 4.92 (1H, d, J = 14.8 Hz, H9a), 4.78 (1H, d, J = 14.9 Hz, 
H9b), 4.10 (1H, d, J = 12.7 Hz, H8a), 3.96 (2H, d, J = 14.8 Hz, H5a), 3.87 (2H, d, J = 14.9 Hz, 
H5b), 3.64 (1H, d, J = 12.5 Hz),  H8b), 3.55 (1H, d, J = 13.6 Hz, H20a), 2.89 (1H, d, J = 13.4 
Hz, H20b), 2.57 (3H, s, H12), 1.03 (3H, s, H6);13C (101 MHz, CDCl3) δ 155.6 (C13) 154.8 (C11) 
148.0 (C19), 141.6 (C4), 139.5 (C14), 130.3 (C10), 128.8 (C16/C17), 128.8 (C16/C17), 128.4 
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(C3), 128.1 (C2), 127.0 (C15), 126.6 (C1), 121.3 (C18), 79.8 (C8), 70.9 (C9), 61.8 (C7), 54.1 
(C5), 41.5 (C20), 22.6 (C12), 22.4 (C6); HRMS (ESI) calcd for [C31H33N2O]+: 449.2593, found 
449.2581; IR max = 3061 (w, C-H), 2848 (s, C-H), 1701 (m, C=N, Ar), 1589 (s, C=C), 1558 (s, 
C=C) 1114 (s, C-O-C). 
6.2.24 Synthesis of methyl 2-acetamido-2-methylpent-4-ynoate (37) 
 
To a solution of 4 (257 mg, 1.82 mmol) in CH2Cl2 (18 mL) at 0 °C was added triethylamine 
(0.380 mL, 2.70 mmol) and acetyl chloride (0.193 mL, 2.70 mmol) and the reaction warmed to 
r.t. and stirred for 6 hours. Upon completion, NH4Cl saturated aqueous solution was added 
and the reaction extracted with EtOAc (3 x 50 mL). The combined organic extracts were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 2:3) to give 37 
(322 mg, 1.76 mmol, 97%) as a white solid. 
Rf = 0.19 (petroleum ether/EtOAc, 7:3); m.p. 98.5 – 99.4 °C; 1H NMR (400MHz, CDCl3) δ 6.22 
(1H, bs, NH), 3.77 (3H, s, H9), 3.05 (1H, dd, J = 16.9, 2.6 Hz, H5a), 2.92 (1H, dd, J = 16.9, 2.6 
Hz, H5b), 2.00 (3H, s, H1), 1.99 (1H, t, J = 2.6 Hz, H7), 1.59 (3H, s, H4); 13C NMR (101MHz, 
CDCl3) δ 173.6 (C8), 169.7 (C2), 79.7 (C6), 71.1 (C7), 58.8 (C3), 53.1 (C9), 26.4 (C5), 23.7 
(C1), 23.0 (C4); HRMS (ESI) cald for [C9H14NO3]+: 184.0968, found 184.0968; IR max = 3385 
(m, N-H), 3233 (m, C≡C-H), 2179 (w, C≡C), 1722 (s, C=O ester), 1663 (s, C=O amide), 1249 
(s, C-O-C). 
6.2.25 Synthesis of N-(1-hydroxy-2-methylpent-4-yn-2-yl)acetamide (38) 
 
To a solution of 37 (810 mg, 4.42 mmol) in THF (44 mL) at 0 °C was LiBH4 (192 mg, 8.81 
mmol) and the reaction stirred for 16 hours. Upon completion, the reaction was quenched with 
water and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with 
brine, dried over Na2SO4 and concentrated in vacuo to give 38 (568 mg, 3.66 mmol, 83%) as 
a white solid. 
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Rf = 0.22 (petroleum ether/EtOAc, 1:4); m.p. 107.6 – 108.8 °C; 1H NMR (400MHz, CDCl3) δ 
5.74 (1H, bs, NH), 4.68 (1H, t, J = 5.9 Hz, OH), 3.71 – 3.63 (2H, m, H8), 2.80 (1H, dd, J = 16.9, 
2.6 Hz, H5a), 2.43 (1H, dd, J = 16.9, 2.6 Hz, H5b), 2.07 (1H, t, J = 2.7 Hz, H7), 2.02 (3H, s, 
H1), 1.33 (3H, s, H4); 13C NMR (101MHz, CDCl3) δ 171.5 (C2), 80.1 (C6), 71.6 (C7), 69.2 (C8), 
57.8 (C3), 26.8 (C5), 24.2 (C1), 22.8 (C4); HRMS (ESI) cald for [C8H14NO2]+: 156.1019, found 
156.1019. IR max = 3308 (m, C≡C-H), 3246 (br m, O-H), 2876 (m, C-H), 1642 (s, C=O), 1378 
(s, C-O), 1052 (s, C-O).  
6.2.26 Synthesis of N-(1-(allyloxy)-2-methylpent-4-yn-2-yl)acetamide (39) 
 
To a solution of 38 (250 mg, 1.61 mmol) in DMF (17.8 mL) at 0 °C was added NaH (70.0 mg, 
1.77 mmol) and the reaction stirred for 15 minutes before allyl bromide (153 uL, 1.77 mmol) 
was added. The reaction was stirred for 3 hours before NH4Cl saturated aqueous solution was 
added and the reaction mixture was extracted with EtOAc (3 x 20 mL). The organic extracts 
were combined, washed with brine and dried over Na2SO4. The crude product was purified by 
flash column chromatography (silica gel; petroleum ether/EtOAc, 3:2) to give 39 (276 mg, 1.41 
mmol, 88%) as a colourless oil.  
Rf  = 0.25 (petroleum ether/EtOAc, 3:2); 1H NMR (400MHz, CDCl3) δ 5.94 – 5.84 (1H, m, H10), 
5.67 (1H, bs, NH), 5.29 – 5.17 (1H, m, H11), 4.01 (2H, d, J = 5.6 Hz, H9), 3.63 (1H, d, J = 9.3, 
H8a), 3.44 (1H, d, J = 9.2 Hz, H8b), 2.89 (1H, dd, J = 16.7, 2.7 Hz, H5a), 2.62 (1H, dd, J = 
16.7, 2.7 Hz, H5b), 1.98 (1H, t, J = 2.7 Hz, H7), 1.94 (3H, s, H1), 1.43 (3H, s, H4); 13C NMR 
(101MHz, CDCl3) δ 170.2 (C2), 134.6 (C10), 117.4 (C11), 80.7 (C6), 73.9 (C8), 72.4 (C9), 70.7 
(C7), 55.7 (C3), 26.1 (C5), 24.5 (C1), 21.3 (C4); HRMS (ESI) cald for [C11H18NO2]+: 196.1329, 
found 196.1332; IR max = 3281 (m, C≡C-H), 3079 (w, C-H), 2929 (w, C-H), 2351 (w, C≡C), 
1653 (s, C=C), 1543 s, (C=C). 
6.2.27 Synthesis of N-(3-methyl-5-vinyl-2,3,4,7-tetrahydrooxepin-3-yl)acetamide 
(40) 
 
A solution of 39 (240 mg, 1.18 mmol) in CH2Cl2 (22.8 mL) was degassed with an argon purge 
for 15 minutes. Grubbs-II (100 mg, 0.118 mmol) was added and the reaction was degassed 
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with ethylene and stirred under this atmosphere for 18 hours. Then, the reaction was 
concentrated in vacuo and purified by flash column chromatography (silica gel; petroleum 
ether/EtOAc, 1:1) to give 40 (120 mg, 0.614 mmol, 52%).  
Rf = 0.22 (petroleum ether/EtOAc, 2:3); 1H NMR (400 MHz, CDCl3) δ 6.31 (1H, dd, J = 17.4, 
10.8 Hz, H5), 5.87 (1H, t, J = 5.2 Hz, H7), 5.66 (1H, br s, NH), 5.33 (1H, d, J = 17.4 Hz, H6t), 
5.07 (1H, d, J = 10.8 Hz, H6c), 4.30 (1H, dd, J = 15.2, 6.2 Hz, H8a), 4.13 (1H, dd, J = 15.2, 4.9 
Hz, H8b), 3.97 (1H, d, J = 12.3 Hz, H9a), 3.50 (1H, d, J = 12.4 Hz, H9b), 3.28 (1H, d, J = 15.0 
Hz, H3a), 2.41 (1H, d, J = 15.0 Hz, H3b), 1.87 (3H, s, H11), 1.44 (3H, s, H1); 13C NMR (101 
MHz, CDCl3) δ 170.2 (C10), 140.0 (C5), 139.5 (C4), 129.7 (C7), 114.1 (C6), 81.4 (C9), 69.1 
(C8), 53.8 (C2), 35.6 (C3), 24.3 (C11), 23.2 (C1); HRMS (ESI) calcd for [C11H17NO2Na]+: 
218.1152, found 218.1146; IR max = 3315 (m, N-H), 2935 (m, C-H), 1655 (s, C=O), 1650 (s, 
C=C), 1541 (s, C=C), 1128 (m, C-O-C). 
6.2.28 Synthesis of N-(4,9-dimethyl-8,10-dioxo-3,4,5,7,7a,8,9,10,10a,10b-
decahydro-1H-oxepino[3,4-e]isoindol-4-yl)acetamide (41) 
 
To a solution of 40 (45.0 mg, 0.230 mmol) in toluene (2.3 mL) was added N-methylmaleimide 
(51.0 mg, 4.62 mmol) and the reaction heated to 110 °C for 5 hours. Then, the reaction was 
cooled to r.t. and concentrated in vacuo to give a mixture of diastereomers (dr = ca. 85:15, 
determined by 1H NMR). The major diastereomer was isolated by flash column 
chromatography (silica gel, EtOAc) to give 41 (49.0 mg, 0.160 mmol, 70%) as a white solid.  
 
Rf = 0.12 (EtOAc); m.p. 134 – 137 ºC; 1H NMR (400 MHz, CDCl3) δ 5.73 – 5.71 (1H, m, H7), 
5.50 (1H, s, NH), 4.26 – 4.16 (2H, m, H15), 3.85 (1H, dd, J = 12.5, 2.2 Hz, H16a), 3.27 (1H, d, 
J = 12.5 Hz, H16b), 3.16 – 3.12 (1H, m, H14), 3.05 – 3.01 (2H, m, H5a & H9), 2.89 (3H, s, 
H11), 2.69 (1H, ddd, J = 15.3, 7.3, 0.93 Hz, H8a), 2.60 – 2.56 (1H, m, H13), 2.35 (1H, d, J = 
14.4 Hz, H5b), 2.16 – 2.08 (1H, m, H8b), 1.83 (3H, s, H1), 1.31 (3H, s, H3); 13C NMR (101 
MHz, CDCl3) δ 179.5 (C10), 178.0 (C12), 169.8 (C2), 139.6 (C6), 125.4 (C7), 81.4 (C16), 72.6 
(C15), 56.7 (C4), 43.8 (C5), 42.7 (C9), 41.5 (C13), 40.6 (C14), 25.0 (C8), 24.9 (C11), 24.0 
(C1), 22.0 (C3); HRMS (ESI) calcd for [C16H23N2O4]+: 307.1658, found 307.1663; IR max = 




6.2.29 Synthesis of N-(1-(but-2-yn-1-yloxy)-2-methylpent-4-yn-2-yl)acetamide 
(42) 
 
A solution of 38 (150 mg, 0.965 mmol) in DMF (9.6 mL) was cooled to 0 °C before NaH (42.0 
mg, 1.06 mmol) was added. The reaction was stirred for 20 minutes before 1-bromo-2-butyne 
(93.0 uL, 1.06 mmol) was added and the reaction was stirred for 3 hours. Upon completion 
NH4Cl saturated aqueous solution was added and the reaction mixture was extracted with 
EtOAc (3 x 20 mL). The combined organic extracts were washed with brine, dried over Na2SO4 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica gel; petroleum ether/EtOAc, 3:2) to give 42 (164 mg, 0.791 mmol, 82%) as a colourless 
oil.  
Rf = 0.22 (petroleum ether/EtOAc, 3:2); 1H NMR (400 MHz, CDCl3) δ 5.67 (1H, bs, NH), 4.13 
(2H, m, H9), 3.89 (1H, d, J = 9.2 Hz, H8a), 3.51 (1H, d, J = 9.2 Hz, H8b), 2.91 (1H, dd, J = 
16.8, 2.7 Hz, H5a), 2.61 (1H, dd, J = 16.7, 2.6 Hz, H5b), 1.99 (1H, t, J = 2.7 Hz, H7), 1.94 (3H, 
s, H1), 1.86 (3H, t, J = 2.3 Hz, H12), 1.44 (3H, s, H4); 13C NMR (101 MHz, CDCl3) δ 170.2 
(C2), 83.0 (C6), 80.7 (C10) 75.0 (C11) 73.6 (C8), 70.7 (C7), 59.4 (C9), 55.6 (C3), 26.0 (C5) 
24.5 (C1), 21.2 (C4) 3.8 (C12); HRMS (ESI) cald for [C12H17NO2Na]+: 230.1152, found 
230.1146; IR max = 3292 (m, C≡C-H) 2922 (w, C-H), 2364 (w, C≡C-R), 2242 (w, C≡C), 1650 
(s, C=O), 1090 (s, C-O). 
6.2.30 Synthesis of N-(4,9-dimethyl-7-phenyl-1,3,4,5-tetrahydrooxepino[3,4-
c]pyridin-4-yl)acetamide (43) 
 
CpCo(CO)2 (96.0 uL, 0.540 mmol) and benzonitrile (104 uL, 1.54 mmol) and) were added to a 
solution of 42 (80.0 mg, 0.386 mmol) in toluene (3.8 mL) previously degassed with an argon 
purge, and the heated to 110 °C for 48 hours in a sealed tube. Then, the reaction was cooled 
to r.t. and the solvents removed in vacuo. The crude product was purified by flash column 
chromatography (silica gel; petroleum ether/EtOAc, 7:3) 43 (16.0 mg, 0.0515 mmol, 22%, 
based on 39% recovered unreacted starting material) as a white solid.  
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Rf = 0.12 (petroleum ether/EtOAc, 1:1); m.p. 147 –151 ºC; 1H NMR (500 MHz, CDCl3) δ 7.98 
– 7.96 (2H, m, H10), 7.47 – 7.42 (3H, m, H7 & H11), 7.38 (1H, m, H12), 5.49 (1H, br s, NH), 
5.13 (1H, d, J = 14.0 Hz, H16a), 4.55 (1H, d, J = 14.0 Hz, H16b), 3.98 (1H, dd, J = 12.3, 2.0 
Hz, H17a), 3.79 (1H, dd, J = 14.3, 2.0 Hz, H5a), 3.64 (1H, d, J = 12.3 Hz, H17b), 3.04 (1H, d, 
J = 14.2 Hz, H5b), 2.67 (3H, s, H14), 1.65 (3H, s, H1), 1.46 (3H, s, H3); 13C NMR (126 MHz, 
CDCl3) δ 170.2 (C2), 156.2 (C8), 154.8 (C13), 148.1 (C6), 139.1 (C9), 130.4 (C15), 128.9 
(C12), 128.7 (C11), 126.9 (C10), 121.0 (C7), 83.0 (C17), 69.8 (C16), 54.0 (C4), 43.6 (C5), 23.9 
(C1), 22.9 (C14), 22.8 (C3); HRMS (ESI) calcd for [C19H23N2O2]+: 311.1760, found 311.1764. 
IR max = 3295 (m, N-H), 3063 (w, C-H), 2919 (m, C-H), 1649 (s, C=O), 1591 (m, C=C), 1539 
(s, C=C), 1441 (s, C=C), 1087 (s, C-O-C). 
6.2.31 Synthesis of 4-methyl-4-(prop-2-yn-1-yl)oxazolidin-2-one (45) 
 
To an ice-cooled stirred solution of 7 (33.0 mg, 0.155 mmol) in THF (1.60 mL) was added t-
BuOK (35.0 mg, 0.312 mmol) and the reaction was allowed to warm to r.t. for 6 hours. The 
reaction was diluted with NH4Cl saturated aqueous solution and extracted with CH2Cl2 (3 x 20 
mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo to give 45 (14.7 mg, 0.106 mmol, 67 %) as a white solid without further purification. 
Rf = 0.26 (petroleum ether/EtOAc, 1:1); m.p. 83.2 – 85.1 °C; 1H NMR (400 MHz, CDCl3) δ 5.92 
(1H, br s, NH), 4.28 (1H, d, J = 8.7 Hz, H2a), 4.10 (1H, d, J = 8.7 Hz, H2b), 2.53 – 2.44 (2H, 
m, H5), 2.09 (1H, t, J = 2.6 Hz, H7), 1.46 (3H, s, H4); 13C (101 MHz, CDCl3) δ 158.7 (C1), 78.7 
(C6), 75.0 (C2), 72.0 (C7), 57.2 (C3), 31.1 (C5), 25.2 (C4); HRMS (ESI) calcd for [C7H10NO2]+: 
140.0706, found 140.0708; IR max = 3235 (s, C≡C-H), 2891 (w, C-H), 2030 (w, C≡C), 1729 (s, 
C=O). 
6.2.32 Synthesis of tert-butyl 2-methyl-2-(prop-2-yn-1-yl)aziridine-1-carboxylate 
(46) 
 
To a solution of 7 (500 mg, 2.34 mmol) in Et2O (40 mL), TsCl (536 mg, 2.81 mmol) and 
powdered KOH (789 mg, 14.1 mmol) were added and the reaction refluxed for 18 hrs. Further 
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KOH (263 mg, 4.69 mmol) was added and the reaction stirred for additional 3 hours. The 
reaction was cooled to r.t and diluted with water. The aqueous solution was extracted with Et2O 
(2 x 60 mL) and the combined organic extracts dried over Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography (silica gel; 
petroleum ether/EtOAc, 4:1) to give the 46 (357 mg, 1.83 mmol, 78%) as a colourless oil. 
Rf = 0.55 (petroleum ether/EtOAc, 9:1); 1H NMR (400 MHz, CDCl3) δ 2.54 (1H, dd, J = 17.1, 
2.6 Hz, H7a), 2.35 (1H, dd, J = 17.1, 2.7 Hz, H7b), 2.23 (1H, s, H4a), 2.10 (1H, s, H4b), 2.06 
(1H, t, J = 2.8 Hz, H9), 1.46 (9H, s, H1), 1.37 (3H, s, H6); 13C (101 MHz, CDCl3) δ 160.7 (C3), 
81.2 (C2), 79.8 (C8), 71.2 (C9), 41.3 (C5), 36.5 (C4), 28.1 (C1), 27.2 (C7), 19.8 (C6); HRMS 
(ESI) calcd for [C11H18NO2]+: 196.1332, found 196.1333; IR max = 3290 (m, C≡C-H), 2975 (w, 
C-H), 2160 (m, C≡C), 1711 (s, C=O), 1159 (m, C-O).  
6.2.33 Synthesis of 4-methyl-4-((1-phenyl-1H-1,2,3-triazol-4-
yl)methyl)oxazolidin-2-one (47) 
 
To a solution of 45 (20.0 mg, 0.140 mmol) in H2O (0.5 mL) and t-BuOH (0.5 mL) was added 
PhN3 (0.5M in tert-butyl methyl ether) (0.431 mL, 0.215 mmol) followed by CuSO4 (3.60 mg, 
0.0420 mmol). The reaction was stirred at r.t. for 24 hours. Upon completion the reaction was 
concentrated in vacuo. The sample was taken up in CH2Cl2 (10 mL) and washed with 5% 
NH4OH aqueous solution (10 mL), dried over Na2SO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel; EtOAc) to give 47 (26.0 mg, 
0.100 mmol, 72%) as a white solid.   
Rf = 0.12 (petroleum ether/EtOAc, 1:1); m.p. 147.3 – 146.7 °C; 1H NMR (400 MHz, CDCl3) δ 
7.99 (1H, s, H7), 7.71 – 7.67 (2H, m, H9), 7.48 – 7.44 (2H, m, H10), 7.40 – 7.36 (1H, m, H11), 
6.97 (1H, s, NH), 4.40 (1H, d, J = 8.6 Hz, H2a), 4.11 (1H, d, J = 8.6 Hz, H2b), 3.10 – 3.02 (2H, 
m, H5), 1.41 (3H, s, H4); 13C (101 MHz, CDCl3) δ 159.3 (C1), 142.9 (C6), 136.9 (C8), 129.7 
(C10), 128.7 (C11), 121.1 (C7), 120.4 (C9), 75.2 (C2), 57.7 (C3), 36.3 (C5), 25.7 (C4); HRMS 
(ESI) calcd for [C13H15N4O2]+: 259.1190, found 259.1196; IR max = 2918 (m, C-H), 1737 (s, 




6.2.34 Synthesis of 7a-methyl-7,7a-dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one 
(48) 
 
InCl3 (62.0 mg, 0.280 mmol) was introduced into 5 mL flask and heated with a heat gun (150°C) 
under vacuum for 2 minutes. After being allowed to cool to r.t., THF (1 mL) was added under 
Argon. The mixture was stirred at r.t. for 10 minutes and cooled to -78 °C. DIBAL-H (1.00 M in 
hexane, 0.279 mL, 0.279 mmol) was added dropwise and the mixture was stirred at -78 °C for 
40 minutes. Then, 45 (25.0 mg, 0.179 mmol) was then added, followed by BEt3 (1.0 M in THF, 
0.0900 mL, 0.0900 mmol) and the mixture was stirred at -78 °C for 3 hours. A solution of iodine 
(274 mg, 1.08 mmol) in THF (0.5 mL) was then added. After 40 minutes, the mixture was 
poured onto a NaHCO3 saturated aqueous solution (5 mL). Na2S2O3 was added under stirring 
until complete decoloration and the aqueous layer was extracted with EtOAc (5 x 10 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was dissolved in toluene (1.8 mL) and CuI (15.0 mg, 0.0788 mmol), Cs2CO3 
(70.0 mg, 0.214 mmol) and N,N’-dimethylethane-1,2-diamine (17.0 μL, 0.158 mmol) were 
added. The mixture was stirred at 85 °C for 2 hours and cooled to r.t., diluted with DCM (5 mL) 
and the organics washed with water (5 mL). The aqueous layer was extracted with DCM (3 x 
5 mL) and the combined organic extracts were dried over Na2SO4, filtered and concentrated 
in vacuo. The crude product was purified by flash column chromatography (silica gel; 
petroleum ether/EtOAc, 2:1) to yield 48 (7.00 mg, 0.0503 mmol, 28%) as a colourless oil. 
 
Rf  = 0.14 (petroleum ether/EtOAc, 85:15); 1H NMR (400 MHz, CDCl3) δ 6.38 – 6.35 (1H, m, 
H3), 5.23 – 5.21 (1H, m, H2), 4.28 (1H, d, J = 8.6 Hz, H5a) 4.20 (1H, d, J = 8.6 Hz, H5b), 2.71 
(1H, dt, J = 16.6, 2.6 Hz, H1a), 2.37 (1H, qd, J = 11.5, 2.8 Hz, H1b), 1.39 (3H, s, H7); 13C (101 
MHz, CDCl3) δ 157.2 (C4), 127.2 (C1), 112.7 (C2), 77.4 (C5), 65.0 (C6), 43.0 (C3), 26.8 (C7); 
HRMS (ESI) [C7H10NO2]+: 140.0706, found 140.0712; IR max = 3133 (m, C-H), 1757 (s, C=O), 
1594 (m, C=C), 1501 (s, C=C), 1041 (s, C-O-C) 762 (s, C-H, cis). 
6.2.35 Synthesis of ethyl 2-azidoacetate  
 
To a solution of ethyl bromoacetate (300 mg, 1.79 mmol) in acetone (7.5 mL) and H2O (2.5 
mL), was added sodium azide (233 mg, 3.60 mmol) and the reaction stirred for 18 hours at r.t. 
The reaction was diluted with brine and extracted with EtOAc (2 x 20 mL). The combined 
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organic extracts were dried over Na2SO4, filtered and concentrated in vacuo to give ethyl 2-
azidoacetate (220 mg, 1.70 mmol, 95%) as a colourless oil without further purification. 
Rf =  0.80 (petroleum ether/EtOAc, 4:1); 1H NMR (400 MHz, CDCl3) δ 4.24 (2H, q, J = 7.2 Hz, 
H3), 3.84 (2H, s, H1), 1.29 (3H, t, J = 7.1 Hz, H4); 13C (101 MHz, CDCl3) δ 168.4 (C2), 61.9 
(C3), 50.4 (C1), 14.2 (C4); IR max = 2986 (m, C-H), 2103 (s, N=N), 1741 (s, C=O), 1193 (C-
O-C). 
These characterisation data are in accordance with that previously reported in the literature.331 
6.2.36 Synthesis of tert-butyl 2-((1-(2-ethoxy-2-oxoethyl)-1H-1,2,3-triazol-5-
yl)methyl)-2-methylaziridine-1-carboxylate (49) 
 
A solution of 48 (50.0 mg, 0.256 mmol) and ethyl 2-azidoacetate (49.6 mg, 0.384 mmol) in 
toluene (3 mL) was degassed with argon before Cp*Ru(COD)Cl (3.90 mg, 0.0102 mmol) was 
added. The reaction was stirred at r.t. for 18 hours and then heated to 60 °C for 3 hours. Further 
Cp*Ru(COD)Cl (7.80 mg, 0.0204 mmol) was added and the reaction stirred at the same 
temperature for 24 hours. Upon completion the reaction was concentrated in vacuo and the 
crude product purified by flash column chromatography (silica gel, petroleum ether/EtOAc, 3:2) 
to give the 49 (35.0 mg, 0.108 mmol, 42%) as a brown oil.  
Rf = 0.12 (petroleum ether/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.61 (1H, s, H9), 5.41 
(1H, d, J = 17.7 Hz, H10a), 5.26 (1H, d, J = 17.8 Hz, H10b) 4.26 – 4.19 (2H, m, H12), 3.01 
(1H, d, J = 15.5 Hz, H7a), 2.73 (1H, d, J = 15.5 Hz, H7b), 2.17, (1H, s, H4a), 2.01 (1H, s, H4b), 
1.41 (9H, s, H1), 1.28 (3H, t, J = 7.3 Hz, H13), 1.24 (3H, s, H6); 13C (101 MHz, CDCl3) δ 166.9 
(C11), 160.3 (C3), 134.1 (C9), 133.7 (C8), 81.8 (C2), 62.3 (C12), 49.5 (C10), 41.4 (C5), 36.1 
(C4), 31.2 (C7), 28.1 (C1), 19.1 (C6), 14.2 (C13); HRMS (ESI) calcd for [C15H25N4O4]+: 
325.1876, found 325.1871; IR max = 2978 (w, C-H), 1749 (S, C=O), 1712 (s, C=O), 1553 (w, 




6.2.37 Synthesis of tert-butyl 2-((1-(2-(benzyloxy)-2-oxoethyl)-1H-1,2,3-triazol-5-
yl)methyl)-2-methylaziridine-1-carboxylate (50) 
 
A solution of 48 (31.0 mg, 0.154 mmol) and benzyl 2-azidoacetate (44.2 mg, 0.231 mmol) in 
toluene (1.00 mL) was degassed with argon before Cp*Ru(COD)Cl (5.00 mg, 0.0130 mmol) 
was added and the reaction heated to 80 °C for 90 minutes. The reaction was filtered through 
Celite washing with EtOAc and the filtrated concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc, gradient 1:1 to 
0:1) to give the 50 (57.0 mg, 0.147 mmol, 95%) as a white solid. 
Rf = 0.34 (petroleum ether/EtOAc, 2:3); m.p. 92.1 – 93.0 oC; 1H NMR (400 MHz, CDCl3) δ 7.62 
(1H, s, H8), 7.38 – 7.31 (5H, m, H1/2/3), 5.49 (1H, d, J = 17.9 Hz, H7a), 5.32 (1H, d, J = 18.0 
Hz, H7b), 5.24 – 5.17 (2H, m, H5), 2.99 (1H, d, J = 15.5 Hz, H10a), 2.68 (1H, d, J = 15.6 Hz, 
H10b), 2.15 (1H, s, H13a), 1.97 (1H, s, H13b), 1.40 (9H, s, H16), 1.21 (3H, s, H11); 13C (101 
MHz, CDCl3) δ 166.8 (C6), 160.3 (C14), 134.8 (C4), 134.2 (C8), 133.7 (C9), 128.9 (C2), 128.9 
(C1), 128.6 (C3), 81.9 (C15), 67.9 (C5), 49.6 (C7), 41.5 (C12), 36.1 (C13), 31.2 (C10), 28.1 
(C16), 19.0 (C11); HRMS (ESI) calcd for [C20H27N4O4]+: 387.2024, found 387.2032; IR max = 
2979 (w, C-H), 1748 (s, C=O), 1704 (s, C=O), 1553 (w, C=C), 1500 (w, C=C). 
6.2.38 Synthesis of 2-((tert-butoxycarbonyl)amino)-2-methylpent-4-yn-1-yl 2-
chloroacetate (51) 
 
To an ice-cooled solution of 7 (84.0 mg, 0.394 mmol) and trimethylamine (65.0 uL, 0.473 mmol) 
in CH2Cl2 (3 mL) was added chloroacetyl chloride (37.6 uL, 0.473 mmol) and the reaction 
warmed to r.t. over 20 minutes before heating to 40 °C for 7 hours. Further chloroacetyl chloride 
(9.40 uL, 0.118 mmol) was added and the reaction heated for a further 1.5 hours. Upon 
completion, the reaction was diluted with H2O and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. The 
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crude product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 
3:2) to give 51 (80.3 mg, 0.278 mmol, 70%) as a colourless oil. 
Rf = 0.14 (petroleum ether/EtOAc, 85:15); 1H NMR (400 MHz, CDCl3) δ 4.68 (1H, br s, NH), 
4.41 (1H, d, J = 11.0 Hz H9a), 4.32 (1H, d, J = 11.0 Hz H9b), 4.08 (2H, s, H11), 2.74 (1H, dd, 
J = 16.7, 2.1 Hz, H5a), 2.54 (1H, dd, J = 16.7, 2.6 Hz, H5b), 2.04 (1H, t, J = 2.7 Hz, H7), 1.41 
(9H, s, H1), 1.38 (3H, s, H8); 13C (101 MHz, CDCl3) δ 167.0 (C10), 154.4 (C3), 79.9 (C2), 79.4 
(C6), 71.7 (C7), 68.8 (C9), 54.0 (C4), 40.8 (C11), 28.4 (C1), 26.9 (C5), 22.0 (C8); HRMS (ESI) 
calcd for [C13H21NO4Cl]+: 290.1159, found 290.1144; IR max = 3295 (w, C≡C-H), 2979 (w, C-
H), 2002 (w, C≡C), 1755 (m, C=O), 1702 (s, C=O), 1243 (m, C-Cl). 
6.2.39 Synthesis of 5-methyl-5-(prop-2-yn-1-yl)morpholin-2-one (53) 
 
To a solution of 51 (24.0 mg, 0.0830 mmol) in CH2Cl2 (0.9 mL) was added TFA (0.85 mL) and 
the reaction stirred at r.t. for 2 hours 30 minutes. The reaction was concentrated in vacuo to 
afford a colourless gum. To a solution of this salt (40.0 mg, 0.138 mmol) in THF (1.30 mL) was 
added triethylamine (77.0 uL, 0.553 mmol) and the reaction stirred for 6 hours. The reaction 
was diluted with water and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts 
were washed with NH4Cl saturated aqueous solution, dried over Na2SO4, filtered and 
concentrated in vacuo to give 53 (16.0 mg, 0.105 mmol, 76%) as a colourless oil. 
Rf = 0.41 (petroleum ether/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3) δ 6.91 (1H, br s, NH), 4.03 
(2H, s, H2), 3.73 (2H, s, H8), 2.78 (1H, dd, J = 17.0, 2.8 Hz, H4a), 2.48 (1H, dd, J = 16.9, 2.7 
Hz, H4b), 2.11 (1H, t, J = 2.8 Hz, H6), 1.40 (3H, s, H7); 13C (101 MHz, CDCl3) δ 166.7 (C1), 
79.5 (C5), 72.1 (C6), 68.3 (C8), 58.0 (C3), 43.0 (C2), 26.9 (C4), 22.2 (C7); HRMS (ESI) cald 
for [C8H12NO2]+: 154.0863, found 154.0862; IR max = 3305 (w, C≡C-H), 3057 (w, C-H), 1666 
(C=O), 1264 (s, C-O). 
6.2.40 Synthesis of 2-chloro-N-(1-hydroxy-2-methylpent-4-yn-2-yl)acetamide (52) 
 
To a solution of 7 (140 mg, 0.656 mmol) in CH2Cl2 (1 mL) was added HCl (2M in Et2O) (4.28 
mL, 0.856 mmol) and the reaction stirred for 22 hours. Then, the reaction was concentrated in 
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vacuo to give the intermediate salt. A solution of the intermediate (93.0 mg) in CH2Cl2 (6.5 mL) 
was cooled to 0 °C before triethylamine (0.260 mL, 1.97 mmol) was added. Chloroacetyl 
chloride (59.0 μL, 0.744 mmol) was added drop-wise and the reaction was warmed to r.t. and 
stirred for 5 hours. Then, NH4Cl saturated aqueous solution (30 mL) was added and extracted 
with EtOAc (3 x 10 mL). The combined organics were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (silica 
gel; petroleum ether/EtOAc 7:3) to give 52 (102 mg, 0.538 mmol, 88%) as a colourless oil.  
Rf = 0.21 (petroleum ether/EtOAc 3:2); 1H NMR (400 MHz, CDCl3) δ 6.91 (1H, br s, NH or OH), 
4.04 (2H, s, H8), 3.95 (1H, s, NH or OH), 3.73 (2H, s, H6), 2.78 (1H, dd, J = 16.9, 2.7 Hz, H3a), 
2.48 (1H, dd, J = 16.9, 2.6 Hz, H3b), 2.11 (1H, t, J = 2.7 Hz, H5), 1.40 (3H, s, H1); 13C NMR 
(101 MHz, CDCl3) δ 166.7 (C7), 79.4 (C4), 72.1 (C5), 68.4 (C6), 58.0 (C2), 43.0 (C8), 26.9 
(C3), 22.2 (C1); HRMS (ESI) calcd for [C8H13NO235Cl]+: 190.0629, found 190.0629. IR max = 
3294 (w, C≡C-H),  2937 (w, C-H), 1660 (s, C=O), 1262 (m, C-OH), 1057 (s, C-OH). 
6.2.41 Synthesis of 5-methyl-5-(prop-2-yn-1-yl)morpholin-3-one (54) 
 
To a solution of 52 (102 mg, 0.540 mmol) in t-BuOH (5.4 mL) was added t-BuOK (65.0 mg, 
0.579 mmol) and the reaction heated to 30 °C for 6 hours. Then, NH4Cl saturated aqueous 
solution was added and the solution extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were dried over Mg2SO4 and concentrated in vacuo. The crude product was purified 
by flash column chromatography (silica gel; petroleum ether/EtOAc 7:3) to give 54 (60.0 mg, 
0.392 mmol, 73%) as a white solid.  
Rf = 0.09 (petroleum ether/EtOAc 3:2); m.p. 77 – 79 °C; 1H NMR (400 MHz, CDCl3) δ 6.32 
(1H, s, NH), 4.18 (1H, d, J = 16.7 Hz, H7a), 4.11 (1H, d, J = 16.7 Hz, H7b), 3.75 (1H, d, J = 
11.8 Hz, H6a), 3.53 (1H, d, J = 11.8 Hz, H6b), 2.56 (1H, dd, J = 16.5, 2.6 Hz, H3a), 2.44 (1H, 
dd, J = 16.5, 2.6 Hz, H3b), 2.11 (1H, t, J = 2.6 Hz, H5), 1.34 (3H, s, H1); 13C NMR (101 MHz, 
CDCl3) δ 168.4 (C8), 79.0 (C4), 72.2 (C5), 71.9 (C6), 67.7 (C7), 53.9 (C2), 30.0 (C3), 23.5 
(C1); HRMS (ESI) calcd for [C8H12NO2]+: 154.0863, found 154.0863; IR max = 3526 (w, N-H), 




6.2.42 Synthesis of 8a-methyl-8,8a-dihydro-1H-pyrrolo[2,1-c][1,4]oxazin-4(3H)-
one (55) 
 
InCl3 (188 mg, 0.852 mmol) was introduced into 10 mL flask and heated with a heat gun (150 
°C) under vacuum for 2 minutes. After being allowed to cool to r.t., THF (4 mL) was added 
under Argon. The mixture was stirred at r.t. for 10 minutes and then cooled to −78 °C. DIBAL-
H (1.0 M in hexane, 0.852 mL, 0.852 mmol) was added drop-wise and the mixture was stirred 
at −78 ºC for 40 minutes. Then, 54 (87.0 mg, 0.570 mmol) in THF (1 mL) was added, followed 
by BEt3 (1.0 M in THF, 0.284 mL, 0.284 mmol) and the mixture was stirred at −78 ºC for 4.5 
hours. A solution of iodine (865 mg, 3.41 mmol) in THF (1 mL) was then added. After 1 hour, 
the mixture was poured onto NaHCO3 saturated aqueous solution (5 mL). Na2S2O3 was added 
under stirring until complete decoloration and the aqueous layer was extracted with EtOAc 
(5x). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The crude sample was purified over a short column (silica gel; 
petroleum ether/EtOAc, 7:3). The crude product (90.0 mg), Cs2CO3 (121 mg, 0.373 mmol) CuI 
(24.0 mg, 0.124 mmol) and N,N-dimethylethyl-1,2-diamine (27.0 uL, 0.249 mmol) in toluene (2 
mL) were heated to 80 °C for 3 hours (in a sealed tube). H2O (10 mL) was added and the 
reaction extracted with CH2Cl2 (5 x 10 mL). The combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to give a mixture of 
desired product and unreacted 55 (ca. 1:1 determined by 1H NMR). The crude product was 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 7:3) to give 50 
(12.0 mg, 0.0783 mmol, 24%) as a white solid (based on 43% recovered unreacted starting 
material).  
 
Rf = 0.17 (petroleum ether/EtOAc, 7:3); m.p. 77 – 79 ºC; 1H NMR (400 MHz, CDCl3) δ 6.87 – 
6.85 (1H, m, H6), 5.34 – 5.32 (1H, m, H7), 4.28 (1H, d, J = 17.1 Hz, H4a), 4.08 (1H, d, J = 17.1 
Hz, H4b), 3.93 (1H, d, J = 11.2 Hz, H3a), 3.58 (1H, d, J = 11.2 Hz, H3b), 2.59 (1H, dt, J = 15.8, 
2.5 Hz, H8a), 2.34 (1H, ddd, J = 15.8, 3.1, 1.3 Hz, H8b), 1.40 (3H, s, H1); 13C NMR (101 MHz, 
CDCl3) δ 164.0 (C5), 127.3 (C6), 111.3 (C7), 72.4 (C3), 66.1 (C4), 61.5 (C2), 40.5 (C8), 24.0 
(C1); HRMS (ESI) calcd for [C8H12N2O]+: 154.0868, found 154.0870; IR max = 3102 (w, C-H), 




6.3 Synthesis of NM450 derivatives 
6.3.1 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methylpent-4-
ynoate (77) 
 
To an ice-cooled solution of 4 (260 mg, 1.84 mmol) in CH2Cl2 (18 mL) was added triethylamine 
(0.385 mL, 2.76 mmol) followed by ethyl malonylchloride (0.354 mL, 2.76 mmol) portionwise. 
The reaction was warmed to r.t. and stirred for 3 hours and then NH4Cl saturated aqueous 
solution was added (20 mL). The organic layer was separated and the aqueous further 
extracted with CH2Cl2 (2 x 15 mL). The combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude sample was purified by flash column chromatography 
(silica gel; Heptane/EtOAc, gradient 0 – 60%) to give 77 (494 mg, 1.23 mmol, 95%) as a 
colourless oil. 
Rf = 0.23 (Petroleum ether/EtOAc, 3:2); 1H (400 MHz, CDCl3) δ 7.81 (1H, br s, NH), 4.20 (2H, 
q, J = 7.1 Hz, H2), 3.75 (3H, s, H8), 3.30 (2H, s, H4), 2.96 (2H, m, H9a & 9b), 1.99 (1H, t, J = 
2.7 Hz, H11), 1.60 (3H, s, H12), 1.28 (3H, t, J = 7.1 Hz, H1);13C (101 MHz, CDCl3) δ 173.2 
(C7), 169.3 (C3), 164.6 (C5), 79.3 (C10), 71.3 (C11), 61.8 (C2), 58.8 (C6), 53.1 (C8), 41.5 
(C4), 26.5 (C9), 22.8 (C12), 14.2 (C1); HRMS (ESI) calcd for [C12H18NO5]+: 256.1185, found 
256.1189; IR max = 3272 (w, C≡C-H), 2984 (w, C-H), 1735 (s, C=O), 1656 (s, C=O), 1124 (s, 
C-O-C). 
6.3.2 General procedure 1 
To a solution of alkyne 77 (1 eq.) in t-BuOH (1.5 mL) and H2O (1.5 mL) was added copper(II) 
sulfate pentahydrate (0.1 eq) and sodium ascorbate (0.3 eq.). The corresponding azide (0.9 
eq.) was then added and the reaction stirred for 16 hours. Upon completion, H2O was added 
and the mixture extracted with EtOAc (3x). The combined organic extracts were dried 




6.3.3 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(1-(2-
(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoate (79) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-2-
(trifluoromethyl) benzene (0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water 
(1.5 mL) were used. The crude product was purified by flash column chromatography (silica 
gel; heptane/EtOAc, 40-100%) to give 79 (78.0 mg, 0.176 mmol, 70%) as a colourless oil. 
Rf = 0.32 (heptane/EtOAc, 7:3); 1H (400 MHz, CDCl3) δ 7.85 – 7.83 (1H, m, H17), 7.75 – 7.71 
(1H, m, H15), 7.68 – 7.66 (3H, m, H12, H16 & NH), 7.56 (1H, d, J = 8.0 Hz, H14), 4.16 (2H, q, 
J = 7.1 Hz, H2), 3.81 (3H, s, H9), 3.68 (1H, d, J = 14.7 Hz, H10a), 3.52 (1H, d, J = 14.6 Hz, 
H10b), 3.27 (2H, s, H4), 1.69 (3H, s, H7), 1.24 (3H, t, J = 7.2 Hz, H1); 13C (101 MHz, CDCl3) δ 
173.9 (C8), 168.8 (C3), 164.7 (C5), 142.8 (C11), 135.1 (q, J = 2.4 Hz, C13), 133.2 (C15),130.4 
(C16), 129.1 (C14), 127.4 (q, J = 3.2 Hz, C17), 125.6 (q, J = 38 Hz, C18), 125.4 (C12), 125.0 
(q, J = 220 Hz, C19), 61.7 (C2), 60.2 (C6), 53.1 (C9), 42.1 (C4), 32.0 (C10), 23.3 (C7), 14.1 
(C1); 19F (376 MHz, CDCl3) δ -59.24 HRMS (ESI) calcd for [C19H22N4O5F3]+: 443.1537, found 
443.1523; IR max = 3315 (w, N-H), 2988 (w, C-H), 1736 (s, C=O), 1677 (s, C=O), 1608 (m, 
C=C), 1509 (s, C=C), 1316 (s, C-O-C). 
6.3.4 Synthesis of methyl 3-(1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl)-2-(3-ethoxy-
3-oxopropanamido)-2-methylpropanoate (80) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-2-chlorobenzene 
(0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. After 
16 hours, further copper(II) sulfate pentahydrate (6.36 mg, 0.0255 mmol) was added and the 
reaction stirred for a further 16 hours. The crude product was purified by flash column 
chromatography (silica gel; heptane/EtOAc, 20-100%) to give 80 (70.0 mg, 0.172 mmol, 69%) 
as a colourless oil. 
Rf = 0.35 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 7.80 (1H, s, H12), 7.65 (1H, 
br s, NH), 7.63 – 7.60 (1H, m, H14), 7.58 – 7.54 (1H, m, H17), 7.47 – 7.41 (2H, m, H16, H15), 
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4.15 (2H, q, J = 7.2 Hz, H2), 3.82 (3H, s, H8), 3.68 (1H, d, J = 7.6 Hz, H10a), 3.51 (1H, d, J = 
7.6 Hz, H10b), 3.28 (2H, s, H4), 1.69 (3H, s, H9), 1.24 (3H, t, J = 7.1 Hz, H1); 13C (101 MHz, 
CDCl3) δ 173.9 (C7), 168.8 (C3), 164.7 (C5), 142.6 (C11), 135.1 (C18), 130.9 (C17), 130.8 
(C16), 128.7 (C13), 128.0 (C15), 127.9 (C14), 125.0 (C12), 61.7 (C2), 60.2 (C6), 53.2 (C8), 
42.3 (C4), 32.1 (C10), 23.3 (C9), 14.2 (C1); HRMS (ESI) calcd for [C18H22N4O535Cl]+: 409.1279, 
found 409.1268; IR max = 3303 (w, N-H), 2986 (w, C-H), 1735 (s, C=O), 1676 (s, C=O), 1670 
(s, C=O), 1535 (s, C=C), 1496 (s, C=C), 1456 (s, C=C). 
6.3.5 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-3-(1-(2-
methoxyphenyl)-1H-1,2,3-triazol-4-yl)-2-methylpropanoate (81) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-2-
methoxybenzene (0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 
mL) were used. The crude product was purified by flash column chromatography (silica gel; 
heptane/EtOAc, 50-100%) to give 81 (66.0 mg, 0.163 mmol, 65%) as a white solid. 
Rf = 0.27 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 7.92 (1H, s, H12), 7.78 (1H, 
dd, J = 7.9, 1.7 Hz, H14), 7.62 (1H, br s, NH), 7.43 – 7.38 (1H, m, H16), 7.12 – 7.06 (2H, m, 
H17, H15), 4.14 (2H, q, J = 7.2 Hz, H2), 3.88 (3H, s, H19), 3.81 (3H, s, H8), 3.61 (1H, d, J = 
14.6 Hz, H10a), 3.47 (1H, d, J  = 14.6 Hz, H10b), 3.28 (2H, s, H4), 1.69 (3H, s, H9), 1.22 (3H, 
t, J = 7.2 Hz, H1); 13C (101 MHz, CDCl3) δ 174.0 (C7), 168.7 (C3), 164.6 (C5), 151.1 (C18), 
142.1 (C11), 130.0 (C16), 126.5 (C13), 125.5 (C14), 125.0 (C12), 121.4 (C15), 112.4 (C17), 
61.7 (C2), 60.2 (C6), 56.1 (C19), 53.1 (C8), 42.5 (C4), 32.4 (C10), 23.1 (C9), 14.1 (C1); HRMS 
(ESI) calcd for [C19H25N4O6]+: 405.1774, found 405.1787; IR max = 3251 (w, N-H) 3056 (w, C-
H) 1752 (s, C=O), 1731 (s, C=O), 1670 (s, C=O), 1557 (m, C=C), 1504 (m, C=C), 1453 (m, 
C=C), 1119 (s, C-O-C). 





Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-2-methylbenzene 
(0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. After 
4 days stirring, further copper(II) sulfate pentahydrate (6.36 mg, 0.0255 mmol) was added and 
stirred for 16 hours. The crude product was purified by flash column chromatography (silica 
gel; heptane/EtOAc, 20-100%) to give 82 (12.0 mg, 0.0309 mmol, 12%) as a colourless oil. 
Rf = 0.36 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 7.64 (1H, br s, NH), 7.57 (1H, 
s, H12), 7.44 – 7.30 (4H, m, H14, H15, H16 & H17), 4.14 (2H, q, J = 7.1 Hz, H2), 3.81 (3H, s, 
H9), 3.66 (1H, d, J = 14.5 Hz, H10a), 3.48 (1H, d, J = 14.7 Hz, H10b), 3.28 (2H, s, H4), 2.19 
(3H, s, H19), 1.70 (3H, s, H7), 1.23 (3H, t, J = 7.2 Hz, H1); 13C (101 MHz, CDCl3) δ 173.9 (C8), 
168.8 (C3), 164.6 (C5), 142.5 (C11), 136.7 (C13), 133.7 (C18), 131.6 (C17), 129.9 (C16), 
126.9 (C15), 126.1 (C14), 124.5 (C12), 61.7 (C2), 60.3 (C6), 53.1 (C9), 42.4 (C4), 32.3 (C10), 
23.2 (C7), 18.0 (C19), 14.2 (C1); HRMS (ESI) calcd for [C19H25N4O5]+: 389.1825, found 
389.1832; IR max = 3292 (w, N-H), 1738 (s, C=O), 1663 (s, C=O), 1540 (s, C=C), 1188 (m, C-
O-C). 
6.3.7 Synthesis of methyl 2-(3-methoxy-3-oxopropanamido)-3-(1-(3-
methoxyphenyl)-1H-1,2,3-triazol-4-yl)-2-methylpropanoate (83) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-3-
methoxybenzene (0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 
mL) were used. The crude product was purified by flash column chromatography (silica gel; 
heptane/EtOAc, 20-100%) to give 83 (67.0 mg, 0.172 mmol, 69%) as a colourless oil. 
Rf = 0.37 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 7.91 (1H, s, H12), 7.41 – 7.37 
(3H, m, H15, H19 & NH), 7.30 – 7.28 (1H, m, H16), 6.96 – 6.93 (1H, m, H14), 4.17 – 4.12 (2H, 
m, H2), 3.88 (3H, s, H18), 3.83 (3H, s, H9), 3.71 (1H, d, J = 14.6 Hz, H10a), 3.48 (1H, d, J = 
14.6 Hz, H10b), 3.28 (2H, s, H4), 1.69 (3H, s, H7), 1.23 (3H, t, J = 7.2 Hz, H1); 13C (101 MHz, 
CDCl3) δ 173.9 (C8), 169.2 (C3), 164.5 (C5), 160.7 (C17), 143.3 (C11), 138.2 (C13), 130.6 
(C15), 121.3 (C12), 114.7 (C16), 112.2 (C14), 106.0 (C19), 61.8 (C2), 60.4 (C6), 55.8 (C18), 
53.2 (C9), 42.5 (C4), 32.1 (C10), 23.2 (C7), 14.1 (C1); HRMS (ESI) calcd for [C19H24N4O6Na]+: 
427.1588, found 427.1586; IR max = 3264 (w, N-H), 3083 (w, C-H), 2952 (w, C-H), 1733 (s, 
C=O), 1660 (s, C=O), 1648 (s, C=O), 1610 (s, C=C), 1595, (s, C=C), 1498 (m, C=C). 
145 
 
6.3.8 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(1-(3-
(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)propanoate (84)  
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-3-
(trifluoromethyl) benzene (0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water 
(1.5 mL) were used. The crude product was purified by flash column chromatography (silica 
gel; heptane/EtOAc, 20-100%) to give 84 (93.0 mg, 0.210 mmol, 84%) as a white solid. 
Rf  = 0.47 (Petroleum ether/EtOAc, 7:13); 1H NMR (400MHz, CDCl3) δ 8.15 (1H, s, H12), 8.11 
– 8.10 (1H, m, H19), 8.06 – 8.04 (1H, m, H14), 7.69 – 7.63 (2H, m, H15 & H16), 7.24 (1H, br 
s, NH), 4.20 – 4.14 (2H, m, H2), 3.84 (3H, s, H9), 3.80 (1H, d, J = 14.6 Hz, H10a), 3.51 (1H, 
d, J = 14.6 Hz, H10b), 3.30 (2H, s, H4), 1.71 (3H, s, H7), 1.25 (3H, t, J = 7.1 Hz, H1); 13C 
(101MHz, CDCl3) 173.8 (C8), 168.8 (C3), 164.6 (C5), 143.7 (C11), 137.5 (C13), 132.3 (q, J = 
33.2 Hz, C18), 130.4 (C15), 125.0 (q, J = 3.7 Hz, C16), 123.4 (q, J = 272.9 Hz, C17), 123.3 
(C14), 121.4 (C12), 117.0 (q, J = 4.0 Hz, C19), 61.7 (C2) 60.4 (C6), 53.2 (C9), 42.8 (C4), 31.7 
(C10), 23.2 (C7), 14.0 (C1); 19F (376 MHz, CDCl3) δ -62.9; HRMS (ESI) calcd for 
[C19H22N4O5F3]+: 443.1542, found 443.1558; IR max = 3277 (w, N-H), 1736 (s, C=O), 1675 (s, 
C=O), 1661 (s, C=O), 1535 (m, C=C), 1460 (s, C=C), 1126 (s, C-O-C). 
6.3.9 Synthesis of methyl 3-(1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)-2-(3-ethoxy-
3-oxopropanamido)-2-methylpropanoate (85) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-3-chlorobenzene 
(0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. The 
crude product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20-
100%) to give 85 (69.0 mg, 0.168 mmol, 68%) as a white solid. 
LCMS MH+ (409.0); Rf = 0.34 (60% EtOAc/Heptane); 1H (400 MHz, CDCl3) δ 8.01 (1H, s, 
H12), 7.84 (1H, t, J = 2.0 Hz, H18), 7.72 – 7.69 (1H, m, H14), 7.45 (1H, t, J = 8.0 Hz, H15), 
7.40 – 7.38 (1H, m, H16), 7.33 (1H, br s, NH), 4.20 – 4.16 (2H, m, H2), 3.83 (3H, s, H8), 3.75 
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(1H, d, J = 14.6 Hz, H10a), 3.49 (1H, d, J = 14.6 Hz, H10b), 3.30 (2H, s, H4), 1.70 (3H, s, H9), 
1.26 (3H, t, J = 4.8 Hz, H1); 13C (101 MHz, CDCl3) δ 173.8 (C7), 168.7 (C3), 164.5 (C5), 143.5 
(C11), 137.9 (C17), 135.5 (C13), 130.7 (C15), 128.5 (C16), 121.2 (C12), 120.5 (C18), 118.2 
(C14), 61.7 (C2), 60.3 (C6), 53.1 (C8), 42.7 (C4), 31.8 (C10), 23.1 (C9), 14.0 (C1); HRMS 
(ESI) calcd for [C18H22N4O535Cl]+: 409.1279, found 409.1277; IR max = 3255 (w, N-H), 3079 
(w, C-H), 2986 (w, C-H), 1744 (s, C=O), 1729 (s, C=O), 1642 (s, C=O), 1597 (s, C=C), 1567 
(s, C=C), 1197 (s, C-O-C). 
6.3.10 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-3-(1-(4-
fluorophenyl)-1H-1,2,3-triazol-4-yl)-2-methylpropanoate (86) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-4-fluorobenzene 
(0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. The 
crude product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20-
100%) to give 86 (81.0 mg, 0.206 mmol, 83%) as a white solid. 
LCMS MH+ (393.0); Rf = 0.37 (petroleum ether/EtOAc, 2:3); 1H (400 MHz, CDCl3) δ  7.90 (1H, 
s, H12), 7.77 – 7.72 (2H, m, H14), 7.37 (1H, br s, NH), 7.23 – 7.17 (2H, m, H15), 4.17 – 4.12 
(2H, m, H2), 3.83 (3H, s, H8), 3.72 (1H, d, J =14.7 Hz, H10a), 3.48 (1H, d, J = 14.8 Hz, H10b), 
3.28 (2H, s, H4), 1.70 (3H, s, H9), 1.24 (3H, t, J = 7.2 Hz, H1); 13C (101 MHz, CDCl3) δ 174.0 
(C7), 168.8 (C3), 164.6 (C5), 162.3 (d, J = 234.4 Hz, C16), 143.6 (C11), 133.5 (C13), 122.3 
(d, J = 8.7 Hz, C14), 121.5 (C12), 116.8 (d, J = 23.0 Hz, C15), 61.8 (C2), 60.4 (C6), 53.2 (C8), 
42.8 (C4), 32.0 (C10), 23.3 (C9), 14.2 (C1); 19F (376 MHz, CDCl3) δ -112.7; HRMS (ESI) calcd 
for [C18H22N4O5F]+: 393.1574, found 393.1563; IR max = 3356 (w, N-H), 2928 (w, C-H), 1736 
(s, C=O), 1665 (s, C=O), 1517 (s, C=C). 
6.3.11 Synthesis of methyl 3-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)-2-(3-
ethoxy-3-oxopropanamido)-2-methylpropanoate (87) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-4-chlorobenzene 
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(0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. The 
crude product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20-
100%) to give 87 (76.0 mg, 0.186 mmol, 74%) as a white solid. 
LCMS MH+ (409.0); Rf = 0.41 (Heptane/EtOAc, 2:3); 1H (400 MHz, CDCl3) δ 7.94 (1H, s, H12), 
7.72 (2H, dt, J = 9.7, 2.5 Hz, H14), 7.48 (2H, dt, J = 9.7, 2.5 Hz, H15), 7.35 (1H, br s, NH), 4.14 
(2H, q, J = 7.2 Hz, H2), 3.83 (3H, s, H8), 3.74 (1H, d, J = 14.6 Hz, H10a), 3.48 (1H, d, J = 14.7 
Hz, H10b), 3.28 (2H, s, H4), 1.70 (3H, s, H9), 1.24 (3H, t, J = 7.1 Hz, H1); 13C (101 MHz, 
CDCl3) δ 173.9 (C7), 168.8 (C3), 164.7 (C5), 143.7 (C11), 135.7 (C16), 134.4 (C13), 130.0 
(C15), 121.5 (C14), 121.3 (C12), 61.8 (C2), 60.4 (C6), 53.3 (C8), 42.9 (C4), 32.0 (C10), 23.3 
(C9), 14.2 (C1); HRMS (ESI) calcd for [C18H22N4O535Cl]+: 409.1279, found 409.1287; IR max = 
3258 (w, N-H), 3078 (w, C-H), 2981 (w, C-H), 1744 (s, C=O), 1729 (s, C=O), 1641 (s, C=O), 
1563 (s, C=C), 1502 (s, C=C), 1198 (s, C-O-C). 
6.3.12 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(1-(p-
tolyl)-1H-1,2,3-triazol-4-yl)propanoate (88) 
 
Following general procedure 1: 77 (65.0 mg, 0.255 mmol), copper(II) sulfate pentahydrate 
(6.36 mg, 0.0255 mmol), sodium ascorbate (15.1 mg, 0.0762 mmol), 1-azido-2-
(trifluoromethyl) benzene (0.5M in TBME, 0.458 mL, 0.230 mmol), t-BuOH (1.5 mL) and water 
(1.5 mL) were used. The crude product was purified by flash column chromatography (silica 
gel; heptane/EtOAc, 20-100%) to give 88 (64.0 mg, 0.165 mmol, 66%) as a white solid. 
LCMS MH+ (389.0); Rf = 0.32 (Heptane/EtOAc, 3:2); 1H (400 MHz, CDCl3) δ 7.86 (1H, s, H12), 
7.61 (2H, dt, J = 8.9, 2.0 Hz H14), 7.45 (1H, br s, NH), 7.29 (2H, d, J = 8.1 Hz, H15), 4.14 (2H, 
q, J = 8.1 Hz, H2), 3.82 (3H, s, H8), 3.67 (1H, d, J = 14.6 Hz, H10a), 3.47 (1H, d, J = 14.6 Hz, 
H10b), 3.28 (2H, s, H4), 2.41 (3H, s, H17), 1.69 (3H, s, H9), 1.23 (3H, t, J = 7.2 Hz, H1); 13C 
(101 MHz, CDCl3) δ 174.0 (C7), 168.7 (C5), 164.7 (C3), 143.3 (C11), 138.7 (C16), 134.9 (C13), 
130.3 (C15), 121.2 (C12), 120.3 (C14), 61.8 (C2), 60.3 (C6), 53.2 (C8), 42.7 (C4), 32.1 (C10), 
23.2 (C9), 21.2 (C17), 14.1 (C1); HRMS (ESI) calcd for [C19H25N4O5]+: 389.1825, found 
389.1831; IR max = 3251 (w, N-H), 3078 (w, C-H), 2979 (w, C-H), 1745 (s, C=O), 1732 (s, 
C=O), 1643 (s, C=O), 1568 (m, C=C), 1520 (m, C=C), 1197 (s, C-O-C). 
6.3.13 General procedure 2 
To a solution of triazole (1 eq.) in THF (0.1M) was added potassium tert-butoxide (1.5 eq.) the 
reaction refluxed for 1-4 hours. Upon completion, 1N HCl (aq.) was added and extracted with 
148 
 
EtOAc (3x). The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude intermediate was dissolved in acetonitrile and H2O (10:1, 0.1M) and refluxed 
until no starting material remained (2-4 hours). The solution was concentrated in vacuo and 
purified by flash chromatography to give the product. 
6.3.14 Synthesis of 5-methyl-5-((1-(2-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidine-2,4-dione (89) 
 
Following general procedure 2: 79 (70.0 mg, 0.158 mmol), potassium tert-butoxide (26.6 mg, 
0.237 mmol) and THF (2 mL) were refluxed for 3 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (2 mL) and H2O (0.2 mL) and refluxed for 3.5 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 50 – 100%) 
to give 89 (34.0 mg, 0.100 mmol, 64%) as a white solid. 
LCMS MH+ 339.2; Rf = 0.20 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.87 (1H, d, J = 7.8 Hz, 
H13), 7.78 – 7.74 (1H, m, H11), 7.70 (1H, t, J = 7.7 Hz H12), 7.66 (1H, s, H8), 7.55 (1H, d, J = 
7.7 Hz, H10), 6.72 (1H, br s, NH), 3.23 (1H, d, J = 15.0 Hz, H6a), 3.14 – 3.07 (2H, m, H4a & 
H6b), 2.95 (1H, d, J = 22.2 Hz, H4b), 1.43 (3H, s, H1); 13C NMR (101 MHz, d6-DMSO) δ 211.2 
(C3), 169. 2 (C5), 141.5 (C7), 134.3 (q, J = 1.7 Hz, H9), 133.9 (C11), 131.1 (C12), 130.0 (q, J 
= 191.1 Hz, C15), 129.2 (C10), 127.4 (q, J = 4.8 Hz, C13), 126.2 (C8), 124.8 (q, J = 31.2 Hz, 
C14), 66.6 (C2), 40.3 (C4), 33.6 (C6), 23.8 (C1);  19F (376 MHz, d6-DMSO) δ 58.1; HRMS (ESI) 
calcd for [C15H14N4O2F3]+: 339.1069, found 339.1069; IR max = 3241 (m, N-H), 1635 (s, C=O), 
1625 (m, C=O), 1503 (s, C=C), 1467 (s, C=C), 1405 (m, C=C). 
6.3.15 Synthesis of 5-((1-(2-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (90) 
 
Following general procedure 2: 80 (50.0 mg, 0.122 mmol), potassium tert-butoxide (27.0 mg, 
0.241 mmol) and THF (1.4 mL) were refluxed for 3 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (3 mL) and H2O (0.3 mL) and refluxed for 4 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20 – 100%) 
to give 90 (19.0 mg, 0.0624 mmol, 51%) as a white solid.  
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Rf = 0.22 (EtOAc/MeOH, 24:1); 1H NMR (400 MHz, CDCl3) δ 7.81 (1H, s, H8), 7.60 – 7.56 (2H, 
m, H10 & H13), 7.48 – 7.42 (2H, m, H11 & H12), 7.11 (1H, br s, NH), 3.25 (1H, d, J = 15.0 Hz, 
H6a), 3.14 (1H, d, J = 15.0 Hz, H6b), 3.06 (1H, d, J = 22.2 Hz, H4a), 2.91 (1H, d, J = 22.2 Hz, 
H4b), 1.46 (3H, s, H1); 13C NMR (101 MHz, CDCl3) δ 209.5 (C3), 169.4 (C5), 141.6 (C7), 134.8 
(C14), 131.1 (C13), 130.9 (C12), 128.7 (C9), 128.2 (C11), 127.8 (C10), 124.9 (C8), 67.6 (C2), 
40.2 (C4), 31.1 (C6), 24.0 (C1); HRMS calcd for [C14H13N4O235ClNa]+: 327.0619, found 
327.0618; IR max = 3250 (m, N-H), 2931 (w, C-H), 1635 (m, C=O), 1620 (m, C=O), 1493 (s, 
C=C).  
6.3.16 Synthesis of 5-((1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (91) 
 
Following general procedure 2: 81 (52.0 mg, 0.129 mmol), potassium tert-butoxide (21.0 mg, 
0.187 mmol) and THF (1.5 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20 – 100%) 
to give 91 (24.0 mg, 0.0799 mmol, 62%) as a white solid. 
LCMS MH+ (300.9); Rf = 0.11 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.92 (1H, s, H8), 7.74 
(1H, dd, J = 7.9, 1.5 Hz, H10), 7.45 – 7.40 (1H, m, H12), 7.12 – 7.06 (3H, m, H11, H13, NH), 
3.88 (3H, s, H15), 3.22 (1H, d, J = 15.0 Hz, H6a), 3.12 (1H, d, J = 15.0 Hz, H6b), 3.04 (1H, d, 
J = 22.2 Hz, H4a), 2.89 (1H, d, J = 22.2 Hz, H4b), 1.46 (3H, s, H1); 13C NMR (101 MHz, CDCl3) 
δ 209.8 (C3), 169.5 (C5), 151.2 (C14), 141.1 (C7), 130.4 (C12), 126.2 (C9), 125.5 (C10), 125.0 
(C8), 121.4 (C11), 112.4 (C13), 67.9 (C2), 56.1 (C15), 40.3 (C4), 33.9 (C6), 24.0 (C1); HRMS 
[C15H17N4O3]+: 301.1301, found 301.1302; IR max = 3246 (w, N-H), 1634 (s, C=O), 1602 (s, 
C=O), 1508 (s, C=C), 1467 (m, C=C).  
6.3.17 Synthesis of 5-((1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (92) 
 
Following general procedure 2: 83 (55.0 mg, 0.136 mmol), potassium tert-butoxide (23.0 mg, 
0.205 mmol) and THF (1.5 mL) were refluxed for 2 hours. After work up, the crude intermediate 
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was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20 – 100%) 
to give 92 (32.0 mg, 0.107 mmol, 78%) as a white film. 
LCMS MH+ (MH+ 300.9); Rf = 0.17 (EtOAc); 1H (400 MHz, CDCl3) δ 7.83 (1H, s, H8), 7.62 (1H, 
br s, NH), 7.36 (1H, t, J = 8.2 Hz, H11), 7.27 – 7.26 (1H, m, H15), 7.19 (1H, dd, J = 7.9, 1.4 
Hz, H12), 6.93 (1H, dd, J = 8.3, 2.2 Hz, H10), 3.86 (3H, s, H14), 3.20 (1H, d, J = 14.9 Hz, H6a), 
3.12 (1H, d, J = 14.9 Hz, H6b), 3.05 (1H, d, J = 22.2 Hz, H2a), 2.90 (1H, d, J = 22.2 Hz, H2b), 
1.46 (3H, s, H5); 13C (101 MHz, CDCl3) δ 209.7 (C3), 170.0 (C1), 160.7 (C13), 142.4 (C7), 
137.9 (C9), 130.6 (C11), 121.1 (C8), 114.7 (C12), 112.3 (C10), 106.3 (C15), 67.8 (C4), 55.8 
(C14), 40.3 (C2), 33.9 (C6), 23.9 (C5); HRMS (ESI) calcd for [C15H17N4O3]+: 301.1301, found 
301.1297; IR max = 3128 (w, N-H), 2976 (w, C-H), 1769 (m, N=N), 1698 (s, C=O), 1608 (s, 
C=C), 1594 (s, C=C), 1503 (s, C=C). 
6.3.18 Synthesis of 5-methyl-5-((1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidine-2,4-dione (93) 
 
Following general procedure 2: 84 (83.0 mg, 0.188 mmol), potassium tert-butoxide (32.0 mg, 
0.285 mmol) and THF (2 mL) were refluxed for 2.5 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20 – 100%) 
to give 93 (47.0 mg, 0.219 mmol, 74%) as an off-white solid. 
Rf = 0.26 (EtOAc); 1H (400 MHz, CDCl3) δ 7.97 (1H, s, H8), 7.95 – 7.91 (2H, m, H10 & H14), 
7.82 (1H, br s, NH), 7.68 – 7.61 (2H, m, H11 & H12), 3.24 (1H, d, J = 14.9 Hz, H6a), 3.16 (1H, 
d, J = 14.9 Hz, H6b), 3.06, (1H, d, J = 22.2 Hz, H3a), 2.88 (1H, d, J = 22.1 Hz, H3b), 1.47 (3H, 
s, H1); 13C (101 MHz, CDCl3) δ 209.5 (C2), 170.2 (C4), 143.0 (C7), 137.2 (C9), 132.5 (q, J = 
33.4 Hz, C13), 130.7 (C11), 125.6 (q, J = 3.6 Hz, C12), 123.5 (q, J = 273.0 Hz, C15), 123.5 
(C10), 121.0 (C8), 117.3 (q, J = 3.9 Hz, C14), 67.8 (C5), 40.3 (C3), 33.9 (C6), 23.9 (C1); 19F 
(376 MHz, CDCl3) δ -62.9; HRMS (ESI) calcd for [C15H14N4O2F3]+: 339.1069, found 339.1064; 
IR max = 3139 (w, N-H) 3104 (w, C-H), 2941 (w, C-H), 1766 (s, C=O), 1697 (s, C=O), 1498 




6.3.19 Synthesis of 5-((1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (94) 
 
Following general procedure 2: 85 (53.0 mg, 0.130 mmol), potassium tert-butoxide (21.0 mg, 
0.187 mmol) and THF (1.4 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; EtOAc) to give 94 (26.0 mg, 
0.0853 mmol, 66%) as an off-white solid. 
Rf = 0.15 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.86 (1H, s, H8), 7.70 (1H, t, J = 1.8 Hz, H14), 
7.60 (1H, dt, J = 7.6, 1.7 Hz, H10), 7.53 (1H, br s, NH), 7.45 – 7.37 (2H, m, H11 & H12), 3.21 
(1H, d, J = 15.0 Hz, H6a), 3.13 (1H, d, J = 15.0 Hz, H6b), 3.08 (1H, d J = 22.2 Hz, H2a), 2.91 
(1H, d, J = 22.2 Hz, H2b), 1.46 (3H, s, H5); 13C NMR (101 MHz, CDCl3) δ 209.5 (C3), 170.0 
(C1), 142.8 (C7), 137.7 (C13), 135.7 (C9), 131.0 (C11), 129.0 (C10), 121.0 (C8), 120.7 (C14), 
118.4 (C12), 67.8 (C4), 40.3 (C2), 33.9 (C6), 23.8 (C5); HRMS (ESI) calcd for 
[C14H14N4O235Cl]+: 305.0805, found 305.0814; IR max = 3136 (w, C-H) 3096 (w, C-H), 2924 (w, 
C-H), 1762 (m, C=O), 1693 (s, C=O), 1594 (s, C=C), 1491 (m, C=C), 1464 (m, C=C).  
6.3.20 Synthesis of 5-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (95) 
 
Following general procedure 2: 86 (65.0 mg, 0.165 mmol), potassium tert-butoxide (28.0 mg, 
0.250 mmol) and THF (1.7 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; EtOAc) to give 95 (35.0 mg, 
0.121 mmol, 73%) as an off-white solid. 
Rf = 0.14 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.81 (1H, s, H8), 7.67 – 7.64 (2H, m, H10), 
7.59 (1H, br s, NH), 7.20 – 7.16 (2H, m, H11), 3.22 (1H, d, J = 15.0 Hz, H6a), 3.13 (1H, d, J = 
15.0 Hz, H6b), 3.05 (1H, d, J = 22.2 Hz, H2a), 2.87 (1H, d, J = 22.2 Hz, H2b), 1.46 (3H, s, H5); 
13C NMR (101 MHz, CDCl3) 209.6 (C3), 170.0 (C1), 162.6 (d, J = 249.4 Hz, C12), 142.7 (C7), 
133.2 (C9), 122. 5 (d, J = 8.6 Hz, C10), 121.2 (C8), 116.9 (d, J = 23.0 Hz, C11), 67.8 (C4), 
40.4 (C2), 33.9 (C6), 23.9 (C5); 19F (376 MHz, CDCl3) δ -111.8; HRMS (ESI) calcd for 
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[C14H14N4O2F]+: 289.1101, found 289.1107; IR max = 3094 (w, C-H), 2902 (w, C-H), 1762 (m, 
C=O), 1690 (s, C=O), 1517 (s, C=C). 
6.3.21 Synthesis of 5-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrrolidine-2,4-dione (96) 
 
Following general procedure 2: 87 (69.0 mg, 0.169 mmol), potassium tert-butoxide (28.0 mg, 
0.249 mmol) and THF (1.7 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 2 hours. The crude 
product was purified by flash column chromatography (silica gel; EtOAc) to give 96 (32.0 mg, 
0.105 mmol, 62%) as an off-white solid. 
Rf = 0.18 (EtOAc); 1H (400 MHz, CDCl3) δ 7.83 (1H, s, H8), 7.62 (2H, d, J = 8.8 Hz, H10), 7.53 
(1H, br s, NH), 7.46 (2H, d, J = 8.8 Hz, H11), 3.21 (1H, d, J = 15.0 Hz, H6a), 3.13 (1H, d, J = 
15.0 Hz, H6b), 3.06 (1H, d, J = 22.2 Hz, H2a), 2.89 (1H, d, J = 22.2 Hz, H2b), 1.46 (3H, s, H5); 
13C (101 MHz, CDCl3) δ 209.6 (C3), 169.9 (C1), 142.8 (C7), 135.3 (C12), 134.8 (C9), 130.1 
(C11), 121.6 (C10), 120.9 (C8), 67.8 (C4), 40.3 (C2), 33.9 (C6), 23.9 (C5); HRMS (ESI) calcd 
for [C14H14N4O235Cl]+: 305.0805, found 305.0811; IR max = 3151 (w, C-H), 3080 2921 (w, C-
H), 2852 (w, C-H), 1766 (m, C=O), 1690 (s, C=O), 1501 (s, C=C), 1425 (s, C=C). 
6.3.22 Synthesis of 5-methyl-5-((1-(p-tolyl)-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidine-2,4-dione (97) 
 
Following general procedure 2: 88 (46.7 mg, 0.125 mmol), potassium tert-butoxide (20.0 mg, 
0.178 mmol) and THF (1.5 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. The crude 
product was purified by flash column chromatography (silica gel; EtOAc) to give 97 (25.0 mg, 
0.0879 mmol, 70%) as an off-white solid. 
Rf = 0.17 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.79 (1H, s, H8), 7.55 (2H, d, J = 8.4 Hz, H10), 
7.38 (1H, br s, NH), 7.28 (2H, d, J = 8.3 Hz, H11), 3.20 (1H, d, J = 15.0 Hz, H6a), 3.11 (1H, d, 
J = 15.0 Hz, H6b), 3.06 (1H, d, J = 22.2 Hz, H2a), 2.91 (1H, d, J = 22.2 Hz, H2b), 2.41 (3H, s, 
H13), 1.45 (3H, s, H5); 13C NMR (101 MHz, CDCl3) δ 209.7 (C3), 169.8 (C1), 142.4 (C7), 139.2 
153 
 
(C12), 134.6 (C9), 130.4 (C11), 121.0 (C8), 120.4 (C10), 67.8 (C4), 40.3 (C2), 33.8 (C6), 23.9 
(C5), 21.2 (C13); HRMS (ESI) calcd for [C15H17N4O2]+: 285.1352, found 285.1359; IR max = 
3138 (w, C-H), 2975 (w, C-H), 2921 (w, C-H), 1760 (m, C=O), 1693 (s, C=O), 1519 (s, C=C).  
6.3.23 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(3-
phenylisoxazol-5-yl)propanoate (98) 
 
To a solution of 77 (65.0 mg, 0.255 mmol) in t-BuOH (1.5 mL) and water (1.5 mL) was added 
N-hydroxybenzimidoyl chloride (36.0 mg, 0.231 mmol), copper(II) sulfate pentahydrate (13.7 
mg, 0.0548 mmol), sodium ascorbate (15.3 mg, 0.0772 mmol) followed by potassium hydrogen 
carbonate (102 mg, 1.02 mmol). The reaction was stirred for 39 hours and then diluted with 
water and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel; petroleum ether/EtOAc, 40 – 60%) to give 98 (46.4 mg, 0.124 
mmol, 49%) as a colourless oil. 
 
Rf = 0.18 (petroleum ether/EtOAc, 3:2); 1H NMR (400 MHz, CDCl3) δ 7.78 (2H, m, H15), 7.69 
(1H, br s, NH), 7.46 – 7.43 (3H, m, H16 & H17), 6.38 (1H, s, H12), 4.13 (2H, q, J = 7.2 Hz, 
H2), 3.84 (3H, s, H9), 3.81 (1H, d, J = 15.0 Hz, H10a), 3.58 (1H, d, J = 15.0 Hz, H10b), 3.30 
(2H, s, H4), 1.68 (3H, s, H7), 1.22 (3H, t, J = 7.2 Hz, H1); 13C NMR (101 MHz, CDCl3) δ 173.4 
(C8), 169.1 (C11), 168.9 (C3), 164.8 (C5), 162.4 (C13), 130.1 (C17), 129.1 (C16), 129.0 (C14), 
126.9 (C15), 101.9 (C12), 61.9 (C2), 59.4 (C6), 53.4 (C9), 42.1 (C4), 32.8 (C10), 23.6 (C7), 
14.1 (C1); HRMS (ESI) calcd for [C19H23N2O6]+: 375.1551, found 375.1548. IR max = 3303 (w, 
N-H), 2978 (w, C-H), 1737 (s, C=O), 1670 (m, C=O), 1657 (C=O), 1535 (m, C=C), 1444 (m, 
C=C). 
6.3.24 Synthesis of 5-methyl-5-((3-phenylisoxazol-5-yl)methyl)pyrrolidine-2,4-
dione (93) 
 
Following general procedure 2: 98 (60.0 mg, 0.160 mmol), potassium tert-butoxide (27.0 mg, 
0.241 mmol) and THF (2 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (2 mL) and H2O (0.2 mL) and refluxed for 2.5 hours. The crude 
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product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20 – 100%) 
to give 99 (26.0 mg, 0.0961 mmol, 38%) as a white solid. 
LCMS MH+ (270.1); Rf = 0.16 (Petroleum ether/EtOAc, 7:13); 1H NMR (400 MHz, CDCl3) δ 
7.77 – 7.75 (2H, m, H11), 7.45 – 7.44 (3H, m, H12 & H13), 6.89 (1H, br s, NH), 6.42 (1H, s, 
H8), 3.23 (1H, d, J = 15.1 Hz, H6a), 3.16 (1H, d, J = 15.1 Hz, H6b), 3.08 (1H, d, J = 22.3 Hz, 
H2a), 2.98 (1H, d, J = 22.3 Hz, H2b), 1.45 (1H, s, H5); 13C NMR (101 MHz, CDCl3) δ 208.2 
(C3), 169.7 (C1), 167.5 (C7), 162.7 (C9), 130.4 (C13), 129.1 (C12), 128.6 (C10), 126.9 (C11), 
102.3 (C8), 67.0 (C4), 39.8 (C2), 35.4 (C6), 24.0 (C5); HRMS (ESI) calcd for [C15H15N2O3]+: 
271.1083, found 271.1088; IR max = 3088 (w, N-H), 1770 (m, N=N), 1698 (s, C=O), 1690 (S, 
C=O), 1607 (m, C=C), 1470 (m, C=C), 1443 (m, C=C). 
6.3.25 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(3-
phenylisoxazol-4-yl)propanoate (100) 
 
A solution of 77 (65.0 mg, 0.255 mmol) in 1,2-dichloroethane (2.5 mL) was degassed for 15 
mins before N-hydroxybenzimidoyl chloride (36.0 mg, 0.231 mmol), triethylamine (39.0 μL, 
0.281 mmol) and Cp*Ru(COD)Cl (9.70 mg, 0.0255 mmol) were added. The reaction was 
stirred at r.t for 42 hours. The reaction was concentrated in vacuo and purified by flash column 
chromatography (silica gel; heptane/EtOAc, 10-65% EtOAc) to give 100 (70.0 mg, 0.187 mmol, 
73%) as a pale-yellow solid. 
LCMS MH+ 375.0; Rf = 0.18 (Petroleum ether/EtOAc, 3:2); 1H (400 MHz, CDCl3) δ 8.33 (1H, 
s, H11), 7.66 (1H, br s, NH), 7.57 – 7.54 (2H, m, H15), 7.49 – 7.46 (3H, m, H16 & H17), 4.20 
(2H, q, J = 7.2 Hz, H2), 3.65 (1H, d, J = 15.2 Hz, H10a), 3.44 (3H, s, H8), 3.28 (1H, d, J = 15.1 
Hz, H10b), 3.05 (2H, s, H4), 1.57 (3H, s, H9), 1.30 (3H, t, J = 7.1 Hz, H1); 13C (101 MHz, 
CDCl3) δ 173.7 (C7), 169.2 (C3), 164.6 (C5), 162.1 (C11), 158.0 (C13), 129.6 (C17), 129.2 
(C14), 129.0 (C16), 128.8 (C15), 112.8 (C12), 61.9 (C2), 60.4 (C6), 52.9 (C8), 41.7 (C4), 28.1 
(C10), 23.3 (C9), 14.2 (C1); HRMS (ESI) calcd for [C19H23N2O6]+: 375.1556, found 375.1555; 
IR max = 3308 (w, N-H), 2985 (w, C-H), 1733 (s, C=O), 1672 (s, C=O), 1655 (s, C=O), 1531 




6.3.26 Synthesis of 5-methyl-5-((3-phenylisoxazol-4-yl)methyl)pyrrolidine-2,4-
dione (101) 
 
Following general procedure 2: 100 (52.0 mg, 0.139 mmol), potassium tert-butoxide (16.0 mg, 
0.143 mmol) and THF (1.5 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (1.5 mL) and H2O (0.1 mL) and refluxed for 4 hours. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, gradient 20-
100%) to give 101 (21.0 mg, 0.0777 mmol, 56%) as a white solid. 
LCMS MH+ 271.0; Rf = 0.27 (EtOAc); 1H (400 MHz, CDCl3) δ 8.31 (1H, s, H8), 7.51 (5H, br s, 
H11, H12 & H13), 6.16 (1H, br s, NH), 3.06 (1H, d, J = 15.0 Hz, H6a), 2.91 (1H, d, J = 22.2 
Hz, H4a), 2.84 (1H, d, J = 15.0 Hz, H6b), 2.60 (1H, d, J = 22.2 Hz, H4b), 1.30 (3H, s, H1), ; 
13C (101 MHz, CDCl3) δ; 209.0 (C3), 169.4 (C5), 162.5 (C8), 157.6 (C9), 130.1 (C13), 129.3 
(C10), 129.3 (C12), 128.6 (C11), 112.0 (C7), 68.4 (C2), 40.3 (C4), 30.5 (C6), 24.1 (C1),HRMS 
(ESI) calcd for [C15H15N2O3]+: 271.1083, found 271.1092; IR max = 3259 (w, N-H), 2932 (w, C-
H), 1645 (s, C=O), 1551 (s, C=O), 1444 (s, C=C).  
6.3.27 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-phenylpent-4-
ynoate (102) 
 
To an ice-cooled solution of 11 (100 mg, 0.490 mmol) in CH2Cl2 (5 mL) was added triethylamine 
(0.103 mL, 0.740 mmol), followed by ethyl 3-chloro-3-oxopropanoate (0.094 mL, 0.740 mmol) 
dropwise. The reaction was stirred for 3 hours 45 minutes and then diluted with NH4Cl 
saturated aqueous solution. The organic layer was separated, and the aqueous further 
extracted with CH2Cl2 (2 x 10 mL). The organic extracts were combined, dried over Na2SO4 
and concentrated in vacuo. The sample was purified by flash column chromatography (silica 
gel; heptane/EtOAc, gradient 10 – 60%) to give 102 (146 mg, 0.460 mmol, 94 %) as a yellow 
oil. 
Rf = 0.36 (Petroleum ether/EtOAc, 3:2); 1H (400 MHz, CDCl3) δ 8.54 (1H, br s, NH), 7.47 – 
7.44 (2H, m, H13), 7.40 – 7.36 (2H, m, H14), 7.34 – 7.30 (1H, m, H15), 4.25 (2H, q, J = 7.2 
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Hz, H2), 3.72 (3H, s, H8), 3.66 (1H, dd, J = 16.7, 2.6 Hz, H9a), 3.50 (1H, dd, J = 16.7, 2.6 Hz, 
H9b), 3.43 – 3.33 (2H, m, H4), 1.94 (1H, t, J = 2.6 Hz, H11), 1.32 (3H, t, J = 7.1 Hz, H1);13C 
(101 MHz, CDCl3) δ 171.6 (C7), 169.3 (C3), 164.2 (C5), 137.6 (C12), 128.9 (C14), 128.5 (C15), 
125.9 (C13), 79.5 (C10), 71.4 (C11), 64.8 (C6), 61.9 (C2), 53.6 (C8), 41.8 (C4), 24.7 (C9), 14.2 
(C1); HRMS (ESI) calcd for [C17H20NO5]+: 318.1341, found 318.1345; IR max = 3287 (w, N-H), 
2983 (w, C-H), 1735 (s, C=O), 1677 (s, C=O), 1519 (s, C=C), 1498 (s, C=C), 1436 (s, C=C). 
6.3.28 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-phenyl-3-(1-
phenyl-1H-1,2,3-triazol-4-yl)propanoate (103) 
 
Following general procedure 1: 102 (72.0 mg, 0.227 mmol), copper(II) sulfate pentahydrate 
(5.66 mg, 0.0227 mmol), sodium ascorbate (13.5 mg, 0.0681 mmol), azidobenzene (0.5M in 
TBME, 0.408 mL, 0.207 mmol), t-BuOH (1.5 mL) and water (1.5 mL) were used. The crude 
product was purified by flash column chromatography (silica gel; heptane/EtOAc, 20-100%) to 
give 103 (52.0 mg, 0.119 mmol, 52 %) as a white solid. 
LCMS MH+ 437.0; Rf = 0.61 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 8.07 (1H, 
br s, NH), 7.84 (1H, s, H15), 7.75 – 7.72 (2H, m, H17),  7.53 – 7.48 (4H, m, H10 & H11), 7.44 
– 7.37 (3H, m, H18 & H19), 7.34 – 7.30 (1H, m, H12), 4.30 (1H, d, J = 14.3 Hz, H13a), 4.17 – 
4.10 (3H, m, H2 & H13b), 3.80 (3H, s, H8), 3.36 – 3.27 (2H, m, H4), 1.23 (3H, t, J = 7.2 Hz, 
H1); 13C (101 MHz, CDCl3) δ 172.4 (C7), 168.7 (C3), 164.1 (C5), 143.3 (C14), 138.7 (C16), 
137.2 (C9), 129.8 (C18), 128.9 (C11), 128.6 (C19), 128.3 (C12), 126.0 (C10), 121.4 (C15), 
120.3 (C17), 65.7 (C6), 61.9 (C2), 53.8 (C8), 42.9 (C4), 30.0 (C13), 14.1 (C1); HRMS (ESI) 
calcd for [C23H25N4O5]+: 437.1825, found 437.1834; IR max = 3246 (w, N-H), 2961 (w, C-H), 
1739 (s, C=O), 1651 (s, C=O), 1598 (m, C=C),  1521 (m, C=C), 1504 (m, C=C). 
6.3.29 Synthesis of 5-phenyl-5-((1-phenyl-1H-1,2,3-triazol-4-




Following general procedure 2: 103 (43.0 mg, 0.0985 mmol), potassium tert-butoxide (17.0 
mg, 0.151 mmol) and THF (1 mL) were refluxed for 2.5 hours. After work up, the crude 
intermediate was dissolved in acetonitrile (1 mL) and H2O (0.1 mL) and refluxed for 3 hours. 
The crude product was purified by flash column chromatography (silica gel; heptane/EtOAc, 
20 – 100%) to give 104 (23.0 mg, 0.0692 mmol, 71%) as white film. 
Rf = 0.49 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.76 (1H, br s, NH), 7.57 – 7.51 (4H, m, H6 & 
H13), 7.50 (1H, s, H11), 7.47 – 7.44 (2H, m, H14), 7.41 – 7.35 (3H, m, H7 & H15), 7.33 – 7.29 
(1H, m, H8), 3.66 – 3.58 (2H, m, H9a & 9b), 3.11 (1H, d, J = 21.8 Hz, H2a), 2.98 (1H, d, J = 
21.8 Hz, H2b); 13C NMR (101 MHz, CDCl3) δ 205.8 (C3), 169.8 (C1), 142.5 (C10), 137.4 (C5), 
136.8 (C12), 129.9 (C14), 129.1 (C7), 129.0 (C15), 128.7 (C8), 125.5 (C6), 120.8 (C11), 120.5 
(C13), 73.1 (C4), 40.0 (C2), 34.2 (C9); HRMS (ESI) calcd for [C19H17N4O2]+: 333.1346, found 
333.1340; IR max = 3256 (w, N-H), 1773 (m, C=O), 1698 (m, N=N), 1667 (s, C=O), 1500 (m, 
C=C), 1412 (m, C=C). 
6.3.30 Synthesis of methyl 2-(3-ethoxy-3-oxopropanamido)-2-methyl-3-(1-
phenyl-1H-1,2,3-triazol-4-yl)propanoate (78) 
 
Following general procedure 1: 77 (400 mg, 1.57 mmol), copper(II) sulfate pentahydrate (39.1 
mg, 0.156 mmol), sodium ascorbate (93.0 mg, 0.469 mmol), azidobenzene (0.5M in TBME, 
2.82 mL, 1.41 mmol), t-BuOH (8 mL) and water (8 mL) were used. The crude product was 
purified by flash column chromatography (silica gel; heptane/EtOAc, 30-100%) to give 78 (450 
mg, 1.20 mmol, 77%) as a white solid. 
LCMS MH+ 375.0; Rf = 0.39 (Petroleum ether/EtOAc, 7:13); 1H (400 MHz, CDCl3) δ 7.91 (1H, 
s, H12), 7.76 – 7.74 (2H, m, H14), 7.52 – 7.49 (2H, m, H15), 7.44 – 7.39 (2H, m, H16 & NH), 
4.14 (2H, q, J = 7.2 Hz, H2), 3.82 (3H, s, H9), 3.70 (1H, d, J = 14.6 Hz, H10a), 3.48 (1H, d, J 
= 14.6 Hz, H10b), 3.28 (2H, s, H4), 1.69 (3H, s, H7), 1.22 (3H, t, J = 7.2 Hz, H1); 13C (101 
MHz, CDCl3) δ 174.0 (C8), 168.8 (C3), 164.7 (C5), 143.4 (C11), 137.2 (C13), 129.8 (C15), 
128.7 (C16), 121.2 (C12), 120.4 (C14), 61.8 (C2), 60.3 (C6), 53.2 (C9), 42.7 (C4), 32.1 (C10), 
23.2 (C7), 14.1 (C1); HRMS (ESI) calcd for [C18H23N4O5]+: 375.1668, found 375.1670; IR max 
= 3256 (w, N-H),  3157 (w, C-H), 3083 (w, C-H), 1732 (s, C=O), 1645 (s, C=O), 1564 (s, C=C), 




6.3.31 Synthesis of 5-methyl-5-((1-phenyl-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidine-2,4-dione (NM450) 
 
Following general procedure 2: 78 (450 mg, 1.20 mmol) potassium tert-butoxide (202 mg, 1.80 
mmol) and THF (12 mL) were refluxed for 3 hours. After work up, the crude intermediate was 
dissolved in acetonitrile (10 mL) and water (1 mL) and refluxed for 3 hours. The crude product 
was purified by flash column chromatography (silica gel; heptane/EtOAc, 20-100%) to give 
NM450 (240 mg, 0.888 mmol, 74%) as a white solid. 
LCMS MH+ (271); Rf = 0.13 (EtOAc); 1H (400 MHz, CDCl3) δ 7.83 (1H, s, H8), 7.68 (2H, d, J 
= 7.8 Hz, H10), 7.52 – 7.48 (2H, m, H11), 7.45 – 7.41 (1H, m, H12), 7.34 (1H, br s, NH), 3.21 
(1H, d, J = 15.0 Hz, H6a), 3.13 (1H, d, J = 15.0 Hz, H6b), 3.07 (1H, d, J = 22.2 Hz, H4a), 2.92 
(1H, d, J = 22.2 Hz, H4b), 1.46 (3H, s, H1); 13C (101 MHz, CDCl3) δ; 209.6 (C3), 169.7 (C5), 
142.5 (C7), 136.9 (C9), 129.9 (C12), 129.0 (C11), 121.0 (C8), 120.5 (C10), 67.7 (C2), 40.3 
(C4), 33.8 (C6), 23.9 (C1); HRMS (ESI) calcd for [C14H14N4O2]+: 271.1190, found 271.1191; IR 
max = 3137 (w, C-H), 2899, (w, C-H), 1759 (m, C=O), 1690 (m, C=O), 1600 (m, C=C), 1505 
(m, C=C).  
6.3.32 Synthesis of 3,3,5-trimethyl-5-((1-phenyl-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidine-2,4-dione (105) 
 
To a solution of NM450 (25.0 mg, 0.0924 mmol) in DMF (1 mL) was added potassium 
carbonate (26.0 mg, 0.188 mmol) followed by iodomethane (0.0120 mL, 0.184 mmol). After 
stirring at r.t. for 18 hours, iodomethane (0.0120 mL, 0.184 mmol) was added and the reaction 
heated to 60 °C for 7 hours. The reaction was quenched with NH4Cl saturated aqueous solution 
and extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed with brine, 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel; heptane/EtOAc, 20 – 100%) to give 105 (10.0 mg, 0.0335 mmol, 
36%) as a yellow solid.  
LCMS MH+ (299.0); Rf = 0.33 (EtOAc); 1H (400 MHz CDCl3) δ 7.80 (1H, s, H10), 7.70 – 7.68 
(2H, m, H12), 7.54 – 7.50 (2H, m, H13), 7.46 – 7.42 (1H, m, H14), 6.96 (1H, br s NH), 3.19 – 
3.10 (2H m, H8a & 8b), 1.46 (3H, s, H7), 1.30 (3H, s, H3), 1.06 (3H, s, H4); 13C (101 MHz 
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CDCl3) δ 216.6 (C5), 176.7 (C1), 142.6 (C9), 136.9 (C11), 130.0 (C13), 129.1 (C14), 121.2 
(C10), 120.6 (C12), 65.7 (C6), 46.3 (C2), 34.2 (C8), 25.0 (C7), 22.8 (C3), 20.4 (C4); HRMS 
(ESI) calcd for [C16H19N4O2]+: 299.1508, found 299.1512; IR max = 3149 (w, N-H), 2971 (w, C-
H), 2932 (w, C-H), 1693 (s, C=O), 1655 (s, C=O), 1596 (s, C=C), 1502 (s, C=C). 
6.3.33 Synthesis of 4-hydroxy-5-methyl-5-((1-phenyl-1H-1,2,3-triazol-4-
yl)methyl)pyrrolidin-2-one (106) 
 
To an ice-cooled solution of NM450 (40.0 mg, 0.148 mmol) in MeOH (1.5 mL) was added 
sodium borohydride (108 mg, 0.285 mmol) and the reaction stirred for 3 days at r.t. Then, 
NH4Cl saturated aqueous solution was added and the reaction extracted with EtOAc (3 x 10 
mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo to 
give 106 (dr ca. 77:23 by 1H NMR, 40.0 mg, 0.147 mmol, 99%) as a white solid. 
LCMS MH+ (273.0); Rf = 0.45, 0.39 (10% MeOH in CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 7.87 
(1H, s, H8), 7.74 – 7.72 (2H, m, H10), 7.56 – 7.52 (2H, m, H11), 7.46 (1H, t, J = 7.4 Hz, H12), 
6.69 (1H, br s, NH), 5.11 (1H, m, OH), 4.59 (1H, t, J = 8.1 Hz, H3’), 4.30 (1H, br s, OH’), 4.19 
–  4.16 (1H, m, H3), 3.25 (1H, d, J = 14.4 Hz, H6a), 3.09 (3H,m, H6b, H6a’ & H6b’), 2.76 (1H, 
dd, J = 17.6, 7.0 Hz, H4a), 2.66 (1H, dd, J = 16.9, 7.9 Hz, H4a’), 2.51 (1H, dd, J = 16.8, 8.5 
Hz, H4b’), 2.28 (1H, dd, J = 17.6, 3.2 Hz, H4b), 1.22 (3H, s, H1); 13C NMR (101 MHz, CDCl3) 
δ 175.5 (C5), 144.2 (C7), 136.9 (C9), 130.0 (C11), 129.2 (C12), 121.3 (C8), 120.6 (C10), 74.0 
(C3), 63.7 (C2), 39.3 (C4), 32.3, (C6), 25.7 (C1); HRMS (ESI) calcd for [C14H17N4O2]+: 
273.1352, found 273.1344; IR max = 3161 (br, OH), 2975 (w, C-H, 2917 (w, C-H), 1667 (s, 
C=O), 1597 (m, C=C), 1502 (m, C=C). 
6.4 Synthesis of NM466 derivatives 
6.4.1 Synthesis of (S)-3-methyl-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one (113) 
 
To a solution of methyl pyruvate (1.20 mL, 13.2 mmol) and molecular sieves (6.00 g) in 
trifluoroethanol (36 mL) was added (S)-phenyl glycinol (1.64 g, 12.0 mmol). The reaction was 
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sealed in vial and irradiated to 120 °C for 50 minutes. The reaction was filtered through celite 
and purified by flash column chromatography (silica gel, petroleum ether/EtOAc, 4:1) to give 
113 (1.04 g, 5.47 mmol, 46%) as a white solid.  
Rf = 0.25 (petroleum ether/EtOAc, 4:1); 1H (400 MHz, CDCl3) δ 7.43 – 7.39 (2H, m, H8) 7.37 
– 7.33 (3H, m, H7 & H9), 4.87 – 4.82 (1H, m, H3), 4.56 (1H, dd, J = 11.6, 4.5 Hz, H4a), 4.26 
(1H, m, H4b), 2.41 (3H, d, J = 2.4 Hz, H1); 13C (101 MHz, CDCl3) δ 160.4 (C2), 155.6 (C5), 
136.9 (C6), 129.0 (C8), 128.4 (C9), 127.2 (C7), 71.6 (C4), 59.8 (C3), 21.9 (C1); HRMS (ESI) 
calcd for [C11H12NO2]+: 190.0868, found 190.0864; IR max =  3034 (w, C-H), 3007 (w, C-H), 
1721 (s, C=O), 1641 (s, C=N), 1455 (s, C=C); [𝛂]𝐃𝟐𝟓 = +214.0 (c = 0.1 in CHCl3). 
6.4.2 Synthesis of (3S,5S)-3-methyl-5-phenyl-3-(prop-2-yn-1-yl)morpholin-2-one 
(115) 
 
To a solution of 113 (960 mg, 5.08 mmol) in DMF (25 mL) cooled to -20 °C was added Zn (495 
mg, 7.62 mmol) followed by propargyl bromide (810 uL, 7.62 mmol). The reaction was slowly 
warmed to 0 °C over 3 hours 40 mins. Upon completion, the reaction was cooled to -15 °C and 
quenched with NH4Cl saturated aqueous solution. The aqueous was extracted with EtOAc (3 
x 20 mL) and the combined organic extracts washed with brine, dried over Na2SO4 and 
concentrated in vacuo. Crude 1H NMR analysis indicated an 87:13 mixture of alkyne and allene 
isomers. The crude mixture was purified by flash column chromatography (silica gel; petroleum 
ether/EtOAc 22:3) to give 115 (606 mg, 2.64 mmol, 52%). 
Rf = 0.25 (petroleum ether/EtOAc 22:3); 1H (400 MHz, CDCl3) δ 7.46 – 7.44 (2H, m, H10), 7.41 
– 7.33 (3H, m, H11 & H12), 4.36 – 4.26 (3H, m, H7 & H8), 3.10 (1H, dd, J = 16.9, 2.4 Hz, H3a), 
2.64 (1H, dd, J = 16.9, 2.6 Hz, H3b), 2.34 (1H, br s, NH), 2.09 (1H, t, J = 2.6 Hz, H5), 1.57 (3H, 
s, H1); 13C (101 MHz, CDCl3) δ 172.2 (C6), 137.7 (C9), 129.0 (C12), 128.9 (C11), 127.4 (C10), 
78.5 (C4), 75.4 (C7), 73.0 (C5), 59.0 (C2), 53.2 (C8), 28.7 (C3), 26.8 (C1); HRMS (ESI) calcd 
for [C14H16NO2]+: 230.1181, found 230.1171; IR max = 3239 (s, C≡C-H), 2916 (w, C-H), 2163 
(w, C≡C), 1730 (s, C=O), 1455 (s, C=C), 1430 (s, C=C), 1146 (s, C-O-C); [𝛂]𝐃𝟐𝟓 = -26.0 (c = 




6.4.2 Synthesis of methyl (S)-2-(((S)-2-hydroxy-1-phenylethyl)amino)-2-
methylpent-4-ynoate (116) 
 
To a solution of 115 (430 mg, 1.88 mmol) in MeOH (18.8 mL) was added SOCl2 (272 uL, 3.75 
mmol) and the reaction stirred for 2 hours at r.t. Then, the reaction was concentrated in vacuo 
and NaHCO3 saturated aqueous solution and EtOAc were added and stirred for 15 minutes. 
The organic layer was separated and the aqueous extracted twice more. The combined 
organic extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel; petroleum ether/EtOAc 7:3) to give 116 
(285 mg, 1.09 mmol, 58%) as a colourless oil. 
Rf = 0.17 (petroleum ether/EtOAc 7:3); 1H (400 MHz, CDCl3) δ 7.34 – 7.30 (2H, m, H10), 7.27 
– 7.23 (3H, m, H11 & H12), 3.84 (1H, dd, J = 9.2, 4.7 Hz, H13a), 3.57 (1H, dd, J = 10.8, 4.4 
Hz, H13b), 3.48 – 3.41 (1H, m, H8), 3.38 (3H, s, H1), 3.02 (1H, br s, OH), 2.54 (1H, dd, J = 
16.6, 2.6 Hz, H4a), 2.47 (1H, dd, J = 16.6, 2.6 Hz, H4b), 2.30 (1H, br s, NH), 2.00 (1H, t, J = 
2.6 Hz, H6), 1.41 (3H, s, H7); 13C (101 MHz, CDCl3) δ 175.0 (C2), 141.1 (C9), 128.6 (C10), 
127.7 (C12), 127.2 (C11), 79.9 (C5), 71.4 (C6), 67.1 (C13), 60.9 (C3), 59.8 (C8), 52.1 (C1), 
30.1 (C4), 22.6 (C7); HRMS (ESI) calcd for [C15H20NO3]+: 262.1443, found 262.1432; IR max 
= 3284 (w, C≡C-H), 2948 (w, C-H), 2342 (w, C≡C), 1728 (s, C=O), 1454 (m, C=C), 1113 (s, 
C-O-C); [𝛂]𝐃𝟐𝟓 = +41 (c = 0.1 in CHCl3). 
6.4.3 Synthesis of methyl (S)-2-amino-2-methylpent-4-ynoate ((S)-4) 
 
To a solution of 116 (250 mg, 0.957 mmol) in MeOH (3 mL) and CH2Cl2 (6 mL) cooled to 0 °C 
was added Pb(OAc)4 (593 mg, 1.33 mmol) and the reaction stirred for 1 hour warming to r.t. 
Then, 2N HCl (aq., 10 mL) was added and stirred for 10 minutes. The resulting suspension 
was filtered through a silica plug, eluting with MeOH and the solvents removed in vacuo. The 
aqueous residue was extracted with EtOAc (3 x 10 mL), basified with Na2CO3 to pH 10-11 and 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo to give (S)-4 (110 mg, 0.779 mmol, 81%) as a colourless oil. 
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Rf = 0.15 (petroleum ether/EtOAc 5:3); 1H (400 MHz, CDCl3) δ 3.72 (3H, s, H7), 2.64 (1H, dd, 
J = 2.6, 16.5 Hz, H3a), 2.44 (1H dd, J = 2.6, 16.5 Hz, H3b), 2.04 (1H, t, J = 2.6 Hz, H5), 1.87 
(2H, br s, NH), 1.36 (3H, s, H1); 13C (101 MHz, CDCl3) δ 176.6 (C6), 79.8 (C4), 71.5 (C5), 57.5 
(C2), 52.6 (C7), 31.0 (C3), 26.0 (C1); HRMS (ESI) calcd for [C7H12NO2]+:142.0868, found 
142.0862; IR max = 3295 (m, N-H), 2953 (w, C-H), 2358 (w, C≡C), 1732 (s, C=O), 1116 (s, C-
O-C) [𝛂]𝐃𝟐𝟓 = -13.0 (c = 0.1 in CHCl3). 
6.4.4 Synthesis of methyl (S)-2-methyl-2-(2-nitrobenzamido)pent-4-ynoate ((S)-
111) 
 
To a solution of (S)-4 (35.0 mg, 0.248 mmol) in CH2Cl2 (2.5 mL) cooled to 0 °C was added 
triethylamine (41.0 uL, 0.298 mmol) followed by 2-nitrobenzoyl chloride (39.0 uL, 0.298 mmol) 
and the reaction stirred for 2 hours warming to r.t. Then, the reaction was quenched with NH4Cl 
saturated aqueous solution and extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was purified 
by flash column chromatography (silica gel; petroleum ether/EtOAc 1:1) to give 111 (48.0 mg, 
0.166 mmol, 67%) as a colourless oil. 
Rf = 0.22 (petroleum ether/EtOAc 11:9); 1H (400 MHz, CDCl3) δ 8.09 – 8.06 (1H, m, H11), 7.70 
– 7.66 (1H, m, H13), 7.61 – 7.57 (2H, m, H12 & H14), 6.74 (1H, br s, NH), 3.85 (3H, s, H7), 
3.34 (1H, dd, J = 16.9, 2.6 Hz, H3a), 2.98 (1H, dd, J = 16.9, 2.6 Hz, H3b), 2.06 (1H, t, J = 2.6 
Hz, H5), 1.78 (3H, s, H1); 13C (101 MHz, CDCl3) δ 173.3 (C6), 165.7 (C8), 146.5 (C10), 133.8 
(C13), 132.8 (C9), 130.7 (C14), 129.0 (C12), 124.7 (C11), 79.5 (C4), 71.4 (C5), 60.1 (C2), 53.4 
(C7), 26.6 (C3), 22.4 (C1); HRMS (ESI) calcd for [C14H15N2O5]+: 291.0981; found: 291.0993; 
IR max = 3280 (w, C≡C-H), 3187 (w, C-H), 3005 (w, C-H), 2159 (w, C≡C) 1751 (s, C=O), 1640 




6.4.5 Synthesis of methyl (S)-2-methyl-2-(N-methyl-2-nitrobenzamido)pent-4-
ynoate ((S)-112) 
 
To a solution of 111 (37.0 mg, 0.127 mmol) in DMF (1.3 mL) at 0 °C was added NaH (60% 
dispersion in mineral oil, 7.60 mg, 0.190 mmol) and the reaction stirred for 15 mins before MeI 
(16.0 uL, 0.254 mmol) was added. After 1 hr stirring at r.t. the reaction was quenched with 
NH4Cl saturated aqueous solution and extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were washed with brine, dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc 
1:1) to give 112 (32.0 mg, 0.105 mmol, 83%) as a white solid. 
Rf = 0.27 (petroleum ether/EtOAc 1:1); 1H (400 MHz, CDCl3) δ 8.19 (1H, dd, J = 8.3, 0.7 Hz, 
H14), 7.72 (1H, td, J = 7.5, 1.6 Hz, H12), 7.59 – 7.55 (1H, m, H13), 7.43 (1H, d, J = 7.4 Hz, 
H11), 3.78 (3H, s, H7), 3.50 (1H, dd, J = 17.3, 2.2 Hz, H3a), 3.02 (3H, s, H8), 2.86 (1H, br s, 
H3b), 2.07 (1H, t J = 2.6 Hz, H5), 1.73 (3H, s, H1); 13C (101 MHz, CDCl3) δ 173.3 (C6), 168.1 
(C9), 145.0 (C15), 134.6 (C12), 133.3 (C10), 129.8 (C13), 128.0, (C11), 124.7 (C14), 80.3 
(C4), 70.9 (C5), 61.9 (C2), 52.6 (C7), 34.4 (C8), 25.0 (C3), 21.4 (C1); HRMS (ESI) calcd for 
[C15H17N2O5]+: 305.1137, found 305.1130; IR max = 3283 (w, N-H), 2923 (w, C-H), 1740 (s, 
C=O), 1640 (s, C=O), 1530 (s, C=C); [𝛂]𝐃𝟐𝟓 = -121.0 (c = 0.1 in CHCl3). 
6.4.6 Synthesis of (S)-3,4-dimethyl-3-propyl-3,4-dihydro-1H-
benzo[e][1,4]diazepine-2,5-dione ((S)-NM466)  
 
To a degassed solution of (S)-112 (23.0 mg, 0.0755 mmol) in MeOH (1 mL) was added Pd/C 
(8.00 mg, 800 μmol) and the reaction stirred under an atmosphere of H2 for 2 hours 15 minutes. 
The reaction was filtered through celite, eluting with MeOH and the solvents removed in vacuo. 
The crude intermediate was dissolved in DMF (0.6 mL) and NaH (60% dispersion in mineral 
oil, 6.00 mg, 0.151 mmol) was added and the reaction stirred for 1.5 hours. Then, the reaction 
was quenched with NH4Cl saturated aqueous solution and extracted with EtOAc (3 x 10 mL). 
The combined organic extracts were washed with brine, dried over Na2SO4 and concentrated 
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in vacuo. The crude product was purified by flash column chromatography (silica gel; 
petroleum ether/EtOAc, 3:2) to give (S)-NM466 (13.6 mg, 0.0552 mmol, 73%) as a white solid. 
Rf = 0.14 (petroleum ether/EtOAc, 3:2); 1H (400 MHz, CDCl3) δ 8.25 (1H, br s, NH), 7.97 (1H, 
dd, J = 1.4, 7.9 Hz, H11), 7.44 (1H, td, J = 1.5, 11.4 Hz, H9), 7.23 – 7.19 (1H, m, H10), 6.90 
(1H, d, J = 8.2 Hz, H8), 3.23 (3H, s, H14), 1.68 (3H, s, H1), 1.63 – 1.57 (1H, H3a), 1.49 – 1.41 
(1H, m, H3b), 1.26 – 1.19 (2H, m, H4), 0.65 (3H, t, J = 7.3 Hz, H5); 13C (101 MHz, CDCl3) δ 
173.3 (C6), 168.3 (C13), 134.9 (C7), 132.5 (C9), 131.4 (C11), 127.8 (C12), 124.8 (C10), 119.1 
(C8), 62.9 (C2), 38.4 (C3), 32.6 (C14), 23.1 (C1), 17.4 (C4), 14.1 (C5); HRMS (ESI) calcd for 
[C14H19N2O2]+: 247.1441, found 247.1430; IR max = 3151 (w, C-H), 2958 (w, C-H), 2873 (w, C-
H), 1676 (s, C=O), 1603 (s, C=O), 1487 (s, C=C), 1432 (m, C=C); [𝛂]𝐃𝟐𝟓 = +269.0 (c = 0.1 in 
CHCl3). 
6.5 Synthesis of alkynes for high-throughput analogue synthesis 
6.5.1 Synthesis of 5-methyl-5-(prop-2-yn-1-yl)pyrrolidine-2,4-dione (60)  
 
Following general procedure 2: 77 (250 mg, 0.980 mmol), potassium tert-butoxide (165 mg, 
1.47 mmol) and THF (10 mL) were refluxed for 2 hours. After work up, the crude intermediate 
was dissolved in acetonitrile (10 mL) and H2O (1 mL) and refluxed for 4 hours. The crude 
product was purified by flash column chromatography (silica gel; petroleum ether/EtOAc, 1:2) 
to give 60 (110 mg, 0.724 mmol, 74%) as a yellow solid. 
Rf = 0.22 (petroleum ether/EtOAc; 1:2); 1H NMR (400 MHz, CDCl3) δ 7.26 (1H, br s, NH), 3.08 
(2H, d, J = 2.3 Hz, H4), 2.58 (1H, dd, J = Hz, H6a), 2.50 (1H, dd, J = HZ, H6a), 2.10 (1H, t, J 
= 2.6 Hz, H8), 1.42 (3H, s, H1); 13C NMR (101 MHz, CDCl3) δ 208.3 (C5), 170.5 (C3) 78.0 (C7), 
72.5 (C8), 67.1 (C2), 40.6 (C4), 28.9 (C6), 23.1 (C1); HRMS (ESI) calcd for [C8H10NO2]+: 
152.0706, found 152.0704. IR max = 3243 (w, C≡C-H), 3155 (w, C-H), 2160 (w, C≡C), 1769 
(s, C=O), 1682 (s, C=O).  




6.5.2 Synthesis of methyl 2-(3-ethylureido)-2-methylpent-4-ynoate (138) 
 
To a solution of amine 4 (250 mg, 1.77 mmol) in CH2Cl2 (18 mL) at 0 °C was added 
ethylisocyanate (280 uL, 3.54 mmol) and the reaction stirred for 18 hours. Then, the solvent 
was removed in vacuo and the product purified by flash column chromatography (silica gel; 
petroleum ether/EtOAc, 2:3) to give 138 (345 mg, 1.63 mmol, 92%) as a white solid.  
Rf = 0.30 (Petroleum ether/EtOAc, 2:3); 1H (400 MHz, CDCl3) δ 5.39 (1H, br s, NH), 4.87 (1H, 
br t, J = 5.3 Hz, NH), 3.74 (3H, s, H10), 3.20 – 3.13 (2H, m H2), 3.00 (1H, dd, J = 16.9, 2.7 Hz, 
H6a), 2.90 (1H, dd, J = 16.9, 2.7 Hz, H6b), 1.99 (1H, t, J = 2.7 Hz, H8), 1.54 (3H, s, H5), 1.10 
(3H, t, J = 7.2 Hz, H1); 13C (101 MHz, CDCl3) δ 174.6 (C9), 157.1 (C3), 80.3 (C7), 71.0 (C8), 
58.2 (C4), 52.8 (C10), 35.3 (C2), 27.4 (C6), 23.7 (C5), 15.4 (C1); HRMS (ESI) calcd for 
[C10H17N2O3]+: 213.1239, found 213.1240; IR max = 3385 (m, N-H), 3324 (m, N-H), 3267 (m, 
C≡C-H), 2974 (w, C-H), 1719 (s, C=O), 1634 (s, C=O), 1557 (s, C=O), 1130 (s, C-O-C). 
6.5.3 Synthesis of methyl 2-methyl-2-(1H-pyrrol-1-yl)pent-4-ynoate (139)  
 
To a solution of amine 4 (250 mg, 1.77 mmol) in 1,2-dichloroethane (9.8 mL), H2O (5.9 mL) 
and acetic acid (1.95 mL) was added NaOAc (174 mg, 2.13 mmol). The reaction was sealed 
in a vial and heated to 90 °C for 5 minutes, then 2,5-dimethoxy tetrahydrofuran (252 uL, 1.95 
mmol) was added and the reaction heated at the same temperature for 19 hours. The reaction 
was cooled to room temperature, diluted with EtOAc and washed with brine. The organic layer 
was dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel; petroleum ether/EtOAc, 9:1) to yield 139 (232 mg, 1.21 
mmol, 68%) as a white solid. 
Rf = 0.56 (petroleum ether/EtOAc, 4:1);1H (400 MHz, CDCl3) δ 6.82 (2H, t, J = 2.2 Hz, H2), 
6.21 (2H, t, J = 2.2 Hz, H1), 3.74 (3H, s, H5), 3.07 (1H, dd, J = 16.8, 2.6 Hz, H7a), 2.99 (1H, 
dd, J = 16.8, 2.6 Hz, H7b), 2.04 (1H, t, J = 2.6 Hz, H9), 1.93 (3H, s, H6); 13C (101 MHz, CDCl3) 
δ 172.0 (C4), 118.8 (C2), 108.8 (C1), 78.5 (C8), 72.3 (C9), 63.1 (C3), 53.2 (C5), 30.1 (C7), 
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22.9 (C6); HRMS (ESI) cald for [C11H14NO2]+ 192.1019, found 192.1012; IR max = 3254 (s, 
C≡C-H), 2952 (w, C-H), 2159 (w, C≡C),1788 (s, C=O), 1108 (s, C-O-C). 
These data are in accordance with the literature.232 
6.5.2 Synthesis of methyl 2-methyl-2-(2,2,2-trifluoroacetamido)pent-4-ynoate 
(140) 
 
To a solution of 4 (210 mg, 1.49 mmol) in CH2Cl2 (15 mL) at 0 °C was added trifluroacetic 
anhydride (414 uL, 2.97 mmol) and triethylamine (414 uL, 2.97 mmol) and the reaction stirred 
for 16 hours. The reaction was diluted with NH4Cl saturated aqueous solution (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried over Na2SO4 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(silica gel; petroleum ether/EtOAc, 4:1) to give 140 (314 mg, 1.32 mmol, 89%) as a colourless 
oil. 
Rf = (0.44, petroleum ether/EtOAc, 4:1); 1H (400 MHz, CDCl3) δ 7.30 (1H, br s, NH), 3.84 (3H, 
s, H6), 3.23 (1H, dd, J = 17.0, 2.6 Hz, H7a), 2.85 (1H, dd, J = 17.0, 2.6 Hz, H7b), 2.04 (1H, t, 
J = 2.6 Hz, H9), 1.69 (3H, s, H1); 13C (101 MHz, CDCl3) δ 172.3 (C5), 156.3 (q, J = 37.4 Hz, 
C3), 115.5 (q, J = 288.4 Hz, C4), 77.8 (C8), 72.1 (C9), 60.2 (C2), 53.8 (C6), 26.2 (C7), 22.2 
(C1); 19F (376 MHz, CDCl3) δ -76.2; HRMS (ESI) calcd for [C9H11NO3F3]+: 238.0686, found 
238.0676; IR max = 3296 (w, C≡C-H), 2956 (w, C-H), 1750 (s, C=O), 1717 (s, C=O), 1150 (s, 
C-O-C). 
6.6 X-Ray crystallography and library screening 
CFI25 protein was expressed and purified at the Structural Genomics Consortium, Oxford, by 
Dr Michael Fairhead following the in-house protocol “PREPX” (Parallel rapid expression and 
purification of proteins for crystallography). The final protein buffer consisting of 10 mM HEPES 
pH 7.5, 0.5 M NaCl, 5% glycerol, 0.5 mM TCEP. Crystals were grown in SWISSCI 3 Lens 
crystallization sitting-drop plates at 20 °C by mixing 50–100 nl of 20 mg/ml protein solution in 
a 1:1 ratio with 50–100 nl reservoir solution consisting of 0.1 M sodium acetate pH 4.2-4.8, 0.1 
M zinc acetate, 5–16%(w/v) PEG 3000 and placing the drops over 20 ml reservoir solution. 




Activin A was cloned, expressed and purified as previously described.276 Activin A crystals 
were grown from 200 nL protein (3.3 mg/mL dissolved in 20 % MeCN), 50 nL seed solution 
and 200 nL well solution. The well solution consisted of 1.4 M ammonium sulfate, 100 mM 
HEPES pH 7.4, 8 % DMSO, and the seed solution consisted of 200 nL of 1.55 M ammonium 
sulfate, 4 % PEG300, 100 mM HEPES pH 7.4, 8 % DMSO solution and 200 nL of mature 
activin A (3.6 mg/mL) dissolved in 20 % MeCN. The resulting crystals were soaked with a 40 
mM compound solution. 
All compounds were dissolved in DMSO at a concentration of 500mM. In cases where 
compounds could not be dissolved at this concentration, the solution was further diluted to 
250mM. Crystal soaking was performed by acoustic transfer using a Labcyte Echo 550. CFI25 
crystals diffracted to 1.5–1.8 Å resolution in space group P3221, with typical unit-cell 
parameters a = 59.6, c = 213.6 Å, α = 90.00, γ = 120.00 and with two CFI25 molecules in the 
asymmetric unit. X-ray diffraction data were collected on beamline I04-1 at Diamond Light 
Source and were processed using the Diamond autoprocessing pipeline, which utilizes xia2,332 
DIALS,333 XDS,334 POINTLESS,335 and CCP4.336 Electron-density maps were generated using 
XChemExplorer via DIMPLE.337 Ligand restraints were generated with AceDRG338 and ligand 
binding was detected with PanDDA,255 with ligands built into PanDDA event maps. Iterative 
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8.1 The full NSQC library 
 
 
Figure 8.1. The full NSQC DOS library. 
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8.2 Computational analysis 
A) Principal Moment of Inertia (PMI) 
General details 
Principal Moment of Inertia (PMI) was performed using Molecular Operating Environment 
(MOE) software package version 2012.10 from the Chemical Computing Group. Merck 
molecular force field 94X (MMFF94x), an all-atom force field parameterised for small organic 
molecules with the Generalised Born solvation model, was used to minimise the energy 
potential of the library members. A LowModeMD search was employed for the conformation 
generation. Detailed settings for conformational search are listed below.  
Rejection Limit 100 
RMS Gradient 0.005 
Iteration Limit 10000 
MM Iteration Limit 500 
RMSD Limit 0.15 
Energy window 3 
Conformation Limit 100 
Only the conformer with the lowest energy was retained for principal moment of inertia (PMI) 
calculations. Normalized PMI ratios (I1/I3 and I2/I3) of these conformers were obtained from 
MOE and then plotted on a triangular graph, with the canonical coordinates (0,1), (0.5,0.5) and 
(1,1) representing a perfect rod, disc and sphere respectively (Figure 3). 
Compound collections analysed and PMI plots 
Collection 1: DOS Library 




















































Table 8.2. Normalised PMI ratio (npr) values of conformers of the DOS Library with the 
lowest energy. 
 
Compound npr1 npr2  Compound npr1 npr2 
14 0.2626 0.9435  64 0.6608 0.9315 
24 0.3226 0.8555  65 0.4033 0.7284 
41 0.2417 0.9216  66 0.348 0.7927 
43 0.2727 0.8894  67 0.4224 0.8973 
45 0.2325 0.9648  68 0.3633 0.8393 
46 0.4231 0.7895  69 0.3696 0.7741 
47 0.0846 0.9619  70 0.2735 0.8451 
48 0.4928 0.7482  71 0.3122 0.813 
49 0.3812 0.8038  72 0.2989 0.8118 
53 0.2465 0.9311  73 0.3747 0.7195 
54 0.4579 0.8303  74 0.3506 0.7691 
55 0.6285 0.7595  75 0.1877 0.9268 
56 0.2034 0.9381  76 0.4495 0.9293 
57 0.3332 0.9538  58a 0.2723 0.9423 
58 0.646 0.695  59a 0.3108 0.8538 
59 0.5321 0.8555  59b 0.3231 0.8831 
60 0.4319 0.7592  59c 0.6047 0.9251 
61 0.313 0.8822  60a 0.221 0.9554 
62 0.2007 0.9149  60b 0.1535 0.9378 
63 0.1761 0.9628  60c 0.538 0.8653 
 
Collection 2: DOS Library Ph. Virtual collection of 40 small molecules based on DOS 





Figure 8.2. The Ph NSQC library. 
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Table 8.4. Normalised PMI ratio (npr) values of conformers of the DOS Library Ph with 
the lowest energy. 
 
Compound npr1 npr2  Compound npr1 npr2 
14’ 0.5367 0.7998  65 0.6252 0.7811 
24’ 0.222 0.9232  66 0.6827 0.7967 
41’ 0.3576 0.8375  67 0.643 0.784 
43’ 0.2845 0.8513  68 0.3867 0.9416 
45’ 0.4475 0.7587  69 0.4424 0.9206 
46’ 0.3872 0.7793  70 0.5677 0.773 
47’ 0.2682 0.8633  71 0.606 0.8234 
48’ 0.3555 0.8412  72 0.4118 0.4118 
53’ 0.5471 0.754  73 0.4118 0.8226 
54’ 0.3858 0.7454  74 0.496 0.8478 
55’ 0.5096 0.9404  75 0.3317 0.8011 
56’ 0.4091 0.8306  76 0.3531 0.8914 
57’ 0.5158 0.8271  23d’ 0.5009 0.7579 
58’ 0.6347 0.7591  58a 0.2371 0.9147 
59’ 0.6175 0.8648  59a 0.2698 0.943 
60’ 0.5456 0.8896  59b 0.3082 0.9453 
61’ 0.5641 0.6922  59c 0.5731 0.8761 
62’ 0.2509 0.2509  60a 0.2834 0.8679 
63’ 0.2509  0.932  60b 0.3405 0.8466 





Figure 8.3. PMI plot of DOS Library Ph. 
Collection 3: Maybridge ‘Ro3’ core fragment collection  
 
This library is based on the core 1000-member collection within the Maybridge Fragment 
library. Details of the library (including SMILES and SDF) are available from 
‘http://www.maybridge.com/’ under the ‘Ro3 Fragment library section. More details can be 




Figure 8.4. PMI plot of Maybridge ‘Ro3’ core collection. 
 
B) Computational evaluation of physicochemical properties 
 
General details 
Computational analysis was carried out using the same MOE software package and settings 
described above in section A. The DOS library compounds were analysed for the for the 
following properties: SlogP, molecular weight (MW), number of hydrogen-bond acceptors 
(HBA), number of hydrogen-bond donors (HBD), number of chiral centres and fraction 
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Fragment-based drug discovery (FBDD) is a well-established approach for the discovery
of novel medicines, illustrated by the approval of two FBBD-derived drugs. This
methodology is based on the utilization of small “fragment” molecules (<300 Da)
as starting points for drug discovery and optimization. Organic synthesis has been
identified as a significant obstacle in FBDD, however, in particular owing to the lack of
novel 3-dimensional (3D) fragment collections that feature useful synthetic vectors for
modification of hit compounds. Diversity-oriented synthesis (DOS) is a synthetic strategy
that aims to efficiently produce compound collections with high levels of structural
diversity and three-dimensionality and is therefore well-suited for the construction of
novel fragment collections. This Mini-Review highlights recent studies at the intersection
of DOS and FBDD aiming to produce novel libraries of diverse, polycyclic, fragment-like
compounds, and their application in fragment-based screening projects.
Keywords: fragment-based drug discovery, diversity-oriented synthesis, medicinal chemistry, organic synthesis,
compound collections
INTRODUCTION
Within the biomedical community there remains a pressing need for new molecules to seed early
stage drug discovery programs. Diversity-oriented synthesis (DOS) emerged in the early 2000s in
response to this challenge, a strategy which involves the efficient and deliberate construction of
multiple scaffolds in a divergent manner (Lee et al., 2000; Schreiber, 2000; Spring, 2003; Burke
and Schreiber, 2004). Nowadays, applications of this methodology span much of the spectrum
of chemical space with examples describing the synthesis of fragment(Hung et al., 2011), small
molecule (Wyatt et al., 2008; Lenci et al., 2015; Caputo et al., 2017), peptide (Kotha et al., 2013;
Contreras-Cruz et al., 2017; Zhang et al., 2017) and macrocyclic (Isidro-Llobet et al., 2011; Kopp
et al., 2012; Beckmann et al., 2013; Dow et al., 2017) collections all abundant within the literature.
Furthermore, as the field of DOS has evolved, research themes have focused on addressing key calls
from within the drug discovery community, namely the deficiencies within compound screening
libraries (Lipkus et al., 2008; Dow et al., 2012), the identification of new bioactive molecules against
challenging biological targets (Stanton et al., 2009; Kato et al., 2016; Kim et al., 2016) and populating
underexplored areas of chemical space with novel structural entities (Thomas et al., 2008; Morton
et al., 2009; Pizzirani et al., 2010). Until recently, however, the majority of DOS successes have
been achieved in high-throughput screening (HTS) contexts (Chou et al., 2011; Laraia et al., 2014;
Aldrich et al., 2015; Kuo et al., 2015).
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Recent applications of DOS, however, exemplify how this
methodology can be utilized to address significant challenges
currently faced within the field of fragment-based drug discovery
(FBDD). FBDD is now a widely adopted technique across
both industry and academia, with two marketed drugs having
emerged from this methodology [vemurafenib (Bollag et al.,
2012), venetoclax (Souers et al., 2013)] and dozens of clinical
candidates (Erlanson et al., 2016). This process involves the
screening of small “fragment” molecule libraries (<300 Da) to
identify efficient, but none the less weakly binding molecules,
which are in turn subsequently elaborated to generate potent
lead compounds (Erlanson and Jahnke, 2016). “Rule of three”
guidelines are commonly employed within FBDD and library
construction, relating to a molecular weight <300 Da, the
number of hydrogen and acceptors/donors ≤3 and a cLogP
≤3 (Congreve et al., 2003). Importantly, due to the additional
physicochemical constraints imposed on these screening libraries
compared to traditional HTS approaches, it is broadly accepted
that this method allows far more efficient sampling of chemical
space, since there are far fewer possible fragment-sized molecules
(Murray and Rees, 2009; Hall et al., 2014).
Despite significant advances in the foundational technologies
of FBDDwhich have aided its implementation, reports associated
with the synthetic intractability of hit fragments support the
view that organic synthesis may be a rate-limiting step in the
FBDD cycle, and in fact across drug discovery as a whole
(Murray and Rees, 2016; Blakemore et al., 2018). In a similar
vein to traditional drug discovery, deficiencies in commercially
available fragment screening collections have been noted, in
particular relating to the overrepresentation of sp2-rich flat
molecules (Hajduk et al., 2011; Hung et al., 2011) that feature
limited numbers of synthetic handles for fragment elaboration.
This latter feature is especially important within FBDD since
this process relies on the merging, growth or linkage of small
fragment molecules to develop initial weak hits (typically µM
or mM range) hits into potent lead compounds. Without these
vital functional handles, this process is significantly more time
consuming, requiring the development of new synthetic routes
to modify relatively simple fragment scaffolds. Furthermore, the
incompatibility of many existing synthetic methodologies with
amines, heterocycles, and unprotected polar functionalities limits
their utilization. Consequently, there is a need for new strategies
and technologies that enable non-traditional disconnections,
late-stage functionalization as well as the incorporation of 3D
elements into drug-like scaffolds.
Thus, appeals from within scientific community have been
made for the development of novel and flexible synthetic
methodologies that enable access to new fragments and their
derivatives, including those with increased 3-dimensionality
and heterocyclic architecture (Keseru et al., 2016; Murray
and Rees, 2016). Despite the debates within the literature on
the requirements of 3D character within fragment libraries,
population of these underrepresented areas can be considered to
complement existing flatter libraries, whilst providing access to
alternative growth vectors, and therefore remains an important
avenue of research (Morley et al., 2013; Fuller et al., 2016). From
the perspective of library construction, the 3D character of the
resulting libraries is commonly judged by the number of chiral
centers and the fraction of sp3 carbons (Fsp3) within a molecule
(Lovering et al., 2009), in addition to visual representations of
the molecular shape space distribution using principal moment
of inertia (PMI) analysis (Sauer and Schwarz, 2003; Kopp et al.,
2012).
With a growing demand for novel heterocycles and 3D-
shaped molecules for use within FBDD campaigns, many
studies centering on the synthesis of 3D fragments around
single heterocycles have been reported, for example using C-H
activation methodologies (Davis et al., 2015; Palmer et al., 2016;
Antermite et al., 2018). This mini-review aims to highlight the
suitability of DOS approaches for addressing these challenges
through the production of multiple scaffolds with a broader
coverage of chemical space. One important feature of this
strategy is the utilization of highly efficient andmodular synthetic
routes, commonly in the form of a build/couple/pair (B/C/P)
algorithm (Nielsen and Schreiber, 2008). This involves (1) the
build phase—construction of common starting materials, (2) the
couple phase—intermolecular coupling of the building blocks
with readily synthesized or commercial materials to form reactive
intermediates and (3) the pair phase—intramolecular reaction or
cyclisation of these precursors to afford distinct scaffolds. Thus,
the flexibility of these strategies often results in methodologies
that can provide efficient access to analogs of a desired scaffold.
Herein, we discuss recent applications of the DOS strategy to the
construction of novel and diverse 3D fragment collections and
their applications in FBDD.
THE APPLICATION OF DOS TO ACCESS
NOVEL FRAGMENTS WITH MULTIPLE
GROWTH VECTORS
The first publication conceptually merging DOS and FBDD
appeared in 2011 in which Hung et al. (2011) described the
application of DOS for the generation of a 3D fragment
collection utilizing allyl proline-based precursors as the basis
for library design. The researchers exploited three proline-
derived building blocks in a B/C/P sequence to facilitate the
formation of a series of fused and spiro bicyclic compounds
(Figure 1B). This was achieved through installation of a second
olefin via N-substitution using a variety of linker types,
furnishing distinct linear precursors. Subsequently subjecting
these intermediates to various intramolecular cyclizations such
as ring closing metathesis (RCM) and oxo-Michael reactions,
yielded 20 compounds based on 12 frameworks. Furthermore,
due to the modular nature of this approach a complete
matrix of stereoisomers of the 5–6, 5–7, 5–8, and 5–9 bicyclic
frameworks could be constructed. Finally, the scaffolds were
derivatized in a post-pair phase manner through functional
group interconversion or olefin reduction to increase the
diversity and the saturation, affording a total of 35 fragments.
Importantly, polar functional handles were installed
throughout the library, enabling potential fragment growth from
different vectors during hit-to-lead efforts. The applicability
of the resultant library to FBDD was demonstrated via
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FIGURE 1 | FBDD-derived drugs and diversity-oriented synthesis of novel fragment libraries. (A) Clinically approved drugs derived from FBDD and their lead
fragments. (B) Hung et al. (2011) Report on DOS of fragment-like molecules. (C) Foley et al. (2015) Lead-like modular route to novel scaffolds. (D) Mayol-Llinàs et al.
(2017) Lead-like scaffold DOS for CNS and FBDD. (E) Haftchenary et al. (2016) DOS of aqueous soluble fragments from 1,2-amino alcohols.
chemoinformatic analysis, which highlighted rule of three
compliance whilst principle moment of inertia (PMI) plots
suggested a broad coverage of 3D molecular shape space.
Amino acid-derived reagents represent valuable building
blocks for use within DOS methodologies owing to their polar
and chiral nature, and their exploitation within these techniques
has become more prevalent within the field. Work by Foley
et al. (2015) described the application of four α,α-amino acid
derived building blocks to generate a library of diverse bicyclic
and tricyclic fragments (Foley et al., 2015). Through variation
in the building block structure and the nature of the pair-phase
cyclisation the researchers constructed 22 different heterocyclic
scaffolds in a synthetically efficient manner (Figure 1C). Firstly,
five different nitrogen substituents were installed on the four
amino acid building blocks: a tert-butyl carbamate, an acyl
urea, a 1,2-diamine, a o-bromobenzylamine or a second allyl
olefin. In turn, pair phase reactions were then explored through
reactivity of these functionalities with either the preinstalled
ester or allyl moieties. This included iodine-mediated cyclisation
followed by azide addition and reactivity of the electrophillic
ester moiety with N-based nucleophiles. Finally, ring closure via
either Pd-mediated Heck reaction or Ru-mediated metathesis
afforded further tri- and bicyclic fragments. The final collection
of 22 scaffolds featured biologically relevant moieties such as
ureas, hydantoins, and lactams, in addition tomultiple functional
synthetic handles. Subsequent virtual enumeration led to a library
of 1,110 compounds that were predicted to possess lead-like
properties and with considerable 3D character, (average Fsp3 =
0.57) and several examples meeting the criteria for FBDD.
In a similar vein, Mayol-Llinàs and co-workers also explored
the use of cyclic α-allyl quaternary ketones in a divergent
and modular synthetic process to generate a library of 30
structurally distinct scaffolds featuring spiro, fused and bridged
architectures (Figure 1D) (Mayol-Llinàs et al., 2017). Instead
of amino acid-based precursors, Tsuji-type decarboxylative
allylation was utilized to generate seven quaternary allylated
building blocks. One example was selected for pilot studies,
during which a variety of transformations were applied in a
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reagent-based approach to yield 12 different scaffolds through
exploitation of four key reactivemoieties within the intermediate.
This included an intramolecular Mannich reaction, a sequence
of hydroboration-oxidation followed by either reduction or
sulfonylation and then cyclisation, base-mediated cyclisation and
Pd-catalyzed aminoarylation. Then, the remaining six precursors
were subjected to the most promising conditions, yielding
an additional 18 scaffolds. Virtual library enumeration was
also conducted using six synthetic transformations, including
reductive amination, urea formation and sulfonylation using 98
medicinal chemistry relevant capping groups. Multiparameter
optimization analysis (Wager et al., 2010) was used to assess
the amenability of this work to a CNS-based drug discovery
context. In addition, it was noted the resulting library possessed
lead-like properties (Doveston et al., 2014) and that many of
the compounds and derivatives would be applicable to a FBDD
setting.
A recent report from Haftchenary at the Broad Institute
detailed the synthesis of a fragment collection based on chiral 1,2-
amino alcohols (Figure 1E) (Haftchenary et al., 2016). Beginning
from a library of nine readily available amino alcohols, a range of
5-, 6-, and 7-membered scaffolds were synthesized in 1–4 steps
using established synthetic procedures. The resulting fragment
collection included medicinally important heterocycles such as
oxazolidinones, morpholinones, and sulfamidate and sultam-
based rings, along with fused and spiro-bicyclic compounds.
FIGURE 2 | Fragment collections derived from DOS and their application to FBDD. (A) Twigg et al. (2016) DOS of partially saturated bicyclic heteroaromatic
fragments. (B) Hassan et al. (2018) DOS fragment library based on twisted amides. (C) Mateu et al. (2018) DOS fragment library based on α,α-disubstituted amino
esters. (D) Foley et al. (2017) synthesis of scaffolds distantly related to natural products. (E) Wang et al. (2016) DOS fragment evolution strategy against GSK3.
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Importantly for a screening context, the aqueous solubility of
each of the 50 final fragments was measured, with values ranging
from 0.085 to >15mM, within the range for many fragment
screening techniques.
Further to the goal of populating fragment space with sp3-
enriched compound collections that possess favorable fragment-
like properties and synthetic exit vectors, Spring and coworkers
disclosed a DOS-related approach to the synthesis of partially
saturated bicyclic heteraromatic (PSBH) molecules (Figure 2A)
(Twigg et al., 2016). The synthetic route centered on the
functionalization of pyrazole and pyridine-based building blocks
featuring possessing amino-, or nitro groups, which were
incorporated as potential solubilizing moieties; alternatively, a
chloro substituent was incorporated as a hydrophobic element.
The build and couple stages comprised of Suzuki cross coupling
and alkylations to install various alkene functionalities, which
were paired using RCM to afford bicyclic scaffolds, each featuring
a positionally defined endocyclic alkene vector for further
functionalization.
The endocyclic alkene was then modified in a post-pairing
event to exemplify its utility as a synthetic growth vector in
these fragments. A variety of alkene transformations, including
dihalogenation, epoxidation, aziridination, cyclopropanation,
halohydrin formation, and hydroboration-oxidation, were
performed to yield a range of further functionalized scaffolds.
The resulting library of compounds was then subjected to
analysis of its physicochemical properties, which compared
favorably to commercial screening libraries in relation to key
properties such as number of chiral centers (0.88 vs. 0.27 or 0.18)
and fraction aromatic (0.43 vs. 0.42 and 0.52), while maintaining
rule of three compliance.
Hassan et al. recently disclosed an interesting example via
the exploitation of twisted bicyclic amide compounds for the
generation of a 3D fragment screening library (Hassan et al.,
2018). In this work five 3-(ω-carboxylate)-substituted piperidine
starting materials were manipulated to produce a 22-member
polycyclic library (Figure 2B). Using substrate-based DOS
methodology, five analogous starting materials based on three
common structures were constructed and via Bu2SnO-mediated
cyclisation these were transformed to afford bicyclo[4.3.1]decane
and bicyclo[3.3.1]nonane scaffolds in moderate yield. The
generality of this methodology was exemplified through the
synthesis of six further compounds through modification of the
N-substituent the bicyclic ring systems.
In turn, these three key scaffolds were ultimately then
divergently modified through manipulation of either the ketone
or amide functionalities to generate a further nine compounds.
The ketone moiety within the bicyclo[3.3.1]nonane was first
modified by the use of either gold- or palladium-mediated
reactions to afford tetra- or tricyclic heteroaromoatic fused
motifs. Alternatively, this moiety could also be reduced and a
variety of heteroaromatics or alkyl moiety installed via either
SNAr or alkylation conditions in a diastereoselective fashion.
Finally, the twisted amide within these scaffolds could also
be manipulated to form either a chloroenamine intermediate,
followed by Suzuki-coupling to install an aryl substituent or
simply by amidine formation. The resultant library was shown
to possess fragment lead-like properties with a high Fsp3 (0.63)
and generally 17 or fewer heavy atoms and a clogP < 2.5.
Furthermore, PMI analysis of the shape distribution suggested
the library possessed significant 3D character to complement
existing fragment collections for screening purposes.
The most recent and final example of synthetic efforts
within this field by Mateu et al. (2018) report the use of
α,α-disubstituted amino esters for the DOS of fragments
incorporating a N-substituted quaternary carbon, an important
and underrepresented motif within screening collections
(Figure 2C). Using a single building block, 40 structurally
diverse molecules based on 27 molecular frameworks were
constructed in a synthetically efficient manner using an average
of only three synthetic steps to access the entire library. This
involved exploiting the three reactive handles within the building
block in different combinations and utilizing a broad range of
chemistries such as [2+2+2] cyclotrimiserizations, Au-, Ru-,
and Cu- mediated cyclizations and regioselective click chemistry
to afford mono-, bi-, and tri-fused heterocycles featuring this
important motif. Importantly, the authors also demonstrated the
versatility of this synthetic methodology through the synthesis
of an alternative quaternary R-substituent and the asymmetric
synthesis of one library member.
Subsequent computational assessment of the resulting library
via PMI analysis revealed a broad distribution of molecular
shape space, in addition to favorable comparisons to a
commercially available fragment collection in terms of 3-
dimensional shape space coverage. Additionally, the mean values
of the physicochemical properties of the library demonstrated the
compatibility of the library for fragment screening, falling within
the Rule of three guidelines, whilst exhibiting more favorable
properties when again compared to existing commercial libraries.
The authors note promising hits identified by X-ray fragment
screening at the XChem screening facility, against proteins from




IDENTIFICATION OF NOVEL BINDERS FOR
CHALLENGING BIOLOGICAL TARGETS
In addition to populating new areas of fragment chemical
space, DOS-derived fragment libraries can play a significant
role in the identification of novel binders to seed future FBDD
programs. Recent work by Foley et al. (2017) demonstrated
the application of DOS-derived fragment libraries in the
identification of novel hits against three epigenetic proteins
from two distinct mechanistic classes (ATAD2, BRD1, and
JMJD2D), via X-ray crystallographic screening methods. The
researchers took inspiration from natural product frameworks,
utilizing intramolecular [5+2] cyclizations to forge bridged
structures incorporating natural product-related heteroaromatic
frameworks (Figure 2D). Ring distortion reactions on these four
initial structures using either expansion, cleavage, annulation,
or substitution methodologies, were performed to divergently
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modify the precursors, ultimately affording a library of
52 fragments based on 23 different scaffolds with bridged
architectures and a high sp3 content. Interestingly, when this
library was screened against the three epigenetic targets via
high-throughput X-ray crystallography methods, 17 hits were
identified against the three proteins, including those binding
in novel regions of the proteins to those described previously.
Moreover, comparisons could be drawn between the natural
product-like fragment library and that obtained from commercial
sources, whereby a significantly higher hit rate against ATAD2
was observed with the 3D fragments synthesized where seven hits
were identified from a 52-member library vs. the commercially
available fragment library where nine hits were identified from
a 700-member library. Although the authors did not report any
biophysical data for the fragments, the identification of novel X-
ray hits from these efforts demonstrate the promise of a merged
DOS-FBDD approach.
Finally, Young and co-workers recently demonstrated the
successful use of the DOS strategy to optimize fragments
against the serine/theronine kinase GSK3β (Wang et al., 2016),
which is overexpressed in cancer and Alzheimer’s disease (Luo,
2009; Hernandez et al., 2012). To initiate the investigation,
a set of 86 fragments was compiled from DOS libraries
constructed via three distinct B/C/P pathways (Figure 2E). The
first DOS fragment library utilized allylproline building blocks
and has been previously discussed in this review (Figure 1A).
The second DOS library coupled enones with amino alcohol
and related building blocks. The final scaffolds were accessed
via catalytic, diastereoselective aza-Michael additions to afford
stereochemically diverse disubstituted heterocycles. The third
DOS library incorporated into this study was generated from
ortho-nitrofluoro arenes and α-amino ester building blocks.
Intermolecular coupling products were obtained via SNAr,
and pairing products were accessed by reduction of the nitro
group followed by spontaneous cyclisation onto the ester
functionality. This modular approach yielded a small collection
of enantiomerically enriched bicyclic piperazinone compounds.
Using this fragment collection, screening against GSK3β
was performed using differential scanning fluorimetry
(DSF) to detect fragment binding. Initial results identified
a benzopiperizinone-library member to exhibit good thermal
stabilization and subsequent assays showed 46% inhibition of
GSK3β at 1mM concentration. A library of derivatives based on
this initial hit were then synthezised using the modular and rapid
DOS chemistry initially developed. Thus, the single enantiomer
variants and other derivatives could easily be constructed to
generate structure-activity relationships (SAR). Preliminary
fragment-level SAR indicated the (R)-enantiomer of the chiral
center to be more potent, and further studies identified the
substituent at this site as an important potential growth vector.
Fragment growth by incorporating large aryl groups into the
scaffold via the same B/C/P pathway yielded the lead compound,
with a large indolyl unit connected to the core heterocycle. This
fragment exhibited a Kd = 9µM, a 60-fold improvement over
the initial fragment hit. Ultimately an X-ray crystal structure of
the lead compound with GSK3β was obtained, revealing it binds
in the ATP pocket of this kinase.
This study demonstrated the successful implementation of
a DOS-based FBDD workflow to evolve fragments against an
important kinase target. Key to the success of this project was
the utility of the DOS concept as a tool to generate skeletally
and stereochemically diverse initial libraries, and later as an
efficient, modular route to analogs for SAR and fragment
growth.
FUTURE PERSPECTIVES
The studies discussed herein have demonstrated the utility of
DOS as an effective approach for populating new areas of
fragment space, in areas largely complementary to existing
fragment collections. In each case, the resulting libraries featured
high structural and shape diversity, increased 3D character and
exemplified synthetic vectors for fragment growth. The latter two
examples discussed detail applications of these libraries for the
identification of novel fragment binders and inhibitors against
challenging protein targets, ultimately demonstrating the utility
of DOS within drug discovery efforts.
It is worth noting the increasing application of computational
virtual library enumeration, an element of which has featured in
several of the publications discussed. It is envisioned that these
methodologies will only increase in their utility when coupled
to in silico-based screening techniques to guide library design
and prioritization of synthesis. Moreover, a focus on applications
of newly developed methodologies to DOS, for example C-H
activation, and site selective late-stage modifications of complex
scaffolds would enable population of underexplored areas of
chemical space and further derivatization of the resulting
scaffolds. Finally, an outstanding requirement within this field
is the establishment of new translational collaborations between
academic and industrial groups to enable the routine screening
of the novel libraries.
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Abstract: N-containing quaternary stereocenters represent
important motifs in medicinal chemistry. However, due to
their inherently sterically hindered nature, they remain un-
derrepresented in small molecule screening collections. As
such, the development of synthetic routes to generate small
molecules that incorporate this particular feature are highly
desirable. Herein, we describe the diversity-oriented synthe-
sis (DOS) of a diverse collection of structurally distinct small
molecules featuring this three-dimensional (3D) motif. The
subsequent derivatisation and the stereoselective synthesis
exemplified the versatility of this strategy for drug discovery
and library enrichment. Chemoinformatic analysis revealed
the enhanced sp3 character of the target library and demon-
strated that it represents an attractive collection of biolog-
ically diverse small molecules with high scaffold diversity.
Introduction
N-containing quaternary stereocenters are important motifs in
medicinal chemistry and are present in significant essential
medicines including the antihypertensive methyldopa (Aldo-
metS) and the anaesthetic ketamine (KetalarS) (Figure 1 a,b).[1]
The presence of this particular stereocenter in the three small
molecules currently under clinical evaluation, Ranirestat,[2] Veli-
parib[3] and Verubecestat[4] (Figure 1 c–e), further highlight its
relevance in drug discovery contexts. The biological activity of
such compounds has been generally shown to be intrinsically
related to their absolute configuration.[5@10] For instance, inves-
tigations have concluded that the presence of a N-containing
quaternary (R)-stereocenter within the core structure is neces-
sary for interaction of the substituents with the pockets of the
b-secretase (BACE1) binding site.[9, 10] Moreover, the presence of
such restricted elements within a small molecule can provide
conformational restrictions owing to their sterically hindered
nature, thereby increasing the molecular complexity of a given
molecule, which has been shown to be desirable chemical fea-
ture for bioactive molecules.[11, 12]
Studies have shown that increased complexity (e.g. sp3-rich
cycles or quaternary carbons) can correlate to an increase in
the selectivity, potency and metabolic stability of drug candi-
dates, along with the successful progression from clinical
stages to drug approval.[13, 14] However, due to their congested
nature, the incorporation of N-containing quaternary stereo-
centers into small molecules poses a synthetic challenge for or-
ganic chemists.[15–19] As a result, small molecules bearing this
particular feature are still under-represented in probe and drug
discovery screening collections.
Figure 1. Examples of bioactive compounds containing a N-substituted qua-
ternary carbon.
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From a synthetic perspective, despite all the advances made
in the field of asymmetric catalysis to generate a-branched
amino-containing compounds,[16–19] the majority of the report-
ed reactions are based on simple scaffolds with restricted
structural diversity and there has been a limited exploration
into the construction of such motifs into more complex mole-
cules. It has, however, been demonstrated that the use of a,a-
disubstituted amino esters as subunits to prepare complex
molecules bearing this sterically hindered motif can be particu-
larly effective. Thus, some examples in the literature have vali-
dated this strategy by the target-oriented synthesis (TOS) of
biologically active small molecules.[20] More recently, allyl-con-
taining cyclic quaternary amino esters have also been used for
the diversity-oriented synthesis (DOS) of small molecule collec-
tions.[21, 22] However, structurally diverse, sp3-rich and complex
libraries are still under-represented in probe and drug discov-
ery screening collections.
In addition to these deficiencies, within the literature, signifi-
cant synthetic challenges have been identified in relation to
the development of chemistries which tolerate polar function-
alities such as amines, N-heterocycles and unprotected polar
groups.[23] Moreover, within a fragment-based drug discovery
context, there have been recent calls for the design and syn-
thesis of novel compounds that feature multiple 3D growth
vectors whilst incorporating polar functionality for molecular
recognition.[24] In response to this, notable examples of effi-
cient syntheses of diverse sp3-rich libraries have been recently
published,[25–32] however there is still an outstanding need for
diverse libraries featuring this key N-containing quaternary ste-
reocenter motif.
With these points in mind, we envisioned that a,a- disubsti-
tuted propargyl amino esters could act as a versatile and pluri-
potent platform for the DOS of structurally diverse screening
collection featuring a stereogenic N-containing quaternary
carbon (Figure 2). In this manner, the reactivity of its three
functional vectors, namely the terminal alkyne, the amine as
well and the ester moieties could be exploited in both inter-
and intramolecular reactions.[33]
Results and Discussion
Synthesis of the DOS library
To validate our hypothesis, we initially selected the racemic a-
methyl propargylglycine 1 (R = Me) as a model substrate to
perform the reagent-based DOS outlined in this work
(Scheme 1). Our investigations began via alkylation of the
amino group in 1 through the introduction of a tert-butyl car-
bamate, propargyl, 2-azido benzoyl or an acyl group to gener-
ate the first set of highly functionalised intermediates (S2–6,
for all intermediates see Scheme S1). Subsequent pairing of
the functionalities present in these intermediates with the ter-
minal alkyne could be achieved through different metal-cata-
lysed cyclisations (Scheme 1, steps a/f). Accordingly, Co-in-
duced [2+2+2] cyclotrimerisation afforded 2 and 3, whilst hy-
droamination using gold catalysis yielded 4 and 6. Finally, in-
tramolecular Ru-mediated click chemistry gave rise to com-
pound 5.
In a similar fashion, Ru-mediated 1,5-click chemistry could
be used to generate acyclic compounds 7 and 8, through in-
termolecular reaction of a protected form of 1 with the com-
mercially available chloro-oxime or the corresponding azido
ester. In turn, lactamisation of the ester moieties within 7 and
8 with the quaternary amine (Scheme 1, steps e/f) afforded the
rigidified scaffolds 9 and 10. Further exploitation of the termi-
nal alkyne handle within 1 via Ru- or Cu-catalysis afforded the
acyclic 1,5- and 1,4-phenyl substituted triazoles 11 and 12, re-
spectively. Finally, Sonogashira cross-coupling of the terminal
alkyne followed by hydrogenation afforded 13 (Scheme 1,
step e).
Next, an exploration into intramolecular cyclisations be-
tween the ester functionality within 1 and the terminal alkyne
was undertaken (Scheme 1, steps c/d). Reduction of the car-
boxylic moiety into the corresponding alcohol provided the
opportunity to introduce additional unsaturated moieties
through the alkylation of the newly generated hydroxyl group
to afford the allylic- and propargylic intermediates. Following
this, metal- catalysed intramolecular cyclisations such as Co-in-
duced [2+2+2] cyclotrimerisations, when starting from the di-
alkyne intermediate or a sequence of ring-closing eynyne
metathesis followed by Diels–Alder cycloaddition, when start-
ing from the allylic intermediate, afforded novel bi- and tricy-
clic oxepine-containing scaffolds 14, 15 and 16. Additionally,
ester hydrolysis of 1 to the carboxylic acid followed by the Cu-
promoted intramolecular cyclisation afforded 17, whilst Ru-
mediated cyclisation of the amino alcohol intermediate with
the terminal alkyne generated 18.
Smaller propargyl-containing fragments featuring different
polar functionalities could also be synthesised via pairing the
amino and ester moieties within 1. Pyrrole 19 was prepared
via Paal-Knorr reaction and a nitrile-based secondary branch
point was introduced to afford 20 (Scheme 1, step a, see Sup-
Figure 2. Synthetic versatility of a,a-disubstituted amino esters for the DOS
of N-substituted quaternary carbon containing small molecules.
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porting Information). Benzodiazepine 21 was prepared starting
from the azido benzoyl intermediate followed by azide reduc-
tion to facilitate the lactamisation reaction with the ester func-
tionality (Scheme 1, steps a/b). Again, acylation of 1 proved
useful in generating acyclic intermediates which could in turn
be cyclized with the ester functionality. For example, Die-
ckmann condensation of the malonyl derivative followed by
decarboxylation, yielded the substituted pyrrolidone 22. More-
over, reduction of the ester to a hydroxyl also provided the op-
portunity to cyclise between this moiety and the amino group
(Scheme 1, steps c/b). In this manner, using a single N-Boc pro-
tected amino alcohol, aziridine 23 and oxazolidinone 26 could
be both synthesized. Finally, two further propargyl-containing
scaffolds were formed by N-acylation followed by hydroxyl-
mediated cyclisation or vice versa, O-acylation followed by ni-
trogen-mediated cyclisation, to yield morpholinones 24 and
25, respectively.
The reactivity of both 19 and 20 could be further exploited
to generate five different scaffolds in a synthetically efficient
manner. Unexpectedly, when extending the reaction time for
the formation of 19, an alternative intramolecular cyclisation
was observed between the terminal alkyne and the in situ hy-
drolysed methyl ester, giving rise to 27. Moreover, gold cataly-
sis promoted the intramolecular cyclisation between the termi-
nal alkyne and a pyrrole within 19 to afford dihydroindolizine
28. We next sought to explore the reactivity of cyano function-
ality within 20. Accordingly, a novel one-step approach to syn-
thesise tricyclic pyrrole-containing scaffolds was developed via
Co-catalysed [2+2+2] cyclotrimerization methodology. Thus,
starting from 20, CpCo(CO)2 and cyclopropylacetylene could
be utilised to furnish fused heterocycles 29 and 30. Further
scaffold exploration using this approach is currently being in-
vestigated in our research group. Additionally, Pd-catalysed re-
duction of the nitrile moiety within 20 allowed the intramolec-
ular cyclisation affording the propyl- substituted pyrrolopipera-
zine 31.
Finally, the terminal alkyne within 25 and 26 could be fur-
ther modified to generate two conformationally restricted
small molecules 32 and 33 via vinyl iodide formation followed
by Buchwald coupling.[34]
To demonstrate the synthetic potential of the propargyl-con-
taining warheads for library enumeration, the alkyne handle
within 19, 21–23 and 26 was further modified (Figure 3 A).
Thus, Cu-catalysed click reaction gave the 1,4-substituted tri-
azoles 19 a, 21 a, 22 a, and 26 a ; Sonogashira cross-coupling af-
forded 21 b and 22 b ; hydrogenation of the alkyne produced
saturated derivatives 21 c and 22 c and, finally, Ru-mediated
click reaction afforded the 1,5- triazole 23 d.
Using the strategy outlined above we synthesised a structur-
ally diverse library of 40 compounds based around 27 molecu-
Scheme 1. Synthesis of structurally diverse N-substituted quaternary carbon containing small molecules from a,a-disubstituted amino ester 1: a) amine deri-
vatisation; b) pairing of the amino and ester moieties; c) ester derivatisation; d) pairing of the alkyne and ester moieties ; e) alkyne derivatisations; f) pairing of
the amino and alkyne moieties. For reaction conditions see Supporting Information.
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lar frameworks relevant for drug discovery (see Figure S1) fea-
turing a N-containing quaternary stereocenter. Each compound
was obtained in no more than five synthetic steps (with an
average of only three steps) starting from 1, which demon-
strates the efficiency of this process. Importantly, the flexibility
of this methodology was further exemplified via the synthesis
of the phenyl-derivative 10’ (Figure 3 B) following the same re-
action conditions used to generate the methyl derivative 10.
The ability to synthesise the asymmetric version of any com-
pound from the library was also validated through the synthe-
sis of the optically pure triazolodiazepine (R)-10 (Figure 3 C)
from (R)-1 (see Supporting Information).
Chemoinformatic assessment
In order to assess the molecular shape distribution of the re-
sulting library, a principal moments of inertia (PMI) analysis
was conducted (Figure 4).[35] Pleasingly, analysis of the DOS li-
brary showed a broad distribution of molecular shape space,
with 93 % of the library out of “flatland”[36] and possessing con-
siderable 3D character. In order to investigate the influence of
the substituent at the quaternary centre on the shape, a virtual
collection based on the phenyl-derivatives (DOS Library Ph, see
Supporting Information) was plotted in the same graph
(Figure 4). Comparative analysis between the two DOS libraries
highlighted a shift to the right-hand side of the plot and more
3D character when modifying the quaternary substituent.
These results suggest that installation and substituent modifi-
cation of the N-containing quaternary sp3 stereocenter repre-
sents a useful strategy for “tuning” the 3D molecular shape
(and thus target binding profile) of a given molecule. Finally,
the commercially available Maybridge “Rule of three” (Ro3)
core fragment library comprising 1000 screening compounds
(see Supporting Information and Figure 4) was analysed and
compared to the DOS library. Importantly, only 28 % of the
Maybridge library appeared out of “flatland” with a high pro-
portion of “disk” and “rod” type compounds, which highlights
the increased diversity and more 3D character displayed by
the DOS library. Interestingly, only two compounds within the
Maybridge collection featured a N-containing quaternary
carbon, exemplifying the limited inclusion of this moiety
within traditional screening collections.
In addition to PMI analysis, calculation of the mean values
for physicochemical properties related to the “rule of three”
guidelines[37] commonly adopted within fragment library gen-
eration (Table 1) was conducted. Notably the DOS library fea-
tured a low mean SlogP (1.37), higher mean number of chiral
centres (1.1) and low fraction of aromatic atoms per molecule
(0.29), compared to commercial libraries (see Supporting Infor-
mation), demonstrating the amenability of the DOS library to
fragment-based drug discovery approaches.[38]
Whilst PMIs are a common way of assessing shape diversity,
the relationship to bioactivity coverage appears to be more
Figure 3. (A) Exemplification of the synthesis of other derivatives via alkyne modifications. Reaction conditions: 19 a, 21 a, 22 a, 26 a : azidobenzene,
CuSO4·5 H2O, tBuOH:H2O, rt, 72–92 %; 21 b and 22 b : PdCl2(PPh3)2, CuI, Et3N, benzyl 2-iodobenzoate, DMF, rt, 16 h, 60 % and 26 %, respectively; 21 c and 22 c :
Pd/C, H2, MeOH, rt, 2 h, 69 % and 87 %, respectively; 23 d : ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, rt @60 8C, 21 h, 42 % (B) Synthesis of the phenyl-contain-
ing derivative. Reaction conditions: i) Boc2O, THF, 70 8C, o/n, 84 %; ii) ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, 80 8C, 1 h, 87 %; iii) TFA, CH2Cl2, 2 h then
NaHCO3, (quantitative yield); iv) PhMe, 150 8C, o/n, 76 %. (C) Synthesis of an enantiopure component of the library. Reaction conditions: i) Boc2O, THF, 70 8C,
o/n, 90 %; ii) ethyl 2-azidoacetate, Cp*RuCl(COD), PhMe, 50 8C, 1 h, 76 %; iii) TFA, CH2Cl2, 2 h then NaHCO3, 93 %; iv) PhMe, 150 8C, o/n, 79 %.
Figure 4. Comparative PMI plot analysis of DOS library (blue circles), May-
bridge core 1000-member “Ro3” Fragment library (green triangles) and the
DOS Ph virtual library (red squares). Compounds within “flatland” (represent-
ed by npr1 + npr2 value <1.1, dashed line) could also be identified; the fur-
ther from this area the molecules move the more they extend into three-di-
mensional space.[36] .
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complex.[39] To assess the coverage of our DOS library in bioac-
tivity space, we compared it to two previously reported fo-
cused synthetic libraries,[40, 41] as well as bioactive compounds
retrieved from ChEMBL, a database of binding and functional
data for a large number of drug-like bioactive compounds. The
molecular weight range of the bioactive compounds selected
for the analysis was between 200 and 700, and the compounds
covered different target classes.[42] Then, their Morgan finger-
prints[43] were generated for multi-dimensional scaling (MDS).
Our DOS library (Figure 5, shown in black) covers a wider area
of biologically relevant chemical space compared to the target-
ed libraries, overlapping with areas occupied by kinase inhibi-
tors, ion channels blockers, membrane receptors ligands and li-
gands of other protein classes.
Currently, the DOS library is being screened via high-
throughput X-ray crystallography methods in collaboration
with the XChem fragment screening facility at the Diamond
Light Source synchrotron. Hits against three different target
classes including hydrolases, the TGF-beta family of growth
factors, and peptidases have been successfully identified. Fur-
ther biological results from these initial campaigns will be pub-
lished in due course.
Conclusion
In summary, we have developed a new, efficient reagent-based
DOS approach using a-methyl-a-propargyl amino esters to
generate a library of 40 structurally diverse small molecules.
Importantly, throughout this sp3-rich library we have installed a
N-containing quaternary stereocenter, polar functionalities and
N-based heterocycles, answering key calls from within the
field. The resultant library also adheres to the fragment rule of
three guidelines, highlighting the amenability to this method
of screening. Furthermore, we have demonstrated the scope
of our library through modifications to the alkyne-containing
scaffolds, the synthesis of a phenyl-containing derivative and
the asymmetric version of an analogue, all of which can be ap-
plied to library enumeration. Finally, cheminformatic analysis
has shown a broad molecular shape distribution, the impor-
tance of the quaternary sp3 carbon in modifying the molecular
shape and the increased diversity and 3D character of the li-
brary when compared to a commercial library. The analysis of
the resulting bioactivity space coverage showcases that the
target library represents an attractive screening collection of
biologically diverse small molecules.
Experimental Section
General remarks
All reagents and solvents were purchased from commercial sources
and used without further purification unless otherwise stated. All
the experiments were carried out under a nitrogen atmosphere
unless otherwise stated. Melting points were measured using a
Bechi B545 melting point apparatus and are uncorrected. Thin
layer chromatography (TLC) was performed on precoated Merck
silica gel GF254 plates. Flash column chromatography was per-
formed on silica gel (230–400 mesh). 1H NMR and 13C NMR were re-
corded on a Bruker Avance 500 MHz instrument in CDCl3 and
MeOD. HRMS was recorded on a Micromass Q-TOF mass spectrom-
eter or a Waters LCT Premier Time of Flight mass spectrometer.
Methyl 3-methyl-7-phenyl-1,2,3,4-tetrahydro-2,6-naphthyridine-
3-carboxylate (2) and methyl 3-methyl-6-phenyl-1,2,3,4-tetrahy-
dro-2,7-naphthyridine-3-carboxylate (3): A solution of methyl 2-
((tert-butoxycarbonyl)amino)-2-methylpent-4-ynoate (S2) (150 mg,
0.62 mmol) in DMF (3.0 mL) was added to a suspension of sodium
hydride (60 % in mineral oil, 30 mg, 0.74 mmol) in DMF(3.2 mL)
cooled to 0 8C. After 10 minutes stirring, propargyl bromide (80
wt.% in toluene, 0.138 minutes stirring, propargyl bromide (80
wt.% in toluene, 0.138 mL, 1.24 mmol) was added and the mixture
was warmed to room temperature and stirred for 4 hours. Then,
the mixture was diluted with saturated aqueous solution of NH4Cl
and the aqueous layer was extracted with EtOAc (3 V). The com-
bined organic layers were washed with brine, dried with Na2SO4,
filtered, and the solvents were evaporated. The crude product was
purified by flash column chromatography (silica gel petroleum
ether/EtOAc, 5:1) to yield 168 mg of methyl 2-((tert-butoxycarbo-
nyl)(prop-2-yn-1-yl)amino)-2-methylpent-4-ynoate (S3) (97 % yield)
as a colourless oil. Rf = 0.40 (petroleum ether/EtOAc; 5:1) ;
1H NMR
(400 MHz, CDCl3): d= 1.43 (s, 9 H), 1.70 (s, 3 H), 1.99 (t, J = 2.6 Hz,
1 H), 2.20 (t, J = 2.4 Hz, 1 H), 2.73 (dd, J = 17.1, 2.5 Hz, 1 H), 3.12 (d,
J = 16.6 Hz, 1 H), 3.69 (s, 3 H), 4.02 (d, J = 18.5 Hz, 1 H), 4.26 ppm
(br s, 1 H); 13C NMR (101 MHz, CDCl3): d= 22.0, 27.0, 28.3, 34.1, 52.4,








SlogP 0–3 1.37 1.92 1.31
MW <300 237 182 222
HBA <3 2.63 1.83 1.81
HBD <3 0.78 1.01 1.04
chiral centres – 1.10 0.14 0.27
fraction Ar – 0.29 0.52 0.42
[a] MW = molecular weight, HBA = number of hydrogen bond acceptors,
HBD = number of hydrogen bond donors. [b] Ideal range based on guide-
lines of Fragment “rule of three”.[37] Green = inside ideal range. Yellow =
extreme of ideal range.
Figure 5. Bioactive space coverage of the DOS library, compared to two tar-
geted compound libraries and seven different bioactivity classes of common
protein targets obtained from ChEMBL (based on Morgan fingerprints and
Multi-Dimensional Scaling, MDS; ellipses cover 90 % of the data in each
class. It can be seen that the DOS library displays significantly wider cover-
age in bioactivity space than the two targeted libraries, covering all
common classes of drug targets used for comparison.
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62.5, 70.9, 71.1, 80.1, 80.9, 81.7, 154.3, 174.0 ppm; HRMS (ESI): m/z
calcd for C15H22NO4 [M+H]
+ : 280.1543; found: 280.1534.
CpCo(CO)2 (6.4 mg, 0.036 mmol) and benzonitrile (0.05 mL,
0.48 mmol) were added to a solution of S3 (68 mg, 0.24 mmol) in
toluene (2.4 mL), previously degassed with argon for 15 minutes,
and the mixture was heated at 110 8C for 36 hours. Then, the sol-
vent was removed under reduced pressure and the crude product
was purified by column chromatography (silica gel; petroleum
ether/EtOAc, gradient from 5:1 to 3:2). The resulting inseparable
mixture of regioisomers (ca. 40:60 ratio as determined by 1H NMR)
was dissolved in CH2Cl2 (1 mL) and TFA (0.5 mL) was then added to
the solution. After 1 hour stirring the solvent was removed under
reduced pressure. The crude product was dissolved in EtOAc
(5 mL) and a saturated aqueous solution of NaHCO3 (5 mL) was
added and the mixture was stirred for 10 minutes. Then, the or-
ganic layer was separated, dried over Na2SO4, filtered and concen-
trated in vacuo. The crude product was purified by flash column
chromatography (silica gel; gradient from EtOAc:MeOH 1:0 to 9:1)
to afford 20 mg of 2 (30 % yield) and 18 mg of 3 (26 % yield) both
as colourless oils.
Data of minor regioisomer (2): Rf = 0.21 (EtOAc):
1H NMR (400 MHz,
CDCl3): d= 1.48 (s, 3 H), 2.37 (br s, 1 H), 2.83 (d, J = 16.7 Hz, 1 H), 3.35
(d, J = 16.7 Hz, 1 H), 3.69 (s, 3 H), 4.05–4.18 (m, 2 H), 7.39 (ddd, J =
7.3, 3.7, 1.3 Hz, 1 H), 7.41–7.49 (m, 3 H), 7.90–7.98 (m, 2 H), 8.37 ppm
(s, 1 H); 13C NMR (101 MHz, CDCl3): d= 26.6, 37.3, 42.6, 52.5, 57.9,
120.6, 126.9, 128.3, 128.8, 128.8, 139.4, 143.2, 147.8, 155.3,
175.9 ppm; HRMS (ESI): m/z calcd for C17H19N2O2 [M+H]
+ :
283.1441; found: 283.1431
Data of major regioisomer (3): Rf = 0.32 (EtOAc):
1H NMR (400 MHz,
CDCl3): d= 1.48 (s, 3 H), 2.03 (br s, 1 H), 2.80 (d, J = 16.2 Hz, 1 H), 3.33
(d, J = 16.2 Hz, 1 H), 3.68 (s, 3 H), 4.08 (d, J = 17.0 Hz, 1 H), 4.19 (d,
J = 17.1 Hz, 1 H), 7.34–7.41 (m, 2 H), 7.41–7.48 (m, 2 H), 7.86–7.97
(m, 2 H), 8.43 ppm (s, 1 H); 13C NMR (101 MHz, CDCl3): d= 26.4, 34.7,
44.7, 52.6, 58.1, 117.8, 126.9, 127.8, 128.8, 129.0, 139.4, 143.3, 150.2,
155.1, 175.8 ppm; HRMS (ESI): m/z calcd for C17H19N2O2 [M+H]
+ :
283.1441; found: 283.1431.
Methyl 2-methyl-2-(1H-pyrrol-1-yl)pent-4-ynoate (19): NaOAc
(97 mg, 1.19 mmol) was added to a stirred solution of 1 (140 mg,
0.99 mmol) in a mixture 5:3:1 of DCE:H2O:AcOH (2.24 mL) and the
reaction was stirred at 90 8C. After 5 minutes, 2,5-dimethoxytetra-
hydrofuran (0.13 mL, 0.99 mmol) was added and the mixture was
stirred at the same temperature overnight. Then, the reaction was
cooled to room temperature, diluted with EtOAc and washed with
saturated aqueous solution of NaCl. The organic layer was dried
over Na2SO4, filtered and the solvents were concentrated in vacuo.
The crude product was purified by flash column chromatography
(silica gel; petroleum ether/EtOAc, 9:1) to yield 115 mg of 19 (61 %
yield) as a white solid. Rf = 0.28 (petroleum ether/EtOAc, 9:1) ; m.p.
55–57 8C; 1H NMR (400 MHz, CDCl3): d= 1.94 (s, 3 H), 2.05 (t, J =
2.6 Hz, 1 H), 3.00 (dd, J = 16.8, 2.6 Hz, 1 H), 3.07 (dd, J = 16.8, 2.6 Hz,
1 H), 3.74 (s, 3 H), 6.21 (t, J = 2.2 Hz, 2 H), 6.83 ppm (t, J = 2.2 Hz,
2 H); 13C NMR (101 MHz, CDCl3): d= 22.8, 30.0, 53.1, 63.1, 72.3, 78.5,
108.8, 118.7, 172.0 ppm; HRMS (ESI): m/z calcd for C11H14NO2
[M+H]+ : 192.1019; found: 192.1013.
Methyl 2-(2-cyano-1H-pyrrol-1-yl)-2-methylpent-4-ynoate (20):
Chlorosulfonyl isocyanate (0.047 mL, 0.55 mmol) was added drop-
wise to a solution of 19 (70 mg, 0.37 mmol) in MeCN (3.6 mL) at
0 8C. After 1 hour stirring, DMF (0.14 mL, 1.85 mmol) was added
and the mixture was stirred for 2 hours. Then, saturated aqueous
solution of NaHCO3 was added and the reaction mixture was ex-
tracted with EtOAc (3x). The combined organic layers were dried
over Na2SO4, filtered and the solvents were concentrated in vacuo.
The crude product was purified by flash column chromatography
(silica gel; petroleum ether/EtOAc, 4:1) to yield 57 mg of 20 (71 %
yield) as colourless oil. Rf = 0.29 (petroleum ether/EtOAc; 5:1) ; mp
64–66 8C; 1H NMR (400 MHz, CDCl3): d= 1.88–2.08 (m, 4 H), 3.09 (dd,
J = 17.5, 2.7 Hz, 1 H), 3.31 (dd, J = 17.5, 2.1 Hz, 1 H), 3.84 (s, 3 H), 6.19
(dd, J = 3.8, 3.0 Hz, 1 H), 6.93 (dd, J = 3.9, 1.5 Hz, 1 H), 7.07 ppm (dd,
J = 2.8, 1.6 Hz, 1 H); 13C NMR (101 MHz, CDCl3): d= 23.8, 29.5, 53.7,
64.5, 72.8, 77.2, 102.9, 108.5, 114.1, 123.2, 125.5, 171.5 ppm; HRMS
(ESI): m/z calcd for C12H12N2NaO2 [M + Na]
+ : 239.0791; found:
239.0783.
3-Methyl-5-methylene-3-(1H-pyrrol-1-yl)dihydrofuran-2(3H)-one
(27): NaOAc (26 mg, 0.32 mmol) was added to a stirred solution of
19 (30 mg, 0.16 mmol) in a mixture 5:3: of DCE:H2O:AcOH (1.6 mL)
and the reaction was stirred at 90 8C for 24 hours. Then, the reac-
tion was cooled to room temperature, diluted with EtOAc and
washed with saturated aqueous solution of NaCl. The organic layer
was dried over Na2SO4, filtered and the solvents were concentrated
in vacuo. The crude product was purified by flash column chroma-
tography to yield 12 mg of 27 (42 % yield) as a colourless oil. Rf =
0.22 (petroleum ether/EtOAc, 9:1) ; 1H NMR (400 MHz, CDCl3): d=
1.85 (s, 3 H), 3.11 (dt, J = 16.2, 1.5 Hz, 1 H), 3.39 (dt, J = 16.2, 1.8 Hz,
1 H), 4.51 (dt, J = 3.2, 1.7 Hz, 1 H), 4.91 (dt, J = 2.8, 2.1 Hz, 1 H), 6.24
(t, J = 2.2 Hz, 2 H), 6.86 ppm (t, J = 2.1 Hz, 2 H); 13C NMR (101 MHz,
CDCl3): d= 24.2, 41.5, 61.6, 91.2, 109.7, 118.4, 151.3, 173.5 ppm;
HRMS (ESI): m/z calcd for C10H12NO2 [M+H]
+ : 178.0861; found:
178.0863.
Methyl 5-methyl-5,6-dihydroindolizine-5-carboxylate (28): A so-
lution of AuSPhos(MeCN)SbF6 (4.8 mg, 5 mol %) in DCE (0.1 mL)
was added drop-wise to a solution of 19 (21 mg, 0.11 mmol) and
ethanol (0.032 mL, 0.55 mmol) in DCE (1.0 mL). The resulting solu-
tion was heated for 2 hours at 40 8C and then the solvent was re-
moved under reduced pressure. The crude product was purified by
flash column chromatography (silica gel; petroleum ether/EtOAc,
4:1) to yield 17 mg of 28 (81 % yield) as a colourless oil. Rf = 0.24
(petroleum ether/EtOAc, 5:1); 1H NMR (400 MHz, CDCl3): d= 1.80 (s,
3 H), 2.49 (dt, J = 16.9, 2.7 Hz, 1 H), 2.95 (dd, J = 16.9, 6.1 Hz, 1 H),
3.64 (s, 3 H), 5.58–5.69 (m, 1 H), 6.12 (d, J = 2.5 Hz, 1 H), 6.22 (t, J =
3.2 Hz, 1 H), 6.46 (dd, J = 9.7, 2.8 Hz, 1 H), 6.85 ppm (s, 1 H); 13C NMR
(101 MHz, CDCl3): d= 24.0, 35.8, 52.9, 61.3, 107.4, 108.9, 117.1,
118.9, 120.8, 130.3, 174.0 ppm; HRMS (ESI): m/z calcd for C11H14NO2
[M+H]+ : 192.1019; found: 192.1012.
Methyl 2-cyclopropyl-6-methyl-5,6-dihydropyrrolo[1,2-h]
[1,7]naphthyridine-6-carboxylate (29) and methyl 3-cyclopropyl-
6-methyl-5,6-dihydropyrrolo[1,2-h][1,7]naphthyridine-6-carbox-
ylate (30): CpCo(CO)2 (13.3 mg, 0.038 mmol) and cyclopropylacety-
lene (0.048 mL, 0.57 mmol) were added to a solution of 20 (40 mg,
0.19 mmol) in toluene (3.5 mL), previously degassed with argon for
15 minutes, and the mixture was heated at 110 8C for 36 hours.
Then, the solvent was removed under reduced pressure and the
crude product was purified by column chromatography (silica gel;
gradient from petroleum/EtOAc, gradient from 4:1 to 2:1) to afford
14 mg of 29 (27 % yield) and 5 mg of 30 (10 % yield) both as white
solids.
Data of major regioisomer (29): Rf = 0.34 (petroleum ether/EtOAc;
4:1) ; mp 108–110 8C; 1H NMR (400 MHz, CDCl3): d= 0.94 (dd, J = 8.2,
3.3 Hz, 2 H), 0.99–1.12 (m, 2 H), 1.88 (s, 3 H), 1.95–2.07 (m, 1 H), 3.06
(d, J = 15.4 Hz, 1 H), 3.43 (d, J = 15.5 Hz, 1 H), 3.54 (s, 3 H), 6.33 (t, J =
3.2 Hz, 1 H), 6.79 (d, J = 7.8 Hz, 1 H), 6.90–6.99 (m, 2 H), 7.28 ppm (d,
J = 7.8 Hz, 1 H); 13C NMR (101 MHz, CDCl3): d= 9.7, 17.2, 24.3, 39.4,
53.0, 61.2, 107.9, 110.1, 117.8, 120.0, 120.2, 131.5, 135.1, 146.9,
161.7, 173.1 ppm; HRMS (ESI): m/z calcd for C17H19N2O2 [M+H]
+ :
283.1441; found: 283.1435.
Data of minor regioisomer (30): Rf = 0.23 (petroleum ether/EtOAc;
2:1) ; 1H NMR (400 MHz, CDCl3): d= 0.67–0.75 (m, 2 H), 0.97–1.03 (m,
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2 H), 1.82–1.92 (m, 4 H), 3.08 (d, J = 15.5 Hz, 1 H), 3.43 (d, J = 15.5 Hz,
1 H), 3.54 (s, 3 H), 6.35 (t, J = 3.0 Hz, 1 H), 6.94 (s, 2 H), 7.07 (s, 1 H),
8.25 ppm (s, 1 H); 13C NMR (101 MHz, CDCl3): d= 8.9, 9.0, 13.1, 24.3,
39.8, 53.1, 61.0, 107.6, 110.3, 120.0, 123.5, 131.0, 132.2, 136.4, 145.3,




(31): PtO2 (34 mg, 0.15 mmol) was added to a solution of 20
(35 mg, 0.15 mmol) in MeOH (3 mL) and the reaction mixture was
stirred under H2 atmosphere (1 atm) for 16 h. Then, the resulting
suspension was filtered and the filtrate was concentrated under re-
duced pressure. The crude product was purified by flash column
chromatography (silica gel; petroleum ether/EtOAc, 1:1) to yield
10 mg of 31 (35 % yield) as colourless oil. Rf = 0.24 (petroleum
ether/EtOAc; 1:1) ; 1H NMR (400 MHz, CDCl3): d= 0.82 (t, J = 7.2 Hz,
3 H), 0.88–1.01 (m, 1 H), 1.11–1.23 (m, 1 H), 1.72 (d, J = 4.5 Hz, 3 H),
1.82 (ddd, J = 13.6, 10.3, 4.3 Hz, 1 H), 2.16 (ddd, J = 13.7, 12.1,
4.6 Hz, 1 H), 4.52–4.63 (m, 2 H), 5.93 (d, J = 2.0 Hz, 1 H), 6.25 (t, J =
3.2 Hz, 1 H), 6.35 (s, 1 H), 6.69 ppm (dd, J = 2.4, 1.8 Hz, 1 H); 13C NMR
(126 MHz, CDCl3): d= 14.0, 17.4, 26.4, 39.8, 43.7, 62.9, 102.8, 109.8,
115.9, 122.1, 172.2 ppm; HRMS (ESI): m/z calcd for C11H17N2O
[M+H]+ : 193.1335; found: 193.1328.
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